Antibodies useful as therapeutic agents against bacterial infections
By developing monoclonal antibodies against the surface of Acinetobacter bauma bacteria, the treatment difficulties of carbapenem-resistant Acinetobacter bauma infection are solved, providing effective diagnostic and treatment methods, especially in hospital settings for patients with chronic diseases. protection.
Patent Information
- Application Number
- CN202280089066.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-11-26
- Filing Date
- 2022-11-25
- Publication Date
- 2024-11-08
AI Technical Summary
Existing treatments are ineffective against carbapenem-resistant Acinetobacter baubani (CRAB) infection and lack effective diagnostic and treatment methods, especially in hospital settings, pose a significant risk to patients with chronic diseases.
Monoclonal antibodies specifically binding to the surface of Acinetobacter bauma bacteria were developed, including antibodies against Oxa-23, OC1 LOS and KL49, which induce complement activation, thereby killing bacteria for diagnosis, prevention and treatment. Infection caused by Acinetobacter bauble.
It provides an effective diagnosis and treatment plan for carbapenem-resistant Acinetobacter bauma, especially in CRAB infection, which can effectively kill bacteria and reduce the risk of infection, and is particularly suitable for infection control in hospital environments.
Smart Images

Figure CN118922440A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to antibodies that bind to Acinetobacter baumannii and their use in the diagnosis, prevention and treatment of bacterial infections caused by Acinetobacter baumannii. Background Art
[0002] The genus Acinetobacter consists of 26 named species and 9 genomic species. Acinetobacter baumannii is a bacterial pathogen primarily associated with hospital-acquired infections. It is a Gram-negative bacillus.
[0003] Acinetobacter baumannii specifically targets wet tissues, such as mucous membranes or exposed skin areas. If left untreated, this infection can lead to sepsis and death. Once Acinetobacter baumannii is in a hospital setting, it poses a significant risk, particularly in ICU wards where patients suffer from chronic conditions.
[0004] Carbapenems are β-lactam antibiotics that are structurally distinct from other commonly used β-lactam antibiotics, such as penicillins and cephalosporins. Carbapenems have been shown to be the drug of choice for treating extended-spectrum β-lactamase (ESBL)-producing bacteria, including strains of Acinetobacter baumannii, which are associated with adverse clinical outcomes in serious infections, such as pneumonia and bacteremia, in hospital settings.
[0005] The World Health Organization lists carbapenem-resistant Acinetobacter baumannii (CRAB) as one of the most threatening pathogens to human health. Indeed, CRAB is a significant cause of ventilator-associated pneumonia (VAP) in many developing and developed countries, and some studies in developing countries have found that CRAB is responsible for more than 30% of neonatal sepsis cases.
[0006] Currently, the classification of Acinetobacter baumannii includes three European clones (ECI-III), eight worldwide clones (WW1-8—now actually eight international clones, IC1-8), and two global clones (GC1 and 2). ECI = WW1 = IC1, ECII = WW2 = IC2, and ECIII = WW3 = IC3, and all are defined by multilocus sequence typing (MLST), while global clones 1 and 2, which are equal to IC1 and 2, respectively, are also supported by whole genome phylogenetics (Pathog Dis. 2014 Aug; 71(3): 292-301. doi: 10.1111 / 2049-632X.12125. Epub 2014 Jan 27, the content of which is incorporated herein by reference).
[0007] Our study showed that GC2 is the major global lineage associated with carbapenem resistance.
[0008] The present invention aims to provide monoclonal antibodies for diagnosing and treating bacterial infections caused by Acinetobacter baumannii. Summary of the Invention
[0009] The invention provides the monoclonal antibody that is applicable to diagnosis, prevention and treatment of the bacterial infection caused by Acinetobacter baumannii.Especially, the invention provides the monoclonal antibody that specifically binds to the bacterial wall of Acinetobacter baumannii antibacterial, such as on for example live bacteria.Advantageously, the invention provides the monoclonal antibody that specifically binds to the bacterial wall of Acinetobacter baumannii antibacterial and induces complement activation (for example as measured by the assay method based on flow cytometry).
[0010] The present invention identifies novel antibody targets on the surface of Acinetobacter baumannii bacteria for the diagnosis, prevention, and treatment of bacterial infections caused by Acinetobacter baumannii. In particular, the present invention demonstrates for the first time that the Oxa-23 enzyme is present on the surface of living bacteria and can be targeted by diagnostic and therapeutic antibodies. Furthermore, the present invention demonstrates for the first time that the lipo-oligosaccharide (LOS) type OC1 is located on the surface of living bacteria and can be targeted by diagnostic and therapeutic antibodies. Finally, the present invention demonstrates for the first time that the KL49 carbohydrate capsular antigen located on the surface of living bacteria can be targeted by diagnostic and therapeutic antibodies. The validation of these new targets on the surface of Acinetobacter baumannii bacteria provides important progress in the diagnosis, prevention, and treatment of bacterial infections caused by Acinetobacter baumannii. Although not limited thereto, the present invention provides particularly important advances in the diagnosis, prevention, and treatment of bacterial infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB), in which existing carbapenem treatments are ineffective. As mentioned above, CRAB is particularly relevant to the G2 lineage of Acinetobacter baumannii.
[0011] The present invention further provides novel monoclonal antibodies that bind to Oxa-23 on the surface of Acinetobacter baumannii bacteria. Such antibodies are particularly useful in the diagnosis of Acinetobacter baumannii. The present invention further provides novel antibodies that bind to Oxa-23 on the surface of Acinetobacter baumannii bacteria and induce complement activation, thereby killing the bacteria. Such antibodies are particularly useful in preventing and treating bacterial infections caused by Acinetobacter baumannii.
[0012] The present invention further provides novel monoclonal antibodies that bind to OC1 LOS on the surface of Acinetobacter baumannii bacteria. Such antibodies are particularly useful in the diagnosis of Acinetobacter baumannii. The present invention further provides novel antibodies that bind to OC1 LOS on the surface of Acinetobacter baumannii bacteria and induce complement activation, thereby killing the bacteria. Such antibodies are particularly useful in the prevention and treatment of bacterial infections caused by Acinetobacter baumannii.
[0013] The present invention further provides novel monoclonal antibodies that bind to KL49 on the surface of Acinetobacter baumannii bacteria. Such antibodies are particularly useful in the diagnosis of Acinetobacter baumannii. The present invention further provides novel antibodies that bind to KL49 on the surface of Acinetobacter baumannii bacteria and induce complement activation, thereby killing bacteria. Such antibodies are particularly useful in preventing and treating bacterial infections caused by Acinetobacter baumannii.
[0014] Antibody sequences are referred to herein by reference to the internal reference number of the relevant antibody as well as the SEQ ID NO. Any disclosure herein citing an antibody reference number is intended to include disclosures with the corresponding nucleic acid or amino acid sequence number (SEQ ID NO) as presented in Tables 1 and 2.
[0015] 3.1 Anti-Oxa-23 Antibodies
[0016] Provided herein are antibodies that specifically bind to Oxa-23. For example, antibodies 1348, 1349, 1540, 1548, and 1550 exemplified herein have been found to specifically bind to Oxa-23 on the outer membrane vesicles (OMVs) of Acinetobacter baumannii bacteria.
[0017] The invention provides an antibody that specifically binds to the Oxa-23 at the surface of Acinetobacter baumannii bacteria, such as on, for example, live bacteria. In one embodiment, the antibody specifically binds to the Oxa-23 at the surface of Acinetobacter baumannii bacteria, as measured by an indirect whole-bacterial cell ELISA. Due to the high correlation between the outer membrane vesicles (OMV) of Acinetobacter baumannii bacteria and live Acinetobacter baumannii bacteria, it has been found that such antibodies also specifically bind to the Oxa-23 on the outer membrane vesicles (OMV) of Acinetobacter baumannii bacteria.
[0018] In one embodiment, the antibody induces complement activation (eg, as measured by a flow cytometry-based assay).
[0019] In one embodiment, the antibody specifically binds Oxa-23 at the surface of Acinetobacter baumannii bacteria and induces complement activation (e.g., as measured by a flow cytometry-based assay), and the HCDR3 is the HCDR3 of antibody 1348, 1349, 1540, 1548, or 1550.
[0020] In one embodiment, the antibody comprises a variable heavy chain (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2, and HCDR3, and a variable light chain (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2, and LCDR3,
[0021] wherein HCDR3 is HCDR3 of antibody 1348, 1349, 1540, 1548 or 1550.
[0022] In one embodiment, the HCDR3 is HCDR3 of antibody 1348.
[0023] In one embodiment, the HCDR3 is HCDR3 of antibody 1349.
[0024] In one embodiment, the HCDR3 is HCDR3 of antibody 1540.
[0025] In one embodiment, the HCDR3 is HCDR3 of antibody 1548.
[0026] In one embodiment, the HCDR3 is HCDR3 of antibody 1550.
[0027] In one embodiment, the present invention provides an anti-Oxa-23 antibody,
[0028] wherein the antibody specifically binds Oxa-23 at the surface of Acinetobacter baumannii bacteria and induces complement activation (e.g., as measured by a flow cytometry-based assay), and
[0029] wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, wherein the variable heavy chain (VH) domain sequence comprises complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, and the variable light chain (VL) domain sequence comprises complementarity determining regions LCDR1, LCDR2 and LCDR3,
[0030] These six CDRs are CDRs of antibodies 1348, 1349, 1540, 1548 or 1550.
[0031] In one embodiment, the present invention provides an anti-Oxa-23 antibody,
[0032] wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, wherein the variable heavy chain (VH) domain sequence comprises complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, and the variable light chain (VL) domain sequence comprises complementarity determining regions LCDR1, LCDR2 and LCDR3,
[0033] These six CDRs are CDRs of antibodies 1348, 1349, 1540, 1548 or 1550.
[0034] In one embodiment, the antibody has 6 CDRs of antibody 1348.
[0035] In one embodiment, the antibody has 6 CDRs of antibody 1349.
[0036] In one embodiment, the antibody has 6 CDRs of antibody 1540.
[0037] In one embodiment, the antibody has 6 CDRs of antibody 1548.
[0038] In one embodiment, the antibody has 6 CDRs of antibody 1550.
[0039] In one embodiment, the antibody specifically binds Oxa-23 at the surface of Acinetobacter baumannii bacteria and induces complement activation (e.g., as measured by a flow cytometry-based assay), and
[0040] The variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence comprise the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence of antibody 1348, 1349, 1540, 1548 or 1550, respectively, optionally with 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs) in the variable heavy chain (VH) domain sequence, and optionally with 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs) in the variable light chain (VL) domain sequence.
[0041] In one embodiment, the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and wherein the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence comprise the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence of antibody 1348, 1349, 1540, 1548 or 1550, respectively, optionally with 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs) in the variable heavy chain (VH) domain sequence, and optionally with 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs) in the variable light chain (VL) domain sequence.
[0042] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1348 and the variable light chain (VL) domain sequence of antibody 1348, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0043] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1349 and the variable light chain (VL) domain sequence of antibody 1349, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR).
[0044] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1540 and the variable light chain (VL) domain sequence of antibody 1540, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0045] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1548 and the variable light chain (VL) domain sequence of antibody 1548, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0046] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1550 and the variable light chain (VL) domain sequence of antibody 1550, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0047] In one embodiment, the antibody specifically binds Oxa-23 at the surface of Acinetobacter baumannii bacteria and induces complement activation (e.g., as measured by a flow cytometry-based assay), and
[0048] The antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and wherein the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence comprise a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence of antibody 1348, 1349, 1540, 1548 or 1550, respectively,
[0049] Provided that the antibody has the CDRs of antibody 1348, 1349, 1540, 1548 or 1550, respectively.
[0050] In one embodiment, the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and wherein the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence comprise a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence of antibody 1348, 1349, 1540, 1548 or 1550, respectively,
[0051] Provided that the antibody has the CDRs of antibody 1348, 1349, 1540, 1548 or 1550, respectively.
[0052] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1348, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1348, provided that the antibody has the CDRs of antibody 1348.
[0053] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1349, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1349, provided that the antibody has the CDRs of antibody 1349.
[0054] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1540, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1540, provided that the antibody has the CDRs of antibody 1540.
[0055] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1548, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1548, provided that the antibody has the CDRs of antibody 1548.
[0056] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1550, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1550, provided that the antibody has the CDRs of antibody 1550.
[0057] In one embodiment, the present invention provides an antibody that specifically binds to Oxa-23 on the surface of Acinetobacter baumannii bacteria.
[0058] wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and wherein the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence comprise the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence of antibodies 1348, 1349, 1540, 1548 or 1550, respectively.
[0059] In one embodiment, the antibody specifically binds Oxa-23 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1348.
[0060] In one embodiment, the antibody specifically binds Oxa-23 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1349.
[0061] In one embodiment, the antibody specifically binds Oxa-23 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1540.
[0062] In one embodiment, the antibody specifically binds Oxa-23 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1548.
[0063] In one embodiment, the antibody specifically binds Oxa-23 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1550.
[0064] In one embodiment, the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and wherein the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence comprise the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence of antibody 1348, 1349, 1540, 1548 or 1550, respectively.
[0065] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1348.
[0066] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1349.
[0067] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1540.
[0068] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1548.
[0069] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1550.
[0070] In one example, the antibody is selected from the group consisting of antibodies 1348, 1349, 1540, 1548 or 1550.
[0071] In one embodiment, the antibody is antibody 1348.
[0072] In one embodiment, the antibody is antibody 1349.
[0073] In one embodiment, the antibody is antibody 1540.
[0074] In one embodiment, the antibody is antibody 1548.
[0075] In one embodiment, the antibody is antibody 1550.
[0076] Antibodies that bind to the same epitope on Oxa-23 as the antibodies described anywhere herein are provided.
[0077] Antibodies that bind to the same epitope as antibody 1348, 1349, 1540, 1548, or 1550 (eg, as defined by their VH and VL sequences) are provided.
[0078] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1348 (eg, defined by its VH and VL sequences).
[0079] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1349 (eg, as defined by its VH and VL sequences).
[0080] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1540 (eg, defined by its VH and VL sequences).
[0081] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1548 (eg, defined by its VH and VL sequences).
[0082] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1550 (eg, defined by its VH and VL sequences).
[0083] The antibody can be contacted with Oxa-23 having a footprint that fully or partially overlaps with the footprint of an antibody disclosed anywhere herein. Competition between antibodies can be determined, for example, using SPR, as described elsewhere herein, and antibodies that compete with the IgG antibodies described anywhere herein for binding to Oxa-23 (compete for binding to their epitopes) can be provided.
[0084] An antibody of the invention can be one that competes for binding to Oxa-23 with any of the anti-Oxa-23 antibodies described herein (such as antibodies 1348, 1349, 1540, 1548, and 1550, eg, as defined by their respective VH and VL sequences).
[0085] The antibody of the present invention may be an antibody that competes with antibody 1348 for binding to Oxa-23.
[0086] The antibody of the present invention may be an antibody that competes with antibody 1349 for binding to Oxa-23.
[0087] The antibody of the present invention may be an antibody that competes with antibody 1540 for binding to Oxa-23.
[0088] The antibody of the present invention may be an antibody that competes with antibody 1548 for binding to Oxa-23.
[0089] The antibody of the present invention may be an antibody that competes with antibody 1550 for binding to Oxa-23.
[0090] The nucleic acid sequences provided by the present invention may comprise sequences encoding the VH domain and / or VL domain of an anti-Oxa-23 antibody as defined anywhere herein.
[0091] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1348.
[0092] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1349.
[0093] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1540.
[0094] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1548.
[0095] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1550.
[0096] 3.2 Anti-OC1 LOS Antibody
[0097] Provided herein are antibodies that specifically bind to OC1 lipooligosaccharide (LOS).For example, antibodies 1042, 1043, 1403, 1405, 1407, 1408, and 1413 exemplified herein have been found to specifically bind to OC1 LOS on the surface of Acinetobacter baumannii bacteria.
[0098] The present invention provides an antibody that specifically binds to OC1 LOS on the surface of Acinetobacter baumannii bacteria, such as on live bacteria. In one embodiment, the antibody specifically binds to OC1 LOS on the surface of Acinetobacter baumannii bacteria, as measured by an indirect whole-bacterial cell ELISA. Because the outer membrane vesicles (OMVs) of Acinetobacter baumannii bacteria are highly related to live Acinetobacter baumannii bacteria, it has been found that such antibodies also specifically bind to OC1 LOS on the outer membrane vesicles (OMVs) of Acinetobacter baumannii bacteria.
[0099] In one embodiment, the antibody induces complement activation (eg, as measured by a flow cytometry-based assay).
[0100] In one embodiment, the antibody specifically binds OC1LOS at the surface of Acinetobacter baumannii bacteria and induces complement activation (e.g., as measured by a flow cytometry-based assay), and the HCDR3 is the HCDR3 of antibody 1042, 1043, 1403, 1405, 1407, 1408, or 1413.
[0101] In one embodiment, the antibody comprises a variable heavy chain (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2, and HCDR3, and a variable light chain (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2, and LCDR3,
[0102] wherein HCDR3 is HCDR3 of antibody 1042, 1043, 1403, 1405, 1407, 1408 or 1413.
[0103] In one embodiment, the HCDR3 is HCDR3 of antibody 1042.
[0104] In one embodiment, the HCDR3 is HCDR3 of antibody 1043.
[0105] In one embodiment, the HCDR3 is HCDR3 of antibody 1403.
[0106] In one embodiment, the HCDR3 is the HCDR3 of antibody 1405.
[0107] In one embodiment, the HCDR3 is HCDR3 of antibody 1407.
[0108] In one embodiment, the HCDR3 is the HCDR3 of antibody 1408.
[0109] In one embodiment, the HCDR3 is HCDR3 of antibody 1413.
[0110] In one embodiment, the present invention provides an anti-OC1 LOS antibody,
[0111] wherein the antibody specifically binds to OC1 LOS at the surface of Acinetobacter baumannii bacteria and induces complement activation (e.g., as measured by a flow cytometry-based assay), and
[0112] wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, wherein the variable heavy chain (VH) domain sequence comprises complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, and the variable light chain (VL) domain sequence comprises complementarity determining regions LCDR1, LCDR2 and LCDR3,
[0113] These six CDRs are CDRs of antibodies 1042, 1043, 1403, 1405, 1407, 1408 or 1413.
[0114] In one embodiment, the present invention provides an anti-OC1 LOS antibody,
[0115] wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, wherein the variable heavy chain (VH) domain sequence comprises complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, and the variable light chain (VL) domain sequence comprises complementarity determining regions LCDR1, LCDR2 and LCDR3,
[0116] These six CDRs are CDRs of antibodies 1042, 1043, 1403, 1405, 1407, 1408 or 1413.
[0117] In one embodiment, the antibody has 6 CDRs of antibody 1042.
[0118] In one embodiment, the antibody has 6 CDRs of antibody 1043.
[0119] In one embodiment, the antibody has 6 CDRs of antibody 1403.
[0120] In one embodiment, the antibody has 6 CDRs of antibody 1405.
[0121] In one embodiment, the antibody has 6 CDRs of antibody 1407.
[0122] In one embodiment, the antibody has 6 CDRs of antibody 1408.
[0123] In one embodiment, the antibody has 6 CDRs of antibody 1413.
[0124] In one embodiment, the antibody specifically binds OC1LOS at the surface of Acinetobacter baumannii bacteria and induces complement activation (e.g., as measured by a flow cytometry-based assay), and
[0125] The variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence comprise the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence of antibody 1042, 1043, 1403, 1405, 1407, 1408 or 1413, respectively, optionally with 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs) in the variable heavy chain (VH) domain sequence, and optionally with 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs) in the variable light chain (VL) domain sequence.
[0126] In one embodiment, the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and wherein the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence comprise the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence of antibody 1042, 1043, 1403, 1405, 1407, 1408 or 1413, respectively, optionally with 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs) in the variable heavy chain (VH) domain sequence, and optionally with 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs) in the variable light chain (VL) domain sequence.
[0127] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1042 and the variable light chain (VL) domain sequence of antibody 1042, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0128] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1043 and the variable light chain (VL) domain sequence of antibody 1043, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR).
[0129] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1403 and the variable light chain (VL) domain sequence of antibody 1403, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR).
[0130] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1405 and the variable light chain (VL) domain sequence of antibody 1405, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0131] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1407 and the variable light chain (VL) domain sequence of antibody 1407, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR).
[0132] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1408 and the variable light chain (VL) domain sequence of antibody 1408, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0133] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1413 and the variable light chain (VL) domain sequence of antibody 1413, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR).
[0134] In one embodiment, the antibody specifically binds OC1 LOS at the surface of Acinetobacter baumannii and induces complement activation (e.g., as measured by a flow cytometry-based assay), and
[0135] The antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and wherein the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence comprise a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence of antibody 1042, 1043, 1403, 1405, 1407, 1408 or 1413, respectively,
[0136] Provided that the antibody has six CDRs of antibody 1042, 1043, 1403, 1405, 1407, 1408 or 1413, respectively.
[0137] In one embodiment, the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and wherein the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence comprise a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence of antibody 1042, 1043, 1403, 1405, 1407, 1408 or 1413, respectively,
[0138] Provided that the antibody has six CDRs of antibody 1042, 1043, 1403, 1405, 1407, 1408 or 1413, respectively.
[0139] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1042, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1042, provided that the antibody has 6 CDRs of antibody 1042.
[0140] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1043, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1043, provided that the antibody has 6 CDRs of antibody 1043.
[0141] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1403, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1403, provided that the antibody has 6 CDRs of antibody 1403.
[0142] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1405, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1405, provided that the antibody has 6 CDRs of antibody 1405.
[0143] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1407, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1407, provided that the antibody has 6 CDRs of antibody 1407.
[0144] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1408, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1408, provided that the antibody has 6 CDRs of antibody 1408.
[0145] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1413, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1413, provided that the antibody has 6 CDRs of antibody 1413.
[0146] In one embodiment, the present invention provides an antibody that specifically binds to OC1 LOS on the surface of Acinetobacter baumannii bacteria,
[0147] wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and wherein the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence comprise the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence of antibody 1042, 1043, 1403, 1405, 1407, 1408 or 1413, respectively.
[0148] In one embodiment, the antibody specifically binds OC1 LOS at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1042.
[0149] In one embodiment, the antibody specifically binds OC1 LOS at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1043.
[0150] In one embodiment, the antibody specifically binds OC1 LOS at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1403.
[0151] In one embodiment, the antibody specifically binds OC1LOS at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1405.
[0152] In one embodiment, the antibody specifically binds OC1LOS at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1407.
[0153] In one embodiment, the antibody specifically binds OC1LOS at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1408.
[0154] In one embodiment, the antibody specifically binds OC1LOS at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1413.
[0155] In one embodiment, the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and wherein the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence comprise the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence of antibody 1042, 1043, 1403, 1405, 1407, 1408 or 1413, respectively.
[0156] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1042.
[0157] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1043.
[0158] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1403.
[0159] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1405.
[0160] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1407.
[0161] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1408.
[0162] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1413.
[0163] In one example, the antibody is selected from the group consisting of antibodies 1042, 1043, 1403, 1405, 1407, 1408 and 1413.
[0164] In one embodiment, the antibody is antibody 1042.
[0165] In one embodiment, the antibody is antibody 1043.
[0166] In one embodiment, the antibody is antibody 1403.
[0167] In one embodiment, the antibody is antibody 1405.
[0168] In one embodiment, the antibody is antibody 1407.
[0169] In one embodiment, the antibody is antibody 1408.
[0170] In one embodiment, the antibody is antibody 1413.
[0171] Antibodies that bind to the same epitope on OC1 LOS as the antibodies described anywhere herein are provided.
[0172] Antibodies that bind to the same epitope as antibody 1042, 1043, 1403, 1405, 1407, 1408, or 1413 (eg, as defined by their VH and VL sequences) are provided.
[0173] In one embodiment, an antibody that binds to the same epitope as antibody 1042 is provided.
[0174] In one embodiment, an antibody that binds to the same epitope as antibody 1043 is provided.
[0175] In one embodiment, an antibody that binds to the same epitope as antibody 1403 is provided.
[0176] In one embodiment, an antibody that binds to the same epitope as antibody 1405 is provided.
[0177] In one embodiment, an antibody that binds to the same epitope as antibody 1407 is provided.
[0178] In one embodiment, an antibody that binds to the same epitope as antibody 1408 is provided.
[0179] In one embodiment, an antibody that binds to the same epitope as antibody 1413 is provided.
[0180] The antibody can be contacted with OC1 LOS having a footprint that fully or partially overlaps with the footprint of an antibody disclosed anywhere herein. Competition between antibodies can be determined, for example, using SPR, as described elsewhere herein, and antibodies that compete with the IgG antibodies described anywhere herein for binding to OC1 LOS (compete for binding to their epitopes) can be provided.
[0181] An antibody of the invention can be an antibody that competes with any anti-OC1 LOS antibody described herein (such as antibodies 1042, 1043, 1403, 1405, 1407, 1408, and 1413, e.g., defined by their VH and VL sequences) for binding to OC1 LOS at the surface of Acinetobacter baumannii bacteria.
[0182] The antibody of the present invention may be an antibody that competes with antibody 1042 for binding to OC1 LOS.
[0183] The antibody of the present invention may be an antibody that competes with antibody 1043 for binding to OC1 LOS.
[0184] The antibody of the present invention may be an antibody that competes with antibody 1403 for binding to OC1 LOS.
[0185] The antibody of the present invention may be an antibody that competes with antibody 1405 for binding to OC1 LOS.
[0186] The antibody of the present invention may be an antibody that competes with antibody 1407 for binding to OC1 LOS.
[0187] The antibody of the present invention may be an antibody that competes with antibody 1408 for binding to OC1 LOS.
[0188] The antibody of the present invention may be an antibody that competes with antibody 1413 for binding to OC1 LOS.
[0189] The nucleic acid sequence provided by the present invention may comprise a sequence encoding the VH domain and / or VL domain of an anti-OC1LOS antibody as defined anywhere herein.
[0190] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1042.
[0191] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1043.
[0192] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1403.
[0193] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1405.
[0194] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1407.
[0195] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1408.
[0196] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1413.
[0197] 3.3 Anti-KL49 Antibody
[0198] Provided herein are antibodies that specifically bind to KL49. For example, antibodies 1345, 1347, 1350, 1351, 1363, 1364, 1397, 1398, 1400, 1401, 1402, 1404, 1409, 1410, 1412, 1414, 1415, and 1416, exemplified herein, have been found to specifically bind to KL49 on the surface of Acinetobacter baumannii bacteria.
[0199] The invention provides an antibody that specifically binds KL49 on the surface of acinetobacter baumannii bacteria, such as on, for example, live bacteria. In one embodiment, the antibody specifically binds KL49 on the surface of acinetobacter baumannii bacteria, as measured by an indirect whole-bacteria cell ELISA. Due to the high correlation between the outer membrane vesicles (OMV) of acinetobacter baumannii bacteria and live acinetobacter baumannii bacteria, it has been found that this type of antibody also specifically binds the KL49 on the outer membrane vesicles (OMV) of acinetobacter baumannii bacteria.
[0200] In one embodiment, the antibody induces complement activation (eg, as measured by a flow cytometry-based assay).
[0201] In one embodiment, the antibody specifically binds KL49 at the surface of Acinetobacter baumannii and induces complement activation (e.g., as measured by a flow cytometry-based assay), and the HCDR3 is the HCDR3 of antibody 1345, 1347, 1350, 1351, 1363, 1364, 1397, 1398, 1400, 1401, 1402, 1404, 1409, 1410, 1412, 1414, 1415 or 1416.
[0202] In one embodiment, the antibody comprises a variable heavy chain (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2, and HCDR3, and a variable light chain (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2, and LCDR3,
[0203] wherein the HCDR3 is the HCDR3 of antibody 1345, 1347, 1350, 1351, 1363, 1364, 1397, 1398, 1400, 1401, 1402, 1404, 1409, 1410, 1412, 1414, 1415 or 1416.
[0204] In one embodiment, the HCDR3 is HCDR3 of antibody 1345.
[0205] In one embodiment, the HCDR3 is HCDR3 of antibody 1347.
[0206] In one embodiment, the HCDR3 is HCDR3 of antibody 1350.
[0207] In one embodiment, the HCDR3 is HCDR3 of antibody 1351.
[0208] In one embodiment, the HCDR3 is HCDR3 of antibody 1363.
[0209] In one embodiment, the HCDR3 is HCDR3 of antibody 1364.
[0210] In one embodiment, the HCDR3 is HCDR3 of antibody 1397.
[0211] In one embodiment, the HCDR3 is HCDR3 of antibody 1398.
[0212] In one embodiment, the HCDR3 is the HCDR3 of antibody 1400.
[0213] In one embodiment, the HCDR3 is the HCDR3 of antibody 1401.
[0214] In one embodiment, the HCDR3 is the HCDR3 of antibody 1402.
[0215] In one embodiment, the HCDR3 is the HCDR3 of antibody 1404.
[0216] In one embodiment, the HCDR3 is the HCDR3 of antibody 1409.
[0217] In one embodiment, the HCDR3 is the HCDR3 of antibody 1410.
[0218] In one embodiment, the HCDR3 is the HCDR3 of antibody 1412.
[0219] In one embodiment, the HCDR3 is HCDR3 of antibody 1414.
[0220] In one embodiment, the HCDR3 is HCDR3 of antibody 1415.
[0221] In one embodiment, the HCDR3 is HCDR3 of antibody 1416.
[0222] In one embodiment, the present invention provides an anti-KL49 antibody,
[0223] wherein the antibody specifically binds KL49 at the surface of Acinetobacter baumannii bacteria and induces complement activation (e.g., as measured by a flow cytometry-based assay), and
[0224] wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, wherein the variable heavy chain (VH) domain sequence comprises complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, and the variable light chain (VL) domain sequence comprises complementarity determining regions LCDR1, LCDR2 and LCDR3,
[0225] Among them, these 6 CDRs are CDRs of antibodies 1345, 1347, 1350, 1351, 1363, 1364, 1397, 1398, 1400, 1401, 1402, 1404, 1409, 1410, 1412, 1414, 1415 or 1416.
[0226] In one embodiment, the present invention provides an anti-KL49 antibody,
[0227] wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, wherein the variable heavy chain (VH) domain sequence comprises complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, and the variable light chain (VL) domain sequence comprises complementarity determining regions LCDR1, LCDR2 and LCDR3,
[0228] Among them, these 6 CDRs are CDRs of antibodies 1345, 1347, 1350, 1351, 1363, 1364, 1397, 1398, 1400, 1401, 1402, 1404, 1409, 1410, 1412, 1414, 1415 or 1416.
[0229] In one embodiment, the antibody has 6 CDRs of antibody 1345.
[0230] In one embodiment, the antibody has 6 CDRs of antibody 1347.
[0231] In one embodiment, the antibody has 6 CDRs of antibody 1350.
[0232] In one embodiment, the antibody has 6 CDRs of antibody 1351.
[0233] In one embodiment, the antibody has 6 CDRs of antibody 1363.
[0234] In one embodiment, the antibody has 6 CDRs of antibody 1364.
[0235] In one embodiment, the antibody has 6 CDRs of antibody 1397.
[0236] In one embodiment, the antibody has 6 CDRs of antibody 1398.
[0237] In one embodiment, the antibody has 6 CDRs of antibody 1400.
[0238] In one embodiment, the antibody has 6 CDRs of antibody 1401.
[0239] In one embodiment, the antibody has 6 CDRs of antibody 1402.
[0240] In one embodiment, the antibody has 6 CDRs of antibody 1404.
[0241] In one embodiment, the antibody has 6 CDRs of antibody 1409.
[0242] In one embodiment, the antibody has 6 CDRs of antibody 1410.
[0243] In one embodiment, the antibody has 6 CDRs of antibody 1412.
[0244] In one embodiment, the antibody has 6 CDRs of antibody 1414.
[0245] In one embodiment, the antibody has 6 CDRs of antibody 1415.
[0246] In one embodiment, the antibody has 6 CDRs of antibody 1416.
[0247] In one embodiment, the antibody specifically binds KL49 at the surface of Acinetobacter baumannii bacteria and induces complement activation (e.g., as measured by a flow cytometry-based assay), and
[0248] The variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence comprise the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence of antibody 1345, 1347, 1350, 1351, 1363, 1364, 1397, 1398, 1400, 1401, 1402, 1404, 1409, 1410, 1412, 1414, 1415 or 1416, respectively, optionally with 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs) in the variable heavy chain (VH) domain sequence, and optionally with 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs) in the variable light chain (VL) domain sequence.
[0249] In one embodiment, the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and wherein the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence comprise the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence of antibody 1345, 1347, 1350, 1351, 1363, 1364, 1397, 1398, 1400, 1401, 1402, 1404, 1409, 1410, 1412, 1414, 1415 or 1416, respectively, optionally with 1, 2, 3, 4 or 5 amino acid alterations outside the complementarity determining regions (CDRs) in the variable heavy chain (VH) domain sequence, and optionally with 1, 2, 3, 4 or 5 amino acid alterations outside the complementarity determining regions (CDRs) in the variable light chain (VL) domain sequence.
[0250] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1345 and the variable light chain (VL) domain sequence of antibody 1345, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0251] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1347 and the variable light chain (VL) domain sequence of antibody 1347, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR).
[0252] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1350 and the variable light chain (VL) domain sequence of antibody 1350, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0253] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1351 and the variable light chain (VL) domain sequence of antibody 1351, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR).
[0254] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1363 and the variable light chain (VL) domain sequence of antibody 1363, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR).
[0255] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1364 and the variable light chain (VL) domain sequence of antibody 1364, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0256] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1397 and the variable light chain (VL) domain sequence of antibody 1397, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR).
[0257] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1398 and the variable light chain (VL) domain sequence of antibody 1398, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR).
[0258] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1400 and the variable light chain (VL) domain sequence of antibody 1400, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0259] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1401 and the variable light chain (VL) domain sequence of antibody 1401, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining region (CDR).
[0260] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1402 and the variable light chain (VL) domain sequence of antibody 1402, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0261] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1404 and the variable light chain (VL) domain sequence of antibody 1404, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0262] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1409 and the variable light chain (VL) domain sequence of antibody 1409, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0263] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1410 and the variable light chain (VL) domain sequence of antibody 1410, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0264] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1412 and the variable light chain (VL) domain sequence of antibody 1412, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0265] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1414 and the variable light chain (VL) domain sequence of antibody 1414, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0266] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1415 and the variable light chain (VL) domain sequence of antibody 1415, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0267] In one embodiment, the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1416 and the variable light chain (VL) domain sequence of antibody 1416, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0268] In one embodiment, the antibody specifically binds KL49 at the surface of Acinetobacter baumannii bacteria and induces complement activation (e.g., as measured by a flow cytometry-based assay), and the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and wherein the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence comprise a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence of antibody 1345, 1347, 1350, 1351, 1363, 1364, 1397, 1398, 1400, 1401, 1402, 1404, 1409, 1410, 1412, 1414, 1415, or 1416, respectively,
[0269] Provided that the antibody has six CDRs of antibody 1345, 1347, 1350, 1351, 1363, 1364, 1397, 1398, 1400, 1401, 1402, 1404, 1409, 1410, 1412, 1414, 1415 or 1416, respectively.
[0270] In one embodiment, the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and wherein the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence respectively comprise the same sequence as antibody 1345, 1347, 1350, 1351, 1363, 1364, 1397, 1398, 1400, 1401, 1402, 1404, 1409, 1410, 1412, 1414, 1415 or 1416. The antibody comprises a variable heavy (VH) domain sequence and a variable light (VL) domain sequence that are at least 90%, at least 95%, at least 98% or at least 99% identical to the sequence of antibody 1345, 1347, 1350, 1351, 1363, 1364, 1397, 1398, 1400, 1401, 1402, 1404, 1409, 1410, 1412, 1414, 1415 or 1416, respectively.
[0271] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1345, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1345, provided that the antibody has 6 CDRs of antibody 1345.
[0272] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1347, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1347, provided that the antibody has 6 CDRs of antibody 1347.
[0273] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1350, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1350, provided that the antibody has 6 CDRs of antibody 1350.
[0274] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1351, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1351, provided that the antibody has 6 CDRs of antibody 1351.
[0275] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1363, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1363, provided that the antibody has 6 CDRs of antibody 1363.
[0276] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1364, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1364, provided that the antibody has 6 CDRs of antibody 1364.
[0277] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1397, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1397, provided that the antibody has 6 CDRs of antibody 1397.
[0278] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to the VH domain sequence of antibody 1398, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to the VL domain sequence of antibody 1398, provided that the antibody has 6 CDRs of antibody 1398.
[0279] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1400, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1400, provided that the antibody has 6 CDRs of antibody 1400.
[0280] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1401, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1401, provided that the antibody has 6 CDRs of antibody 1401.
[0281] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1402, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1402, provided that the antibody has 6 CDRs of antibody 1402.
[0282] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1404, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1404, provided that the antibody has 6 CDRs of antibody 1404.
[0283] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1409, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1409, provided that the antibody has 6 CDRs of antibody 1409.
[0284] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1410, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1410, provided that the antibody has 6 CDRs of antibody 1410.
[0285] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1412, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1412, provided that the antibody has 6 CDRs of antibody 1412.
[0286] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1414, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1414, provided that the antibody has 6 CDRs of antibody 1414.
[0287] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1415, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1415, provided that the antibody has 6 CDRs of antibody 1415.
[0288] In one embodiment, the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VH domain sequence of antibody 1416, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98%, or at least 99% identical to the VL domain sequence of antibody 1416, provided that the antibody has 6 CDRs of antibody 1416.
[0289] In one embodiment, the present invention provides an antibody that specifically binds to KL49 on the surface of Acinetobacter baumannii bacteria,
[0290] wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and wherein the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence comprise the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence of antibody 1345, 1347, 1350, 1351, 1363, 1364, 1397, 1398, 1400, 1401, 1402, 1404, 1409, 1410, 1412, 1414, 1415 or 1416, respectively.
[0291] In one embodiment, the antibody specifically binds KL49 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1345.
[0292] In one embodiment, the antibody specifically binds KL49 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1347.
[0293] In one embodiment, the antibody specifically binds KL49 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1350.
[0294] In one embodiment, the antibody specifically binds KL49 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1351.
[0295] In one embodiment, the antibody specifically binds KL49 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1363.
[0296] In one embodiment, the antibody specifically binds KL49 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1364.
[0297] In one embodiment, the antibody specifically binds KL49 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1397.
[0298] In one embodiment, the antibody specifically binds KL49 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1398.
[0299] In one embodiment, the antibody specifically binds KL49 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1400.
[0300] In one embodiment, the antibody specifically binds KL49 on the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1401.
[0301] In one embodiment, the antibody specifically binds KL49 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1402.
[0302] In one embodiment, the antibody specifically binds KL49 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1404.
[0303] In one embodiment, the antibody specifically binds KL49 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1409.
[0304] In one embodiment, the antibody specifically binds KL49 on the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1410.
[0305] In one embodiment, the antibody specifically binds KL49 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1412.
[0306] In one embodiment, the antibody specifically binds KL49 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1414.
[0307] In one embodiment, the antibody specifically binds KL49 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1415.
[0308] In one embodiment, the antibody specifically binds KL49 at the surface of Acinetobacter baumannii bacteria, wherein the antibody comprises the VH and VL domain sequences of antibody 1416.
[0309] In one embodiment, the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and wherein the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence comprise the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence of antibody 1345, 1347, 1350, 1351, 1363, 1364, 1397, 1398, 1400, 1401, 1402, 1404, 1409, 1410, 1412, 1414, 1415 or 1416, respectively.
[0310] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1345.
[0311] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1347.
[0312] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1350.
[0313] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1351.
[0314] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1363.
[0315] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1364.
[0316] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1397.
[0317] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1398.
[0318] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1400.
[0319] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1401.
[0320] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1402.
[0321] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1404.
[0322] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1409.
[0323] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1410.
[0324] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1412.
[0325] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1414.
[0326] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1415.
[0327] In one embodiment, the antibody comprises the VH domain sequence and VL domain sequence of antibody 1416.
[0328] In one example, the antibody is selected from the group consisting of antibodies 1345, 1347, 1350, 1351, 1363, 1364, 1397, 1398, 1400, 1401, 1402, 1404, 1409, 1410, 1412, 1414, 1415 and 1416.
[0329] In one embodiment, the antibody is antibody 1345.
[0330] In one embodiment, the antibody is antibody 1347.
[0331] In one embodiment, the antibody is antibody 1350.
[0332] In one embodiment, the antibody is antibody 1351.
[0333] In one embodiment, the antibody is antibody 1363.
[0334] In one embodiment, the antibody is antibody 1364.
[0335] In one embodiment, the antibody is antibody 1397.
[0336] In one embodiment, the antibody is antibody 1398.
[0337] In one embodiment, the antibody is antibody 1400.
[0338] In one embodiment, the antibody is antibody 1401.
[0339] In one embodiment, the antibody is antibody 1402.
[0340] In one embodiment, the antibody is antibody 1404.
[0341] In one embodiment, the antibody is antibody 1409.
[0342] In one embodiment, the antibody is antibody 1410.
[0343] In one embodiment, the antibody is antibody 1412.
[0344] In one embodiment, the antibody is antibody 1414.
[0345] In one embodiment, the antibody is antibody 1415.
[0346] In one embodiment, the antibody is antibody 1416.
[0347] Antibodies that bind to the same epitope on KL49 as the antibodies described anywhere herein are provided.
[0348] Antibodies that bind to the same epitope as antibody 1345, 1347, 1350, 1351, 1363, 1364, 1397, 1398, 1400, 1401, 1402, 1404, 1409, 1410, 1412, 1414, 1415, or 1416 (e.g., defined by their VH and VL sequences) are provided.
[0349] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1345 (eg, as defined by its VH and VL sequences).
[0350] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1347 (eg, as defined by its VH and VL sequences).
[0351] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1350 (eg, as defined by its VH and VL sequences).
[0352] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1351 (eg, as defined by its VH and VL sequences).
[0353] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1363 (eg, as defined by its VH and VL sequences).
[0354] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1364 (eg, as defined by its VH and VL sequences).
[0355] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1397 (eg, as defined by its VH and VL sequences).
[0356] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1398 (eg, as defined by its VH and VL sequences).
[0357] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1400 (eg, defined by its VH and VL sequences).
[0358] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1401 (eg, defined by its VH and VL sequences).
[0359] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1402 (eg, defined by its VH and VL sequences).
[0360] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1404 (eg, defined by its VH and VL sequences).
[0361] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1409 (eg, as defined by its VH and VL sequences).
[0362] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1410 (eg, defined by its VH and VL sequences).
[0363] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1412 (eg, defined by its VH and VL sequences).
[0364] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1414 (eg, defined by its VH and VL sequences).
[0365] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1415 (eg, defined by its VH and VL sequences).
[0366] In one embodiment, an antibody is provided that binds to the same epitope as antibody 1416 (eg, defined by its VH and VL sequences).
[0367] The antibody can be contacted with KL49 having a footprint that completely or partially overlaps with the footprint of an antibody disclosed anywhere herein. Competition between antibodies can be determined, for example, using SPR, as described elsewhere herein, and antibodies that compete with the IgG antibodies described anywhere herein for binding to KL49 (compete for binding to their epitopes) can be provided.
[0368] The antibodies of the invention may be antibodies that compete for binding to KL49 with any of the anti-KL49 antibodies described herein (such as antibodies 1345, 1347, 1350, 1351, 1363, 1364, 1397, 1398, 1400, 1401, 1402, 1404, 1409, 1410, 1412, 1414, 1415, and 1416, e.g., as defined by their respective VH and VL sequences).
[0369] The antibody of the present invention may be an antibody that competes with antibody 1345 for binding to KL49.
[0370] The antibody of the present invention may be an antibody that competes with antibody 1347 for binding to KL49.
[0371] The antibody of the present invention may be an antibody that competes with antibody 1350 for binding to KL49.
[0372] The antibody of the present invention may be an antibody that competes with antibody 1351 for binding to KL49.
[0373] The antibody of the present invention may be an antibody that competes with antibody 1363 for binding to KL49.
[0374] The antibody of the present invention may be an antibody that competes with antibody 1364 for binding to KL49.
[0375] The antibody of the present invention may be an antibody that competes with antibody 1397 for binding to KL49.
[0376] The antibody of the present invention may be an antibody that competes with antibody 1398 for binding to KL49.
[0377] The antibody of the present invention may be an antibody that competes with antibody 1400 for binding to KL49.
[0378] The antibody of the present invention may be an antibody that competes with antibody 1401 for binding to KL49.
[0379] The antibody of the present invention may be an antibody that competes with antibody 1402 for binding to KL49.
[0380] The antibody of the present invention may be an antibody that competes with antibody 1404 for binding to KL49.
[0381] The antibody of the present invention may be an antibody that competes with antibody 1409 for binding to KL49.
[0382] The antibody of the present invention may be an antibody that competes with antibody 1410 for binding to KL49.
[0383] The antibody of the present invention may be an antibody that competes with antibody 1412 for binding to KL49.
[0384] The antibody of the present invention may be an antibody that competes with antibody 1414 for binding to KL49.
[0385] The antibody of the present invention may be an antibody that competes with antibody 1415 for binding to KL49.
[0386] The antibody of the present invention may be an antibody that competes with antibody 1416 for binding to KL49.
[0387] The nucleic acid sequence provided by the present invention may comprise a sequence encoding the VH domain and / or VL domain of an anti-KL49 antibody as defined anywhere herein.
[0388] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1345.
[0389] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1347.
[0390] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1350.
[0391] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1351.
[0392] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1363.
[0393] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1364.
[0394] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1397.
[0395] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1398.
[0396] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1400.
[0397] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1401.
[0398] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1402.
[0399] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1404.
[0400] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1409.
[0401] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1410.
[0402] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1412.
[0403] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1414.
[0404] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1415.
[0405] The nucleic acid may comprise a sequence encoding the VH domain and / or VL domain of antibody 1416.
[0406] 3.4 Antibodies—Overview
[0407] In one embodiment, the antibody as defined anywhere herein exhibits complement dependent cytotoxicity (CDC) activity.
[0408] An antibody as defined anywhere herein may be human IgG1 or human IgG4. In one embodiment, the antibody is human IgG1. In one embodiment, the antibody is human IgG1 comprising the constant region sequence of SEQ ID NO: 418. In one embodiment, the antibody is human IgG4. In one embodiment, the antibody is human IgG4 comprising the constant region sequence of SEQ ID NO: 436.
[0409] An antibody as defined anywhere herein may be human IgAl (eg, comprising the constant region sequence of SEQ ID NO: 484) or human IgA2 (eg, comprising the constant region sequence of SEQ ID NO: 485).
[0410] The antibody as defined anywhere herein may comprise a kappa light chain constant region, preferably the constant domain sequence SEQ ID NO: 448. The present invention provides a vector comprising a nucleic acid as defined anywhere herein; optionally, wherein the vector is a CHO vector.
[0411] The present invention provides a host cell comprising a nucleic acid as defined anywhere herein or a vector as defined anywhere herein.
[0412] The present invention provides a pharmaceutical composition comprising an antibody as defined anywhere herein and a pharmaceutically acceptable excipient.
[0413] The present invention provides a pharmaceutical composition comprising an isolated nucleic acid encoding an antibody as defined anywhere herein, or an isolated nucleic acid as defined anywhere herein, and a pharmaceutically acceptable excipient.
[0414] In one embodiment, the pharmaceutical composition is formulated for administration by injection.
[0415] In one embodiment, the pharmaceutical composition is formulated for intravenous, intramuscular, or subcutaneous administration.
[0416] In one embodiment, the pharmaceutical composition further comprises at least one additional therapeutic agent.
[0417] In one embodiment, the additional therapeutic agent is at least one, preferably one or two, additional antibodies.
[0418] In one embodiment, the additional therapeutic agent is a carbapenem.
[0419] In one embodiment, the additional therapeutic agent is colistin.
[0420] In one embodiment, the pharmaceutical composition comprises a first antibody that specifically binds to Oxa-23 and a second antibody that specifically binds to OC1 LOS.
[0421] In one embodiment, the pharmaceutical composition comprises a first antibody that specifically binds Oxa-23 and a second antibody that specifically binds KL49.
[0422] In one embodiment, the pharmaceutical composition comprises a first antibody that specifically binds to OC1 LOS and a second antibody that specifically binds to KL49.
[0423] In one embodiment, the pharmaceutical composition comprises a first antibody that specifically binds to Oxa-23, a second antibody that specifically binds to OC1 LOS, and a third antibody that specifically binds to KL49.
[0424] The present invention provides a diagnostic kit comprising at least one antibody as defined herein. In one embodiment, the diagnostic kit comprises a first antibody that specifically binds to Oxa-23 and a second antibody that specifically binds to OC1 LOS. In one embodiment, the diagnostic kit comprises a first antibody that specifically binds to Oxa-23 and a second antibody that specifically binds to KL49. In one embodiment, the diagnostic kit comprises a first antibody that specifically binds to OC1 LOS and a second antibody that specifically binds to KL49. In one embodiment, the diagnostic kit comprises a first antibody that specifically binds to Oxa-23, a second antibody that specifically binds to OC1 LOS, and a third antibody that specifically binds to KL49.
[0425] The present invention provides a kit comprising a pharmaceutical composition as defined herein. In one embodiment, the kit further comprises at least one additional therapeutic agent. In one embodiment, the additional therapeutic agent is an additional pharmaceutical composition comprising at least one, preferably one or two, additional antibodies. In one embodiment, the kit further comprises a carbapenem. In one embodiment, the kit further comprises a colistin.
[0426] In one embodiment, the at least one additional antibody is selected from the group consisting of: an antibody that specifically binds Oxa-23, an antibody that specifically binds OC1 LOS, and an antibody that specifically binds KL49.
[0427] In one embodiment, the kit comprises a first antibody that specifically binds Oxa-23 and a second antibody that specifically binds OC1LOS.
[0428] In one embodiment, the kit comprises a first antibody that specifically binds Oxa-23 and a second antibody that specifically binds KL49.
[0429] In one embodiment, the kit comprises a first antibody that specifically binds to OC1 LOS and a second antibody that specifically binds to KL49.
[0430] In one embodiment, the kit comprises a first antibody that specifically binds to Oxa-23, a second antibody that specifically binds to OC1LOS, and a third antibody that specifically binds to KL49.
[0431] In one embodiment, the kit further comprises a label or instructions for preventing and / or treating bacterial infections caused by Acinetobacter baumannii in humans; optionally, the label or instructions include a marketing authorization number (e.g., FDA or EMA authorization number); optionally, the kit includes an IV device or injection device containing the antibody. Preferably, the antibody is contained in a sealed container.
[0432] Optionally, the kit comprises instructions for the simultaneous, separate or sequential administration of the therapeutic agents therein.
[0433] An antibody as defined anywhere herein or a composition as defined anywhere herein may be provided for use as a medicament.
[0434] An antibody as defined anywhere herein or a composition as defined anywhere herein may be provided for use in a method of treating a bacterial infection caused by Acinetobacter baumannii, the method comprising administering the antibody or composition to a patient.
[0435] An antibody as defined anywhere herein or a composition as defined anywhere herein may be provided for use in a method of preventing a bacterial infection caused by Acinetobacter baumannii, the method comprising administering the antibody or composition to a patient.
[0436] When an antibody that specifically binds to Oxa-23 as defined anywhere herein is administered to a patient, the presence of Oxa-23 may have been determined in a sample from that patient, although this is not necessary.
[0437] When an antibody that specifically binds to OC1 LOS as defined anywhere herein is administered to a patient, the presence of OC1 LOS may have been determined in a sample from that patient, although this is not necessary.
[0438] When an antibody that specifically binds KL49 as defined anywhere herein is administered to a patient, the presence of KL49 may have been determined in a sample from that patient, although this is not required.
[0439] Also provided is the use of an antibody as defined anywhere herein, or a composition as defined anywhere herein, in the manufacture of a medicament for use in a method of treating a bacterial infection caused by Acinetobacter baumannii.
[0440] Also provided is the use of an antibody as defined anywhere herein, or a composition as defined anywhere herein, in the manufacture of a medicament for use in a method of preventing a bacterial infection caused by Acinetobacter baumannii.
[0441] The present invention provides a method of treating a bacterial infection caused by Acinetobacter baumannii in a patient, the method comprising administering to the patient a therapeutically effective amount of an antibody as defined anywhere herein or a composition as defined anywhere herein.
[0442] The present invention provides a method of preventing a bacterial infection caused by Acinetobacter baumannii in a patient, the method comprising administering to the patient a therapeutically effective amount of an antibody as defined anywhere herein or a composition as defined anywhere herein.
[0443] In one embodiment, the bacterial infection caused by Acinetobacter baumannii is a nosocomial bacterial infection caused by Acinetobacter baumannii.
[0444] In one embodiment, the patient has a lower respiratory tract infection, such as pneumonia.
[0445] In one embodiment, the patient has sepsis.
[0446] In one embodiment, the patient has bacteremia.
[0447] In one embodiment, the method further comprises administering at least one additional therapeutic agent.
[0448] In one embodiment, the administration of the additional therapeutic agent is simultaneous, separate or sequential.
[0449] In one embodiment, the additional therapeutic agent is at least one, preferably one or two, additional antibodies.
[0450] In one embodiment, the method comprises administering a first antibody that specifically binds Oxa-23 and a second antibody that specifically binds OC1 LOS.
[0451] In one embodiment, the method comprises administering a first antibody that specifically binds Oxa-23 and a second antibody that specifically binds KL49.
[0452] In one embodiment, the method comprises administering a first antibody that specifically binds to OC1 LOS and a second antibody that specifically binds to KL49.
[0453] In one embodiment, the method comprises administering a first antibody that specifically binds Oxa-23, a second antibody that specifically binds OC1LOS, and a third antibody that specifically binds KL49.
[0454] In one embodiment, the method further comprises administering a carbapenem.
[0455] In one embodiment, the method further comprises administering colistin.
[0456] Also provided is the use of an antibody as defined anywhere herein for determining the presence or absence of Acinetobacter baumannii in a sample.Determining the presence of Acinetobacter baumannii in a sample can be used to diagnose an infection caused by Acinetobacter baumannii in a patient.
[0457] Also provided is a method of determining the presence or absence of Acinetobacter baumannii in a sample, the method comprising contacting the sample with an antibody as defined anywhere herein; and testing for binding between the antibody and Acinetobacter baumannii in the sample; wherein detection of binding indicates the presence of Acinetobacter baumannii in the sample, and wherein the absence of binding indicates the absence of Acinetobacter baumannii in the sample.
[0458] Also provided is the use of an antibody that specifically binds Oxa-23, as defined herein, for determining the presence or absence of Oxa-23 in a sample. Determining the presence of Oxa-23 in a sample can be used to determine a treatment regimen for a patient. For example, if the presence of Oxa-23 is determined in a patient's sample, then the patient can be determined to be treated with an antibody that specifically binds Oxa-23. The patient may or may not have been diagnosed with an infection with Acinetobacter baumannii.
[0459] Also provided is the use of an antibody that specifically binds to OC1 LOS, as defined herein, for determining the presence or absence of OC1 LOS in a sample. Determining the presence of OC1 LOS in a sample can be used to determine a treatment regimen for a patient. For example, if the presence of OC1 LOS is determined in a sample from a patient, then the patient can be determined to be treated with an antibody that specifically binds to OC1 LOS. The patient may or may not have been diagnosed with an infection with Acinetobacter baumannii.
[0460] Also provided is the use of an antibody that specifically binds KL49 as defined herein for determining the presence or absence of KL49 in a sample. Determining the presence of KL49 in a sample can be used to determine a treatment regimen for a patient. For example, if the presence of KL49 is determined in a patient's sample, it can be determined that the patient is treated with an antibody that specifically binds KL49. The patient may or may not have been diagnosed as being infected with Acinetobacter baumannii.
[0461] In one embodiment, the antibody is conjugated to a detectable label.
[0462] In one embodiment, sample is obtained from the people who have or suspected infected Acinetobacter baumannii. In one embodiment, sample is obtained from the people who have or suspected infected one or more bacterial infection symptoms of Acinetobacter baumannii. In one embodiment, sample is serum, blood plasma or whole blood sample, oral cavity or nasal swab, urine, feces or cerebrospinal fluid (CFS), or wherein sample is from the organ or the tissue that any suspected Acinetobacter baumannii infects.
[0463] A diagnostic kit is provided for use as defined herein or for a method as defined herein. The diagnostic kit may comprise an antibody as defined herein and optionally one or more buffer solutions. In one embodiment, the diagnostic kit comprises a first reagent comprising an antibody as defined herein and a second reagent comprising a detection molecule that binds to the first reagent. In one embodiment, the detection molecule is an antibody comprising or conjugated to a detectable marker.
[0464] 4. Attached photos
[0465] Figure 1a Time-resolved core genome phylogeny of GC2 Acinetobacter baumannii isolates in the Ho Chi Minh ICU. Shading indicates the period of empirical treatment of VAP in the ICU with the carbapenem antibiotic imipenem. Labeled AEs are the five carbapenem-resistant genomic subclades of GC2. Also listed on the right are the capsular K locus subtypes of the 10 strains tested for OMV production. Four strains successfully generated OMVs and used to immunize Kymab Intellisellect transgenic mice are marked with an asterisk (*).
[0466] Figure 1b Scanning electron microscopy images of unfixed OMV preparations produced from clinical isolates of Acinetobacter baumannii used for immunization. OMVs were prepared from Acinetobacter baumannii strains BAL_191, BAL_276, BAL_215, and BAL_084. Approximately 95% of the OMVs in this preparation had diameters between 25 and 70 nm, while larger OMVs with diameters >80 nm comprised 2% of the preparation. Amorphous structures were also observed, comprising 3% of the preparation.
[0467] Figure 2a .Protocol for OMV immunization. Ten mice received a prime dose of approximately 1 μg of OMV on day 0 of the study. Subsequently, the mice were divided into two study groups and five mice in group 1 were sacrificed on day 7 to harvest their spleens and lymph nodes. Five mice in group 2 received an additional boost on day 36 and were then sacrificed on day 43. Blood was collected before the prime and boost doses and on day 7. The reactivity of these sera to the immunizing OMVs was assessed by ELISA. Organs harvested on day 7 versus organs harvested on day 43 can be analyzed for B cell reactivity using IntelliSelect screening technology. PB = pre-bleed; SB = serial bleed; TB = endpoint bleed.
[0468] Figure 2b. with the Kymab Intellisellect transgenic mice of the mixed pool immunity of 4 kinds of GC2 Acinetobacter baumannii OMV to the polyclonal serum reaction of immune OMV, as determined by ELISA.(a) for the antigen-specific IgG1 kinetics of 4 kinds of GC2 Acinetobacter baumannii OMV of immunity reaction.To the total antigen-specific IgG1 reaction of 4 kinds of independent GC2 Acinetobacter baumannii OMV (BAL_084, BAL_191, BAL_215 and BAL_276 shown in bold) for immunity and suitable for the reaction of other 2 kinds of GC2 Acinetobacter baumannii OMV (BAL_339 and BAL_377) that do not exist in the 43rd day immunity pool of research.The specific IgG1 reaction of all immune mice is suitable, and all human Ig isotypes are represented by the specific antibody existing in the polyclonal serum.With respect to the pre-blood collection before the initial exemption, calculated the antigen-specific relative endpoint titer.
[0469] Figure 3 Gating strategy for sorting antigen-specific IgG+ B cells from the spleens of GC2 CRAB OMV-immunized mice.
[0470] Figure 4 a. Sunspot diagram of 951 pairs of VH and VL chain sequences recovered from the spleens of four Kymab Intellisellect transgenic mice immunized with GC2 CRAB OMVs. Each VH and VL paired sequence is represented by a circle, colored according to the individual mouse from which it originated. Sequences within the lineage inferred to be derived from a common B cell progenitor are connected by black lines.
[0471] Figure 4 b. Table indicating the number of IgH&L paired sequences, the proportion that mapped to high quality sequences and assigned to clusters of related sequences indicative of actively evolving B cell responses to the immunogen.
[0472] Figure 5a Comparison of mAb binding to GC2 A. baumannii OMVs and intact, unfixed bacterial cells, as determined by ELISA. mAbs identified as binders in both ELISA binding assays: mAbs that bound to both intact, unfixed GC2 A. baumannii bacterial cells and OMVs at levels above the assay threshold shown in the graph are represented in green. Two mAbs that only bound to intact, unfixed bacterial cells are represented in orange. mAbs that failed to bind to the intact bacterial cell wall are represented in white.
[0473] Figure 5b mAbs were selected for CHO expression and purification based on their ability to bind to intact bacterial cell walls and to elicit C3b deposition, as described above. Examples of selections for subsequent CHO expression are shown in bold.
[0474] Figure 7a Table indicating the identified targets of each mAb. The methods used included collecting phylogenetic information from HCI (see above), serological expression cloning (SEC) using genomic phage libraries, and western blotting (WB) with specific mAbs. mAbs indicated in bold (*) were tested in an in vivo challenge model of Acinetobacter baumannii to demonstrate therapeutic efficacy.
[0475] Figure 7b Example Western blot analysis reveals that the mAb binds to three different targets: a high molecular weight target (KL49 capsule - top panel), a 10 kD target (OC1 LOS - middle panel), and a 30 kD protein (Oxa-23 - bottom panel). DETAILED DESCRIPTION
[0476] The present invention provides monoclonal antibodies for use in diagnosing and treating patients with bacterial infections caused by Acinetobacter baumannii.
[0477] The antibodies described herein are described according to the following concepts, aspects, sentences, arrangements and embodiments. Unless otherwise indicated, all concepts, embodiments, sentences, arrangements and aspects should be understood to be capable of being combined with any other concepts, aspects, sentences, arrangements or embodiments, unless such a combination does not have technical significance or is otherwise clearly indicated.
[0478] The CDR, VH and VL sequences of the antibodies mentioned herein are provided in Table 1.
[0479] 5.1 Definition
[0480] Unless otherwise defined herein, scientific and technical terms shall have the meanings commonly understood by those of ordinary skill in the art. In addition, unless the context requires otherwise, singular terms shall include plural forms, and plural terms shall include the singular form.
[0481] Unless the context clearly indicates otherwise, the singular terms "a", "an", and "the" include plural referents. Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise.
[0482] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. The abbreviation "eg (for example)" is derived from the Latin exempli gratia and is used herein to indicate a non-limiting example. Thus, the abbreviation "eg (for example)" is synonymous with the term "for example (for example)".
[0483] In the specification and claims, the term "about" is used to modify values such as the amount of ingredients in the composition, concentration, volume, process temperature, process time, yield, flow rate, pressure, and the like, and ranges thereof, to describe examples of the present disclosure. The term "about" refers to numerical variations that may occur, for example, due to typical measurement and handling procedures used to prepare compounds, compositions, concentrates, or formulations for use; through inadvertent errors in these procedures; through differences in the manufacture, origin, or purity of the starting materials or ingredients used to implement the method, and similar approximate considerations. The term "about" also encompasses amounts that differ due to aging of a formulation having a specific initial concentration or mixture, as well as amounts that differ due to mixing or processing a formulation having a specific initial concentration or mixture. When modified with the term "about," the claims appended hereto include equivalents to these amounts.
[0484] As used herein, "administer" or "administration" refers to the act of injecting or otherwise physically delivering a substance (e.g., an antibody or its encoding nucleic acid provided herein, e.g., in an expression vector) present in vitro into a patient, such as by mucosal, intradermal, intravenous, intramuscular delivery, inhalation (e.g., atomization), and / or any other physical delivery method described herein or known in the art. When treating an infection or its symptoms, the substance is typically administered after the infection or its symptoms occur. When preventing an infection or its symptoms, the substance is typically administered before the infection or its symptoms occur.
[0485] The terms "antibody," "immunoglobulin," or "Ig" are used interchangeably herein and refer to immunoglobulin molecules that recognize and specifically bind to a target (such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or a combination of the foregoing) through at least one antigen recognition site within the variable region of the immunoglobulin molecule. As used herein, the term "antibody" encompasses intact polyclonal antibodies, intact monoclonal antibodies, antibody fragments (such as Fab, Fab', F(ab')2, and Fv fragments), single-chain Fv (scFv) mutants, multispecific antibodies such as bispecific antibodies (including dual binding antibodies), chimeric antibodies, humanized antibodies, human antibodies, fusion proteins comprising an antigenic determinant of an antibody, and any other modified immunoglobulin molecule comprising an antigen recognition site, as long as the antibody exhibits the desired biological activity. The term "antibody" may also refer to a Y-shaped glycoprotein with a molecular weight of approximately 150 kDa composed of four polypeptide chains: two light (L) chains and two heavy (H) chains. There are five mammalian Ig heavy chain isotypes, represented by the Greek letters alpha (α), delta (δ), epsilon (ε), gamma (γ), and mu (μ). The type of heavy chain defines the class of antibody, i.e., IgA, IgD, IgE, IgG, and IgM, respectively. The gamma and alpha classes are further divided into subclasses based on differences in constant domain sequence and function, such as IgG1, hIgG2, mIgG2A, mIgG2B, IgG3, IgG4, IgA1, and IgA2. In mammals, there are two types of immunoglobulin light chains, λ and κ. The "variable region" or "variable domain" of an antibody refers to the amino-terminal domain of the heavy or light chain of an antibody. The variable domains of the heavy and light chains can be referred to as "VH" and "VL," respectively. These domains are typically the most variable parts of an antibody (relative to other antibodies of the same class) and contain the antigen binding site. An example of an antibody is a heavy chain only (ie, H2) antibody comprising a heavy chain (5'-VH-(optional hinge)-CH2-CH3-3') dimer and no light chain.
[0486] The antibodies described herein can be oligoclonal, polyclonal, monoclonal (including full-length monoclonal antibodies), camelized, chimeric, CDR-grafted, multispecific, bispecific (including bibinding antibodies), catalytic, chimeric, humanized, fully human, anti-idiotypic, including antibodies and fragments, variants or derivatives thereof that can be labeled in soluble or bound form, alone or in combination with other amino acid sequences provided by known technology. The antibodies can be from any species. The antibodies described herein can be naked or conjugated to other molecules (such as toxins, radioisotopes, etc.).
[0487] The terms "antigen binding domain," "antigen binding region," "antigen binding fragment," and similar terms refer to the portion of an antibody (e.g., the complementarity determining region (CDR)) that comprises the amino acid residues that interact with an antigen and confer upon the binding agent its specificity and affinity for the antigen. The antigen binding region can be from any animal species, such as rodents (e.g., rabbits, rats, or hamsters) and humans. Preferably, the antigen binding region is of human origin.
[0488] The antigen-binding fragments described herein may include single-chain Fv (scFv), single-chain antibodies, single-domain antibodies, domain antibodies, Fv fragments, Fab fragments, F(ab') fragments, F(ab')2 fragments, antibody fragments exhibiting desired biological activity, disulfide-stabilized variable regions (dsFv), dimeric variable regions (diabodies), anti-idiotypic (anti-Id) antibodies (including, for example, anti-Id antibodies directed against antibodies), intrabodies, linear antibodies, single-chain antibody molecules, and multispecific antibodies formed from any of the above antibody fragments and epitope-binding fragments. In particular, the antibodies and antibody fragments described herein may include immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, i.e., molecules containing an antigen-binding site. Digestion of antibodies with papain produces two identical antigen-binding fragments, also referred to as "Fab" fragments and "Fc" fragments, which have no antigen-binding activity but have the ability to crystallize. As used herein, "Fab" refers to an antibody fragment comprising one constant region and one variable region of each of the heavy and light chains. The term "Fc region" herein is used to define the C-terminal region of an immunoglobulin heavy chain, including native sequence Fc regions and variant Fc regions. An "Fc fragment" refers to the carboxyl-terminal portion of the two H chains linked together by disulfide bonds. The effector functions of an antibody are determined by the sequences in the Fc region, which is also recognized by Fc receptors (FcRs) found on certain types of cells. Digestion of an antibody with pepsin produces a F(ab')2 fragment, in which the two arms of the antibody molecule remain connected and contain two antigen-binding sites. The F(ab')2 fragment has the ability to cross-link antigens.
[0489] " Fv " used herein refers to the smallest fragment of an antibody that retains an antigen recognition site and an antigen binding site. This region is composed of a dimer of a heavy chain variable domain and a light chain variable domain in a tight, non-covalent or covalently bound manner. It is under this configuration that the three CDRs of each variable domain interact to determine the antigen binding site on the surface of the VH-VL dimer. In general, these six CDRs give the antibody antigen binding specificity. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigens, although the affinity is lower than that of the entire binding site.
[0490] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous antibody population, i.e., each antibody constituting the population is identical, except for possible naturally occurring mutations and / or post-translational modifications (such as isomerization, amidation) that may exist in small amounts. Monoclonal antibodies are highly specific and are directed against a single antigenic determinant or epitope. In contrast, polyclonal antibody preparations typically include different antibodies directed against different antigenic determinants (or epitopes). As used herein, the term "monoclonal antibody" encompasses complete and full-length monoclonal antibodies and antibody fragments (such as Fab, Fab', F(ab')2, Fv), single-chain (scFv) mutants, fusion proteins comprising antibody portions, and any other modified immunoglobulin molecules comprising antigen recognition sites. In addition, "monoclonal antibody" refers to such antibodies prepared in a variety of ways, including but not limited to hybridomas, phage selections, recombinant expression, and transgenic animals.
[0491] The monoclonal antibodies herein may include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and / or light chain is identical or homologous to the corresponding sequence in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical or homologous to the corresponding sequence in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies that exhibit the desired biological activity.
[0492] The term "humanized antibody" refers to a subset of chimeric antibodies in which "hypervariable regions" from a non-human immunoglobulin (donor antibody) replace residues from the hypervariable regions of a human immunoglobulin (recipient antibody). Generally, a humanized antibody will comprise substantially all of at least one, and usually two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin sequence and all or substantially all of the framework regions are those of a human immunoglobulin sequence, although the framework regions may include one or more substitutions that improve antibody performance, such as binding affinity, isomerization, immunogenicity, and the like.
[0493] The term "hypervariable region", "CDR region" or "CDR" refers to the region of the variable domain of an antibody where the sequence is highly variable and / or forms structurally well-defined loops. Typically, the antigen binding site of an antibody includes the following six hypervariable regions: three in VH (CDRH1, CDRH2, CDRH3), and three in VL (CDRL1, CDRL2, CDRL3). These regions of the heavy and light chains of an antibody confer antigen-binding specificity to the antibody. CDRs can be defined according to the Kabat system (see Kabat, EA et al., 1991, "Sequences of Proteins of Immunological Interest", 5th ed., NIH Publication No. 91-3242, US Department of Health and Human Services). Other systems can be used to define CDRs, such as the system devised by Chothia et al. (see Chothia, C. & Lesk, AM, 1987, "Canonical structures for the hypervariable regions of immunoglobulins", J. Mol. Biol., 196, 901-917) and the IMGT system (see Lefranc, MP, 1997, "Unique database numbering system for immunogenetic analysis", Immunol. Today, 18, 50). Antibodies typically contain three heavy chain CDRs and three light chain CDRs. The terms CDR or CDRs are used herein to refer to one or more of these regions. One skilled in the art can readily compare different nomenclature systems and determine whether a particular sequence can be defined as a CDR.
[0494] "Human antibody" refers to an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody produced by a human and / or an antibody prepared using any technology for preparing human antibodies, and specifically excludes humanized antibodies comprising non-human antigen binding residues. The term "specific binding" refers to a measurable and reproducible interaction, such as the binding between a target and an antibody, which determines the presence of the target in the presence of a heterogeneous population of molecules including biomolecules. For example, an antibody that specifically binds to a target (which may be an epitope) is an antibody that binds to the target with greater affinity, avidity, greater ease and / or longer duration than it binds to other targets. In one example, the degree of binding of an antibody to an unrelated target is less than about 10% of the binding of the antibody to the target, as measured, for example, by radioimmunoassay (RIA).
[0495] As used herein, "license number" or "marketing authorization number" refers to the number issued by a regulatory agency when the agency determines that a specific medical product and / or composition can be sold and / or provided for sale within its jurisdiction. As used herein, "regulatory agency" refers to one of the agencies responsible for assessing the safety and effectiveness of, for example, medical products and / or compositions and controlling the sale / listing of such products and / or compositions in a given area. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EPA) are only two examples of such regulatory agencies. Other non-limiting examples can include SDA, MPA, MHPRA, IMA, ANMAT, Drug Office, Department of Health, Hong Kong, China, CDSCO, Medsafe and KFDA.
[0496] As used herein, the term "carrier" refers to a diluent, adjuvant (e.g., Freund's adjuvant (complete and incomplete)), excipient, or vehicle with which a therapeutic agent is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those derived from petroleum, animal, plant, or synthetic sources, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. When the pharmaceutical composition is administered intravenously, water is a preferred carrier. Saline solutions and aqueous dextrose and glycerol solutions can also be used as liquid carriers, particularly for injectable solutions.
[0497] As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients (eg, antibodies), optionally in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients, optionally in the specified amounts.
[0498] As used herein, the term "comprising" or "comprises" is used with respect to antibodies, uses, compositions, methods, and corresponding components thereof, which are essential to the method or composition, but may also include unspecified elements, whether essential or not.
[0499] The term "consisting of" refers to the antibodies, uses, compositions, methods and corresponding components as described herein, which do not include any elements not listed in the description of the examples.
[0500] As used herein, the term "consisting essentially of" refers to those elements required for a given embodiment. The term permits the presence of elements that do not materially affect the basic, novel, or functional characteristics of the embodiment.
[0501] "Effective amount" refers to the amount that effectively achieves the desired effect (including treatment or prevention results) within the necessary dosage and time period. "Therapeutically effective amount" refers to the minimum concentration required to achieve a measurable improvement or prevention of a particular condition. The therapeutically effective amount herein can vary according to factors such as the patient's infection status, age, sex, and body weight, and the ability of the antibody to elicit the desired response in an individual. The therapeutically effective amount is also the amount in which the toxic or deleterious effects of the antibody are exceeded by the therapeutic beneficial effects. A "preventionally effective amount" refers to an effective amount measured in dosages and continued for the desired period of time to achieve the desired prevention result. In some instances, the effective amount of an antibody is from about 0.1 mg / kg (mg antibody / kg subject body weight) to about 100 mg / kg. In certain instances, the effective amount of the antibody provided herein is about 0.1 mg / kg, about 0.5 mg / kg, about 1 mg / kg, 3 mg / kg, 5 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, about 35 mg / kg, about 40 mg / kg, about 45 mg / kg, about 50 mg / kg, about 60 mg / kg, about 70 mg / kg, about 80 mg / kg, about 90 mg / kg or about 100 mg / kg (or ranges therein). In some instances, "effective amount" as used herein also refers to the amount of the antibody that achieves a particular result (e.g., inducing complement activation).
[0502] As used herein, the term "epitope" refers to a local area on the surface of an antigen that is capable of binding to one or more antigen-binding regions of an antibody and has antigenic or immunogenic activity in an animal (preferably a mammal, most preferably a human) and is capable of eliciting an immune response. An epitope with immunogenic activity is a portion of an antigen (e.g., a polypeptide, carbohydrate, or lipid molecule) that elicits an antibody response in an animal. An epitope with antigenic activity is a portion of an antigen to which an antibody specifically binds, as determined by any method well known in the art (e.g., by an immunoassay described herein). An antigenic epitope does not necessarily have to be immunogenic. An epitope is typically composed of a chemically active surface group of, for example, an amino acid or sugar side chain molecule and has specific three-dimensional structural characteristics and specific charge characteristics. The region in a polypeptide that contributes to an epitope may be a continuous amino acid of the polypeptide, or the epitope may be from two or more discontinuous regions of the polypeptide. An epitope may or may not be a three-dimensional surface feature of an antigen. As described elsewhere herein, competition between antibodies may also be determined, for example, using SPR.
[0503] As used herein, the term "excipient" refers to an inert substance commonly used as a diluent, vehicle, preservative, binder or stabilizer for a drug, and includes, but is not limited to, proteins (e.g., serum albumin, etc.), amino acids (e.g., aspartic acid, glutamic acid, lysine, arginine, glycine, histidine, etc.), fatty acids and phospholipids (e.g., alkyl sulfonates, octanoates, etc.), surfactants (e.g., SDS, polysorbates, nonionic surfactants, etc.), sugars (e.g., sucrose, maltose, trehalose, etc.), and polyols (e.g., mannitol, sorbitol, etc.). See also Remington's Pharmaceutical Sciences (1990) Mack Publishing Co., Easton, Pa., which is hereby incorporated by reference in its entirety.
[0504] When used with respect to antibodies, the term "heavy chain" refers to five different types of amino acid sequences based on the constant region of the heavy chain, referred to as alpha (α), delta (δ), epsilon (ε), gamma (γ) and mu (μ). These different types of heavy chains are well known and produce five classes of antibodies, i.e., IgA, IgD, IgE, IgG and IgM, including two subclasses of IgA, i.e., IgA1 and IgA2, and four subclasses of IgG, i.e., IgG1, IgG2, IgG3 and IgG4. Preferably, the heavy chain is a human heavy chain. In human populations, there are multiple heavy chain constant region alleles for each immunoglobulin or immunoglobulin subclass. The nucleotide and amino acid sequences of these allelic variants can be consulted in publicly available databases such as IMGT, ENSEMBL Swiss-Prot and Uniprot. Allelic variants can also be identified in various genome sequencing projects. In one example, the antibodies disclosed herein comprise a heavy chain encoded by an IgG1 constant region allele, including but not limited to human IGHG1*01, IGHG1*02, IGHG1*03, IGHG1*04, and IGHG1*05 (nucleotides and corresponding amino acid sequences of which are listed in Table 2). In one example, the antibodies disclosed herein comprise a protein encoded by an IgG4 constant region allele, including but not limited to human IGHG4*01, IGHG4*02, IGHG4*03, and IGHG4*04 (nucleotides and corresponding amino acid sequences of which are listed in Table 2). In another example, the heavy chain is an IgA isotype, human IgA1 or human IgA2, exemplary amino acid sequences of which are shown in Table 2. In another example, the heavy chain is a disabled IgG isotype, such as a disabled IgG4. In certain instances, the antibody comprises a human γ4 constant region. In another example, the heavy chain constant region does not bind to Fc-γ receptors and, for example, comprises a Leu235Glu mutation. In another example, the heavy chain constant region comprises a Ser228Pro mutation to increase stability. In another example, the heavy chain constant region is IgG4-PE. In another example, the antibodies disclosed herein comprise a heavy chain constant region encoded by a murine IgG1 constant region allele, including but not limited to mouse IGHG1*01 or IGHG1*02.
[0505] As used herein, the term "host" refers to an animal, preferably a mammal, most preferably a human.
[0506] As used herein, the term "host cell" refers to a particular subject cell transfected with a nucleic acid molecule and the progeny or potential progeny of such a cell. The progeny of such a cell may differ from the parent cell transfected with the nucleic acid molecule due to mutations or environmental influences that may occur in subsequent generations or due to integration of the nucleic acid molecule into the host cell genome.
[0507] In the context of administering other therapies, the term "combination" refers to the use of more than one therapy. The use of the term "combination" does not limit the order in which the subject is administered therapy for infection. The first therapy can be administered to the subject before (for example, 1 minute, 45 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks or 12 weeks), simultaneously or afterwards (for example, 1 minute, 45 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks or 12 weeks). Any other therapy can be administered in any order with other other therapies. In some instances, the antibody can be administered in combination with one or more therapies.
[0508] As used herein, an "injection device" refers to a device designed to perform an injection, which includes the step of temporarily fluidically coupling the injection device to a person's tissue (typically subcutaneous tissue). The injection further includes administering a quantity of liquid medication into the tissue and separating or removing the injection device from the tissue. In some instances, the injection device may be an intravenous device or IV device, which is a type of injection device used when the target tissue is blood within the circulatory system (e.g., blood within a vein). A common, but non-limiting example of an injection device is a needle and syringe.
[0509] As used herein, "instructions" refers to written, printed, or graphic material displayed on the immediate container of an article of manufacture, such as written material displayed on a vial containing a pharmaceutically active agent, or detailed information regarding the composition and use of a product of interest contained in a kit containing a composition of interest. The instructions describe the intended method of treatment to be administered or performed.
[0510] An "isolated" or "purified" antibody or protein is one that has been identified, separated, and / or recovered from the components of its production environment (e.g., natural or recombinant). For example, the antibody or protein is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the antibody is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of antibodies in which the antibody is separated from cellular components of cells, the antibody is isolated from cells, or is recombinantly produced. Thus, antibodies that are substantially free of cellular material include antibody preparations having less than about 30%, 20%, 10%, or 5% (by dry weight) of heterologous proteins (also referred to herein as "contaminating proteins"). When the antibody is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation. When the antibody is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., separated from chemical precursors or other chemicals that participate in the synthesis of the protein. Thus, such preparations of antibodies have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or components other than the antibody of interest. In a preferred embodiment, the antibody is isolated or purified.
[0511] The term "Kabat numbering" and similar terms are recognized in the art and refer to a system for numbering amino acid residues in the heavy chain variable region of an antibody, or antigen-binding portion thereof, that are more variable (i.e., hypervariable) than other amino acid residues (Kabat et al., (1971) Ann. NY Acad. Sci., 190:382-391; and Kabat et al. (1991) Sequences of Proteins of Immunological Interest, 5th ed., US Department of Health and Human Services, NIH Publication No. 91-3242). For the heavy chain variable region, the hypervariable region generally ranges from amino acid positions 31 to 35 of CDR1, amino acid positions 50 to 65 of CDR2, and amino acid positions 95 to 102 of CDR3.
[0512] As used herein, "label" or "labeled" refers to the addition of a detectable moiety to a polypeptide, such as a radioactive label, a fluorescent label, an enzyme label, a chemiluminescent label, or a biotin group or gold. Radioisotopes or radionuclides can include 3H, 14C, 15N, 35S, 90Y, 99Tc, 115In, 125I, 131I, fluorescent labels can include rhodamine, lanthanide phosphors, or FITC, and enzyme labels can include horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase. By way of illustration and not limitation, additional labels include: enzymes such as glucose-6-phosphate dehydrogenase ("G6PDH"), α-D-galactosidase, glucose oxidase, glucoamylase, carbonic anhydrase, acetylcholinesterase, lysozyme, malate dehydrogenase, and peroxidase; dyes (e.g., cyanine dyes such as Cy5™, Cy5.5™, or Cy7™); additional fluorescent labels or fluorophores including, for example, fluorescein and its derivatives, fluorescent dyes, GFP (GFP stands for "green fluorescent protein"), other fluorescent proteins (e.g., mCherry, mTomato), dansyl, umbelliferone, phycoerythrin, phycocyanin, allophycocyanin, o-phthalaldehyde, and fluorescamine; fluorophores such as lanthanide cryptates and chelates, for example, europium, and the like (Perkin Elmer and Cisbio). Assays); chemiluminescent labels or chemiluminescent agents, such as isoluminol, luminol and dioxetane; sensitizers; coenzymes; enzyme substrates; particles, such as latex or carbon particles; metal sols; microcrystals; liposomes; cells, etc., which may be further labeled with a dye, catalyst or other detectable group; molecules, such as biotin, digoxigenin or 5-bromodeoxyuridine; toxin moieties, for example, toxin moieties selected from the group consisting of: Pseudomonas exotoxin (PE or a cytotoxic fragment or mutant thereof), diphtheria toxin or a cytotoxic fragment or mutant thereof, botulinum toxin A, B, C, D, E or F, ricin or a cytotoxic fragment thereof (e.g., ricin A), abrin or a cytotoxic fragment thereof, saporin or a cytotoxic fragment thereof, pokeweed antiviral toxin or a cytotoxic fragment thereof, and brentuxine 1 or a cytotoxic fragment thereof.
[0513] When used in reference to an antibody, the term "light chain" refers to an immunoglobulin light chain, which has two types in mammals, i.e., λ (lambda) and κ (kappa). Preferably, the light chain is a human light chain. Preferably, the light chain constant region is a human constant region. In the human population, there are multiple light chain constant region alleles. The nucleotide and amino acid sequences of these allelic variants can be accessed on publicly available databases such as IMGT, ENSEMBL Swiss-Prot, and Uniprot. In one example, the antibodies disclosed herein comprise proteins encoded by human κ constant region alleles, including but not limited to IGKC*01, IGKC*02, IGKC*03, IGKC*04, and IGKC*05 (the nucleotide and corresponding amino acid sequences of which are listed in Table 2). In one example, the antibodies disclosed herein comprise proteins encoded by human lambda constant region alleles, including but not limited to IGLC1*01, IGLC1*02, IGLC2*01, IGLC2*02, IGLC2*03, IGLC3*01, IGLC3*02, IGLC3*03, IGLC3*04, IGLC6*01, IGLC7*01, IGLC7*02, and IGLC7*03 (nucleotide and corresponding amino acid sequences of which are listed in Table 2). In another example, the antibodies disclosed herein comprise light chain constant regions encoded by mouse kappa constant region alleles, including but not limited to IGKC*01, IGKC*03, or IGKC*03 (nucleotide and corresponding amino acid sequences of which are listed in Table 2). In another example, the antibodies disclosed herein comprise a light chain constant region encoded by a mouse lambda constant region allele, including but not limited to IGLC1*01, IGLC2*01 or IGLC3*01 (the nucleotide and corresponding amino acid sequences of which are listed in Table 2).
[0514] For peptide, polypeptide or antibody sequences, "percent (%) amino acid sequence identity" is defined as the percentage of amino acid residues in the candidate sequence that are identical with the amino acid residues in the specified peptide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for determining percent amino acid sequence identity can be achieved in various ways known to those skilled in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN or MEG ALIGN TM(DNASTAR) software. In one example, the % identity is about 70%. In one example, the % identity is about 75%. In one example, the % identity is about 80%. In one example, the % identity is about 85%. In one example, the % identity is about 90%. In one example, the % identity is about 92%. In one example, the % identity is about 95%. In one example, the % identity is about 97%. In one example, the % identity is about 98%. In one example, the % identity is about 99%. In one example, the % identity is 100%.
[0515] The term "naturally occurring" or "native" when used in connection with biological materials such as nucleic acid molecules, polypeptides, host cells, etc., refers to those found in nature and not manipulated by humans.
[0516] As used herein, "packaging" refers to how the components are organized and / or confined into a unit suitable for distribution and / or use. Packaging can include, for example, boxes, bags, syringes, ampoules, vials, tubes, flip-top packaging, barriers and / or containers for maintaining sterility, labels, etc.
[0517] As used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the US Pharmacopoeia, European Pharmacopoeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
[0518] As used herein, the terms "polynucleotide," "nucleotide," "nucleic acid," "nucleic acid molecule," and other similar terms are used interchangeably and include DNA, RNA, mRNA, and the like.
[0519] As used herein, the terms "prevent," "preventing," and "prevention" refer to the complete or partial inhibition of the development, recurrence, onset, or spread of an infection resulting from the administration of a therapy or combination of therapies provided herein (e.g., a combination of prophylactic or therapeutic agents, such as antibodies).
[0520] The term "soluble" refers to a polypeptide that lacks one or more transmembrane or cytoplasmic domains present in its native or membrane-associated form. In one example, a "soluble" form of a polypeptide lacks a transmembrane domain and a cytoplasmic domain.
[0521] The term "subject" or "patient" refers to any animal, including but not limited to mammals. As used herein, the term "mammal" refers to any vertebrate that nurses its young and gives birth to live young (eumammalian or placental mammals) or lays eggs (metatherian or non-placental mammals). Examples of mammalian species include, but are not limited to, humans and other primates, including non-human primates such as chimpanzees and other apes and monkeys; farm animals such as cattle, sheep, pigs, goats, and horses; domestic mammals such as dogs and cats; laboratory animals, including rodents such as mice, rats (including cotton rats), and guinea pigs; birds, including poultry, wild birds, and game birds, such as chickens, turkeys, and other birds of the quail family, ducks, geese, and the like.
[0522] As used herein, "substantially all" means at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or about 100%.
[0523] As used herein, the term "surfactant" refers to organic substances with an amphiphilic structure; that is, they are composed of groups with opposing solubility tendencies, typically an oil-soluble hydrocarbon chain and a water-soluble ionic group. Surfactants can be classified as anionic, cationic, and nonionic surfactants based on the charge of the surface active moiety. Surfactants are commonly used as wetting agents, emulsifiers, solubilizers, and dispersants in various pharmaceutical compositions and biomaterial formulations.
[0524] As used herein, the term "tag" refers to any type of portion that is connected to, for example, a polypeptide and / or a polynucleotide encoding an antibody as described herein. For example, a polynucleotide encoding an antibody as described herein can contain one or more other nucleotide sequences encoding tags that encode, for example, a detectable portion or a portion that contributes to affinity purification. When translated, the tag and the antibody can be in the form of a fusion protein. The term "detectable" or "detection" about a tag refers to any tag that can be visualized or wherein the presence of a tag can be determined and / or measured (for example, by quantitatively) in other ways. A non-limiting example of a detectable tag is a fluorescent tag.
[0525] As used herein, the term "therapeutic agent" refers to any agent that can be used to treat, control or improve a bacterial infection caused by Acinetobacter baumannii and / or the symptoms associated therewith. In certain instances, the term "therapeutic agent" refers to an antibody. In certain other instances, the term "therapeutic agent" refers to an agent other than an antibody. Preferably, the therapeutic agent is an agent that is known to be useful for, has been used for, or is currently being used to treat, control or improve a bacterial infection caused by Acinetobacter baumannii and / or one or more symptoms associated therewith.
[0526] As used herein, term " treatment " refers to any scheme, method and / or medicament that can be used for preventing, controlling, treating and / or improving the bacterial infection caused by Acinetobacter baumannii.In some instances, term " therapy " refers to biological therapy, supportive therapy and / or those skilled in the art (such as medical staff) known to be used for preventing, managing, treating and / or improving the other therapies of the bacterial infection caused by Acinetobacter baumannii.
[0527] The term "treat," "treatment," and "treating" refers to reducing or improving progress, severity, and / or the duration of the bacterial infection caused by Acinetobacter baumannii by administering one or more therapies (including but not limited to administering one or more prophylactics or therapeutic agents, such as antibodies). In a particular example, such terms refer to reducing bacterial load, and / or suppress or reduce one or more symptoms relevant to the bacterial infection caused by Acinetobacter baumannii. The minimization of bacterial load can be measured by counting the bacterial colonies cultivated on nutrient agar plates after organ homogenate plating. IL-6 levels are measured by ELISA.
[0528] The term "variable region" or "variable domain" refers to a portion of the light and heavy chains, typically the amino-terminal approximately 120 to 130 amino acids in the heavy chain and approximately 100 to 110 amino acids in the light chain, which vary greatly in sequence between antibodies and are used for the binding and specificity of each particular antibody to its specific antigen. The variability of the sequence is concentrated in those regions called complementarity determining regions (CDRs), while the more highly conserved regions in the variable domain are called framework regions (FRs). The CDRs are primarily responsible for the interaction between the antibody and the antigen. The amino acid position numbering used herein is based on IMGT (Lefranc MP "IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains", Dev. Comp. Immunol. 27 (1): 55-77 (2003)). In a preferred embodiment, the variable region is a human variable region.
[0529] Definitions of commonly used terms in cell biology and molecular biology can be found in: The Merck Manual of Diagnosis and Therapy, 19th ed., published by Merck Research Laboratories, 2006 (ISBN 0-911910-19-0); Robert S. Porter et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); Benjamin Lewin, Genes X, published by Jones & Bartlett Publishing, 2009 (ISBN-10: 0763766321); Kendrew et al. (eds.), Molecular Biology and Biotechnology: A Comprehensive Guide to Molecular Biology. Reference [Molecular Biology and Biotechnology: A Comprehensive Reference Book], published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8), and Current Protocols in Protein Sciences [Current Protocols in Protein Sciences] 2009, Wiley Intersciences, Coligan et al., eds.
[0530] Unless otherwise indicated, the present disclosure was performed using standard procedures as described, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual (4th ed.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA (2012); Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (1995); or Methods in Enzymology: Guide to Molecular Cloning Techniques, Vol. 152, SL Berger and AR Kimmel, eds., Academic Press Inc., San Diego, USA (1987); Current Protocols in Protein Current Protocols in Protein Science (CPPS) (John E. Coligan et al., eds., John Wiley and Sons, Inc.), Current Protocols in Cell Biology (CPCB) (Juan S. Bonifacino et al., eds., John Wiley and Sons, Inc.), and Culture of Animal Cells: A Manual of Basic Technique, R. Ian Freshney, Publisher: Wiley-Liss; 5th ed. (2005), Animal Cell Culture Methods (Methods in Cell Biology, Vol. 57, Jennie P. Mather and David Barnes, eds., Academic Press, 1st ed., 1998), the entireties of which are incorporated herein by reference.
[0531] Additional terms are defined herein within the description of various examples of the disclosure.
[0532] In the disclosure herein relating to an antibody defined by an antibody sequence, the antibody sequence may be defined by reference to an internal reference number of the antibody or a SEQ ID NO. Any disclosure herein citing an internal reference number of an antibody should also be considered a disclosure of the same subject matter, wherein the sequence defined by the internal reference number of the antibody is replaced by the corresponding SEQ ID NO.
[0533] 5.2 Anti-Oxa-23 Antibodies
[0534] The antibodies of the invention bind to Oxa-23 at the surface of intact bacteria (ie, with an unbroken membrane / cell wall), such as on, for example, living bacteria.
[0535] Oxa-23 carbapenemase is a 30 kD protein expressed by the oxa-23 gene. Oxa-23 is a class D beta-lactamase, a group of enzymes involved in resistance to carbapenem antibiotics (Docquier JD, Mangani S. Structure-Function Relationships of Class D Carbapenemases. Curr Drug Targets. 2016; 17(9): 1061-71. doi: 10.2174 / 1389450116666150825115824. PMID: 26302798., the contents of which are incorporated herein by reference).
[0536] The Oxa-23 gene, encoding the Oxa-23 carbapenemase, is widely present in clinical isolates of Acinetobacter baumannii and affects treatment with carbapenem antibiotics.
[0537] The sequence of the wild-type Oxa-23 enzyme is provided as GenBank Accession No. AJ132105.1 and is shown below:
[0538] MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQTDKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWEKDMTLGEAMKLSAVPVYQELARRI GLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPLKVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDIKPQVGWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII(SEQ ID NO:200).
[0539] The identification of mAbs that bind to Oxa-23 is of significant significance. The inventors unexpectedly discovered that Oxa-23 can be targeted by antibodies located in or closely associated with the cell membrane of Acinetobacter baumannii, a previously unknown finding. In other words, the inventors unexpectedly discovered that the Oxa-23 enzyme is a membrane protein present on the surface of living bacteria. Furthermore, the inventors unexpectedly discovered that antibodies can be used to block the enzymatic function of Oxa-23, thereby sensitizing Acinetobacter baumannii to carbapenems. Furthermore, the inventors unexpectedly discovered that the Oxa-23 binding epitope is highly conserved among strains of the G2 clone of Acinetobacter baumannii. Specifically, the binding epitope is believed to be conserved in at least 60% of strains of the G2 clone of Acinetobacter baumannii. Therefore, the present invention demonstrates that targeting the Oxa-23 enzyme is highly attractive as a target for antibody-based diagnosis and treatment of Acinetobacter baumannii. In other words, antibodies that target Oxa-23 on the surface of living bacteria can be considered pan-Acinetobacter baumannii antibodies.
[0540] Therefore, the antibodies of the present invention that specifically bind to Oxa-23 are very important for diagnosing infections caused by Acinetobacter baumannii and treating infections caused by Acinetobacter baumannii in patients, especially when the presence of Oxa-23 in the patient is determined.
[0541] Prior to the present invention, Oxa-23 had not been considered as a potential antibody target at the bacterial surface because it was generally believed to be associated with the bacterial periplasm (Chiu CH, Liu YH, Wang YC, Lee YT, Kuo SC, Chen TL, Lin JC, Wang FD. In vitro activity of SecA inhibitors in combination with carbapenems against carbapenem-hydrolysing class D β-lactamase-producing Acinetobacter baumannii. J Antimicrob Chemother. 2016 Dec;71(12):3441-3448. doi:10.1093 / jac / dkw331. Epub 2016 Aug 19. PMID:27543656, the contents of which are incorporated herein by reference). This target was only unexpectedly identified and validated by the inventors' approach for antibody discovery.
[0542] In particular examples, the antibody is a fully human antibody, such as a fully human monoclonal antibody.
[0543] Antibody 1348 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 21, which includes the CDRH1 amino acid sequence of SEQ ID No: 22 (IMGT), the CDRH2 amino acid sequence of SEQ ID No: 23 (IMGT), and the CDRH3 amino acid sequence of SEQ ID No: 24 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 20. Antibody 1348 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 26, which includes the CDRL1 amino acid sequence of SEQ ID No: 27 (IMGT), the CDRL2 amino acid sequence of SEQ ID No: 28 (IMGT), and the CDRL3 amino acid sequence of SEQ ID No: 29 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 25. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2). The VL domain can be combined with any light chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2).
[0544] Antibody 1349 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 31, which includes the CDRH1 amino acid sequence of SEQ ID No: 32 (IMGT), the CDRH2 amino acid sequence of SEQ ID No: 33 (IMGT), and the CDRH3 amino acid sequence of SEQ ID No: 34 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 30. Antibody 1349 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 36, which includes the CDRL1 amino acid sequence of SEQ ID No: 37 (IMGT), the CDRL2 amino acid sequence of SEQ ID No: 28 (IMGT), and the CDRL3 amino acid sequence of SEQ ID No: 38 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 35. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2). The VL domain can be combined with any light chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2). In one embodiment, the heavy chain constant region sequence is SEQ ID NO: 418. In one embodiment, the light chain constant region sequence is SEQ ID NO: 448. In one embodiment, the antibody comprises a heavy chain comprising a heavy chain variable region (VH) amino acid sequence of SEQ ID NO: 31 and a heavy chain constant region amino acid sequence of SEQ ID NO: 418. In one embodiment, the antibody comprises a light chain comprising a light chain variable region (VL) amino acid sequence of SEQ ID NO: 36 and a light chain constant region amino acid sequence of SEQ ID NO: 448. In one embodiment, the antibody is antibody 1349. Antibody 1349 has a heavy chain variable region (VH) amino acid sequence of SEQ ID NO: 31, a heavy chain constant region amino acid sequence of SEQ ID NO: 418, a light chain variable region (VL) amino acid sequence of SEQ ID NO: 36, and a light chain constant region amino acid sequence of SEQ ID NO: 448. Antibody 1540 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 21, comprising a CDRH1 amino acid sequence of SEQ ID No: 22 (IMGT), a CDRH2 amino acid sequence of SEQ ID No: 23 (IMGT), and a CDRH3 amino acid sequence of SEQ ID No: 24 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 20.Antibody 1540 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 26, which includes the CDRL1 amino acid sequence (IMGT) of SEQ ID No: 27, the CDRL2 amino acid sequence (IMGT) of SEQ ID No: 28, and the CDRL3 amino acid sequence (IMGT) of SEQ ID No: 29. The light chain nucleic acid sequence of the VL domain is SEQ ID No: 25. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2). The VL domain can be combined with any light chain constant region sequence described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2).
[0545] Antibody 1548 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 172, which comprises the CDRH1 amino acid sequence of SEQ ID No: 3 (IMGT), the CDRH2 amino acid sequence of SEQ ID No: 173 (IMGT), and the CDRH3 amino acid sequence of SEQ ID No: 174 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 171. Antibody 1548 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 176, which comprises the CDRL1 amino acid sequence of SEQ ID No: 149 (IMGT), the CDRL2 amino acid sequence of SEQ ID No: 177 (IMGT), and the CDRL3 amino acid sequence of SEQ ID No: 178 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 175. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2). The VL domain can be combined with any of the light chain constant region sequences described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2).
[0546] Antibody 1550 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 180, which comprises a CDRH1 amino acid sequence of SEQ ID No: 181 (IMGT), a CDRH2 amino acid sequence of SEQ ID No: 173 (IMGT), and a CDRH3 amino acid sequence of SEQ ID No: 182 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 179. Antibody 1550 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 184, which comprises a CDRL1 amino acid sequence of SEQ ID No: 185 (IMGT), a CDRL2 amino acid sequence of SEQ ID No: 28 (IMGT), and a CDRL3 amino acid sequence of SEQ ID No: 186 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 183. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2). The VL domain can be combined with any of the light chain constant region sequences described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2).
[0547] 5.3 Anti-OC1 LOS Antibody
[0548] The antibodies of the invention bind to OC1 LOS at the surface of intact bacteria (ie with an unbroken membrane / cell wall), such as on, for example, living bacteria.
[0549] Bacterial lipopolysaccharides (LPS) and lipooligosaccharides (LOS) are unique and complex glycolipids that provide characteristic components of the outer membrane of Gram-negative bacteria. LPS and LOS consist of a core oligosaccharide bound to repeating sugar units extending from the cell surface. LPS and LOS form the protective barrier known to coat the bacterial wall.
[0550] Prior to the present invention, LPS and LOS had not been considered as potential antibody targets on the bacterial surface due to their structural and antigenic diversity. This was due in part to prior research involving the KDO sugar molecule. It was only through the methods used by the inventors for antibody discovery that this target was unexpectedly identified and validated.
[0551] OC1 LOS is a 10 kD lipooligosaccharide expressed by the OC1 gene. Its structural details can be found in Kenyon JJ, Nigro SJ, Hall RM. Variation in the OC locus of Acinetobacter baumannii genomes predicts extensive structural diversity in the lipooligosaccharide. PLoS One. 2014 Sep 23;9(9):e107833. doi:10.1371 / journal.pone.0107833. PMID:25247305; PMCID:PMC4172580, the contents of which are incorporated herein by reference.
[0552] The present inventors unexpectedly discovered that OC1 LOS is not only targetable by diagnostic and therapeutic antibodies, but also that its binding epitope is highly conserved among strains of the G2 clone of Acinetobacter baumannii. Specifically, its binding epitope is believed to be conserved in at least 70% of strains of the G2 clone of Acinetobacter baumannii. Therefore, targeting OC1 LOS is highly attractive as a target for antibody-based diagnosis and treatment of Acinetobacter baumannii. In other words, antibodies that target OC1 LOS on the surface of living bacteria can be considered pan-Acinetobacter baumannii antibodies.
[0553] Without wishing to be bound by theory, it is believed that the antibodies of the invention bind to the core oligosaccharide of OC1 LOS.
[0554] The antibody specifically binding to OC1 LOS of the present invention is very important for diagnosing infections caused by Acinetobacter baumannii and treating infections caused by Acinetobacter baumannii in patients, especially when OC1 LOS is confirmed to exist in the patient.
[0555] In particular examples, the antibody is a fully human antibody, such as a fully human monoclonal antibody.
[0556] Antibody 1042 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 188, which comprises the CDRH1 amino acid sequence of SEQ ID No: 32 (IMGT), the CDRH2 amino acid sequence of SEQ ID No: 33 (IMGT), and the CDRH3 amino acid sequence of SEQ ID No: 189 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 187. Antibody 1042 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 191, which comprises the CDRL1 amino acid sequence of SEQ ID No: 37 (IMGT), the CDRL2 amino acid sequence of SEQ ID No: 28 (IMGT), and the CDRL3 amino acid sequence of SEQ ID No: 192 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 190. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2). The VL domain can be combined with any of the light chain constant region sequences described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2).
[0557] Antibody 1043 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 194, which comprises a CDRH1 amino acid sequence of SEQ ID No: 195 (IMGT), a CDRH2 amino acid sequence of SEQ ID No: 33 (IMGT), and a CDRH3 amino acid sequence of SEQ ID No: 196 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 193. Antibody 1043 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 198, which comprises a CDRL1 amino acid sequence of SEQ ID No: 37 (IMGT), a CDRL2 amino acid sequence of SEQ ID No: 9 (IMGT), and a CDRL3 amino acid sequence of SEQ ID No: 199 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 197. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2). The VL domain can be combined with any of the light chain constant region sequences described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2).
[0558] Antibody 1403 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 88, which comprises the CDRH1 amino acid sequence of SEQ ID No: 22 (IMGT), the CDRH2 amino acid sequence of SEQ ID No: 89 (IMGT), and the CDRH3 amino acid sequence of SEQ ID No: 90 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 87. Antibody 1403 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 92, which comprises the CDRL1 amino acid sequence of SEQ ID No: 93 (IMGT), the CDRL2 amino acid sequence of SEQ ID No: 28 (IMGT), and the CDRL3 amino acid sequence of SEQ ID No: 94 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 91. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2). The VL domain can be combined with any light chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2).
[0559] Antibody 1405 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 103, which comprises a CDRH1 amino acid sequence of SEQ ID No: 104 (IMGT), a CDRH2 amino acid sequence of SEQ ID No: 33 (IMGT), and a CDRH3 amino acid sequence of SEQ ID No: 105 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 102. Antibody 1405 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 107, which comprises a CDRL1 amino acid sequence of SEQ ID No: 27 (IMGT), a CDRL2 amino acid sequence of SEQ ID No: 28 (IMGT), and a CDRL3 amino acid sequence of SEQ ID No: 108 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 106. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2). The VL domain can be combined with any of the light chain constant region sequences described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2).
[0560] Antibody 1407 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 110, which includes a CDRH1 amino acid sequence of SEQ ID No: 111 (IMGT), a CDRH2 amino acid sequence of SEQ ID No: 33 (IMGT), and a CDRH3 amino acid sequence of SEQ ID No: 112 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 109. Antibody 1407 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 114, which includes a CDRL1 amino acid sequence of SEQ ID No: 115 (IMGT), a CDRL2 amino acid sequence of SEQ ID No: 28 (IMGT), and a CDRL3 amino acid sequence of SEQ ID No: 116 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 113. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2). The VL domain can be combined with any of the light chain constant region sequences described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2).
[0561] Antibody 1408 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 118, which comprises a CDRH1 amino acid sequence of SEQ ID No: 104 (IMGT), a CDRH2 amino acid sequence of SEQ ID No: 33 (IMGT), and a CDRH3 amino acid sequence of SEQ ID No: 119 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 117. Antibody 1408 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 121, which comprises a CDRL1 amino acid sequence of SEQ ID No: 122 (IMGT), a CDRL2 amino acid sequence of SEQ ID No: 28 (IMGT), and a CDRL3 amino acid sequence of SEQ ID No: 123 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 120. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2). The VL domain can be combined with any of the light chain constant region sequences described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2).
[0562] Antibody 1413 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 144, which includes a CDRH1 amino acid sequence of SEQ ID No: 145 (IMGT), a CDRH2 amino acid sequence of SEQ ID No: 33 (IMGT), and a CDRH3 amino acid sequence of SEQ ID No: 146 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 143. Antibody 1413 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 148, which includes a CDRL1 amino acid sequence of SEQ ID No: 149 (IMGT), a CDRL2 amino acid sequence of SEQ ID No: 150 (IMGT), and a CDRL3 amino acid sequence of SEQ ID No: 151 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 147. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2). The VL domain can be combined with any of the light chain constant region sequences described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2).
[0563] 5.4 Anti-KL49 Antibody
[0564] The antibodies of the invention bind to KL49 at the surface of intact bacteria (ie, with an unbroken membrane / cell wall), such as on, for example, living bacteria.
[0565] KL49 is a form of capsular polysaccharide (CPS) produced by Acinetobacter baumannii strains and surrounding the outer cell membrane. CPS is a high-molecular-weight carbohydrate with a dense structure composed of repeating oligosaccharide units that provides a barrier against environmental stressors and confers resistance to antimicrobial compounds and immune protection mechanisms.
[0566] The structure of the KL49 capsular antigen is described in Singh JK, Adams FG, Brown MH. Diversity and Function of Capsular Polysaccharide in Acinetobacter baumannii. Front Microbiol. 2019 Jan 9;9:3301. doi:10.3389 / fmicb.2018.03301. PMID:30687280; PMCID:PMC6333632, the contents of which are incorporated herein by reference.
[0567] The presence of the KL49 capsule is associated with hypervirulence and increased mortality, and A. baumannii KL49 is currently becoming the predominant clone in Southeast Asia (Zhou K, Tang X, Wang L, Guo Z, Xiao S, Wang Q, Zhuo C. An Emerging Clone (ST457) of Acinetobacter baumannii Clonal Complex 92 With Enhanced Virulence and Increasing Endemicity in South China. Clin Infect Dis. 2018 Nov 13;67(suppl_2):S179-S188. doi:10.1093 / cid / ciy691. PMID:30423046, the contents of which are incorporated herein by reference). Therefore, the present inventors discovered that KL49 protein exists on the surface of living bacteria and can be targeted by diagnostic and therapeutic antibodies, which is of great value for the early diagnosis and treatment of these patients.
[0568] Therefore, the antibodies that specifically bind to KL49 of the present invention are very important for diagnosing infections caused by Acinetobacter baumannii and treating infections caused by Acinetobacter baumannii in patients, especially when the presence of KL49 in the patient is determined.
[0569] In particular examples, the antibody is a fully human antibody, such as a fully human monoclonal antibody.
[0570] Antibody 1345 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 2, which includes a CDRH1 amino acid sequence of SEQ ID No: 3 (IMGT), a CDRH2 amino acid sequence of SEQ ID No: 4 (IMGT), and a CDRH3 amino acid sequence of SEQ ID No: 5 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 1. Antibody 1345 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 7, which includes a CDRL1 amino acid sequence of SEQ ID No: 8 (IMGT), a CDRL2 amino acid sequence of SEQ ID No: 9 (IMGT), and a CDRL3 amino acid sequence of SEQ ID No: 10 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 6. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2). The VL domain can be combined with any light chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2).
[0571] Antibody 1347 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 12, which comprises the CDRH1 amino acid sequence of SEQ ID No: 3 (IMGT), the CDRH2 amino acid sequence of SEQ ID No: 13 (IMGT), and the CDRH3 amino acid sequence of SEQ ID No: 14 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 11. Antibody 1347 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 16, which comprises the CDRL1 amino acid sequence of SEQ ID No: 17 (IMGT), the CDRL2 amino acid sequence of SEQ ID No: 18 (IMGT), and the CDRL3 amino acid sequence of SEQ ID No: 19 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 15. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2). The VL domain can be combined with any light chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2).
[0572] Antibody 1350 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 40, which comprises a CDRH1 amino acid sequence of SEQ ID No: 3 (IMGT), a CDRH2 amino acid sequence of SEQ ID No: 13 (IMGT), and a CDRH3 amino acid sequence of SEQ ID No: 41 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 39. Antibody 1350 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 16, which comprises a CDRL1 amino acid sequence of SEQ ID No: 17 (IMGT), a CDRL2 amino acid sequence of SEQ ID No: 18 (IMGT), and a CDRL3 amino acid sequence of SEQ ID No: 19 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 42. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2). The VL domain can be combined with any light chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2).
[0573] Antibody 1351 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 44, which comprises the CDRH1 amino acid sequence of SEQ ID No: 3 (IMGT), the CDRH2 amino acid sequence of SEQ ID No: 13 (IMGT), and the CDRH3 amino acid sequence of SEQ ID No: 45 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 43. Antibody 1351 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 47, which comprises the CDRL1 amino acid sequence of SEQ ID No: 17 (IMGT), the CDRL2 amino acid sequence of SEQ ID No: 18 (IMGT), and the CDRL3 amino acid sequence of SEQ ID No: 10 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 46. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2). The VL domain can be combined with any light chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2).
[0574] Antibody 1363 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 49, which comprises the CDRH1 amino acid sequence of SEQ ID No: 3 (IMGT), the CDRH2 amino acid sequence of SEQ ID No: 13 (IMGT), and the CDRH3 amino acid sequence of SEQ ID No: 50 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 48. Antibody 1363 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 52, which comprises the CDRL1 amino acid sequence of SEQ ID No: 17 (IMGT), the CDRL2 amino acid sequence of SEQ ID No: 18 (IMGT), and the CDRL3 amino acid sequence of SEQ ID No: 19 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 51. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2). The VL domain can be combined with any light chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2).
[0575] Antibody 1364 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 54, which comprises the CDRH1 amino acid sequence of SEQ ID No: 3 (IMGT), the CDRH2 amino acid sequence of SEQ ID No: 13 (IMGT), and the CDRH3 amino acid sequence of SEQ ID No: 55 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 53. Antibody 1364 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 57, which comprises the CDRL1 amino acid sequence of SEQ ID No: 58 (IMGT), the CDRL2 amino acid sequence of SEQ ID No: 18 (IMGT), and the CDRL3 amino acid sequence of SEQ ID No: 59 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 56. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2). The VL domain can be combined with any light chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2).
[0576] Antibody 1397 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 61, which comprises the CDRH1 amino acid sequence of SEQ ID No: 3 (IMGT), the CDRH2 amino acid sequence of SEQ ID No: 13 (IMGT), and the CDRH3 amino acid sequence of SEQ ID No: 62 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 60. Antibody 1397 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 64, which comprises the CDRL1 amino acid sequence of SEQ ID No: 17 (IMGT), the CDRL2 amino acid sequence of SEQ ID No: 18 (IMGT), and the CDRL3 amino acid sequence of SEQ ID No: 59 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 63. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2). The VL domain can be combined with any light chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2).
[0577] Antibody 1398 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 66, which comprises the CDRH1 amino acid sequence of SEQ ID No: 3 (IMGT), the CDRH2 amino acid sequence of SEQ ID No: 13 (IMGT), and the CDRH3 amino acid sequence of SEQ ID No: 67 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 65. Antibody 1398 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 69, which comprises the CDRL1 amino acid sequence of SEQ ID No: 17 (IMGT), the CDRL2 amino acid sequence of SEQ ID No: 18 (IMGT), and the CDRL3 amino acid sequence of SEQ ID No: 59 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 68. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2). The VL domain can be combined with any light chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2).
[0578] Antibody 1400 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 71, which comprises the CDRH1 amino acid sequence of SEQ ID No: 3 (IMGT), the CDRH2 amino acid sequence of SEQ ID No: 13 (IMGT), and the CDRH3 amino acid sequence of SEQ ID No: 72 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 70. Antibody 1400 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 74, which comprises the CDRL1 amino acid sequence of SEQ ID No: 17 (IMGT), the CDRL2 amino acid sequence of SEQ ID No: 18 (IMGT), and the CDRL3 amino acid sequence of SEQ ID No: 59 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 73. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2). The VL domain can be combined with any light chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2).
[0579] Antibody 1401 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 76, which comprises the CDRH1 amino acid sequence of SEQ ID No: 3 (IMGT), the CDRH2 amino acid sequence of SEQ ID No: 13 (IMGT), and the CDRH3 amino acid sequence of SEQ ID No: 77 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 75. Antibody 1401 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 79, which comprises the CDRL1 amino acid sequence of SEQ ID No: 17 (IMGT), the CDRL2 amino acid sequence of SEQ ID No: 18 (IMGT), and the CDRL3 amino acid sequence of SEQ ID No: 80 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 78. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2). The VL domain can be combined with any light chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2).
[0580] Antibody 1402 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 82, which comprises a CDRH1 amino acid sequence of SEQ ID No: 3 (IMGT), a CDRH2 amino acid sequence of SEQ ID No: 13 (IMGT), and a CDRH3 amino acid sequence of SEQ ID No: 83 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 81. Antibody 1402 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 85, which comprises a CDRL1 amino acid sequence of SEQ ID No: 17 (IMGT), a CDRL2 amino acid sequence of SEQ ID No: 18 (IMGT), and a CDRL3 amino acid sequence of SEQ ID No: 86 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 84. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2). The VL domain can be combined with any light chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2).
[0581] Antibody 1404 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 96, which comprises a CDRH1 amino acid sequence of SEQ ID No: 3 (IMGT), a CDRH2 amino acid sequence of SEQ ID No: 97 (IMGT), and a CDRH3 amino acid sequence of SEQ ID No: 98 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 95. Antibody 1404 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 100, which comprises a CDRL1 amino acid sequence of SEQ ID No: 101 (IMGT), a CDRL2 amino acid sequence of SEQ ID No: 18 (IMGT), and a CDRL3 amino acid sequence of SEQ ID No: 59 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 99. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2). The VL domain can be combined with any light chain constant region sequence described herein (the nucleotide sequence and corresponding amino acid sequence of which are shown in Table 2).
[0582] Antibody 1409 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 125, which comprises the CDRH1 amino acid sequence of SEQ ID No: 3 (IMGT), the CDRH2 amino acid sequence of SEQ ID No: 13 (IMGT), and the CDRH3 amino acid sequence of SEQ ID No: 126 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 124. Antibody 1409 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 128, which comprises the CDRL1 amino acid sequence of SEQ ID No: 17 (IMGT), the CDRL2 amino acid sequence of SEQ ID No: 18 (IMGT), and the CDRL3 amino acid sequence of SEQ ID No: 129 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 127. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2). The VL domain can be combined with any of the light chain constant region sequences described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2).
[0583] Antibody 1410 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 131, which comprises a CDRH1 amino acid sequence of SEQ ID No: 3 (IMGT), a CDRH2 amino acid sequence of SEQ ID No: 13 (IMGT), and a CDRH3 amino acid sequence of SEQ ID No: 132 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 130. Antibody 1410 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 134, which comprises a CDRL1 amino acid sequence of SEQ ID No: 17 (IMGT), a CDRL2 amino acid sequence of SEQ ID No: 18 (IMGT), and a CDRL3 amino acid sequence of SEQ ID No: 135 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 133. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2). The VL domain can be combined with any of the light chain constant region sequences described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2).
[0584] Antibody 1412 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 137, which comprises a CDRH1 amino acid sequence of SEQ ID No: 3 (IMGT), a CDRH2 amino acid sequence of SEQ ID No: 138 (IMGT), and a CDRH3 amino acid sequence of SEQ ID No: 139 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 136. Antibody 1412 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 141, which comprises a CDRL1 amino acid sequence of SEQ ID No: 142 (IMGT), a CDRL2 amino acid sequence of SEQ ID No: 18 (IMGT), and a CDRL3 amino acid sequence of SEQ ID No: 86 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 140. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2). The VL domain can be combined with any of the light chain constant region sequences described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2).
[0585] Antibody 1414 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 153, which comprises a CDRH1 amino acid sequence of SEQ ID No: 154 (IMGT), a CDRH2 amino acid sequence of SEQ ID No: 155 (IMGT), and a CDRH3 amino acid sequence of SEQ ID No: 156 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 152. Antibody 1414 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 158, which comprises a CDRL1 amino acid sequence of SEQ ID No: 17 (IMGT), a CDRL2 amino acid sequence of SEQ ID No: 18 (IMGT), and a CDRL3 amino acid sequence of SEQ ID No: 159 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 157. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2). The VL domain can be combined with any of the light chain constant region sequences described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2).
[0586] Antibody 1415 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 161, which comprises a CDRH1 amino acid sequence of SEQ ID No: 3 (IMGT), a CDRH2 amino acid sequence of SEQ ID No: 162 (IMGT), and a CDRH3 amino acid sequence of SEQ ID No: 163 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 160. Antibody 1415 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 165, which comprises a CDRL1 amino acid sequence of SEQ ID No: 17 (IMGT), a CDRL2 amino acid sequence of SEQ ID No: 18 (IMGT), and a CDRL3 amino acid sequence of SEQ ID No: 135 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 164. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2). The VL domain can be combined with any of the light chain constant region sequences described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2).
[0587] Antibody 1416 has a heavy chain variable region (VH) amino acid sequence of SEQ ID No: 167, which comprises the CDRH1 amino acid sequence of SEQ ID No: 3 (IMGT), the CDRH2 amino acid sequence of SEQ ID No: 13 (IMGT), and the CDRH3 amino acid sequence of SEQ ID No: 168 (IMGT). The heavy chain nucleic acid sequence of the VH domain is SEQ ID No: 166. Antibody 1416 has a light chain variable region (VL) amino acid sequence of SEQ ID No: 170, which comprises the CDRL1 amino acid sequence of SEQ ID No: 17 (IMGT), the CDRL2 amino acid sequence of SEQ ID No: 18 (IMGT), and the CDRL3 amino acid sequence of SEQ ID No: 10 (IMGT). The light chain nucleic acid sequence of the VL domain is SEQ ID No: 169. The VH domain can be combined with any heavy chain constant region sequence described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2). The VL domain can be combined with any light chain constant region sequence described herein (the nucleotide and corresponding amino acid sequences of which are shown in Table 2). In one embodiment, the heavy chain constant region sequence is SEQ ID NO: 418. In one embodiment, the light chain constant region sequence is SEQ ID NO: 448. In one embodiment, the antibody comprises a heavy chain comprising a heavy chain variable region (VH) amino acid sequence of SEQ ID NO: 167 and a heavy chain constant region amino acid sequence of SEQ ID NO: 418. In one embodiment, the antibody comprises a light chain comprising a light chain variable region (VL) amino acid sequence of SEQ ID NO: 170 and a light chain constant region amino acid sequence of SEQ ID NO: 448. In one embodiment, the antibody is antibody 1416. Antibody 1416 has a heavy chain variable region (VH) amino acid sequence of SEQ ID NO: 167, a heavy chain constant region amino acid sequence of SEQ ID NO: 418, a light chain variable region (VL) amino acid sequence of SEQ ID NO: 170, and a light chain constant region amino acid sequence of SEQ ID NO: 448).
[0588] 5.5 Antibody Function-Binding Measurement
[0589] This can be done, for example, by immunoassays (eg, ELISA), BIAcore TM or other techniques known to those skilled in the art to identify antibodies that specifically bind to the surface of Acinetobacter baumannii bacteria.
[0590] When an antibody specifically binds to a target with an affinity higher than that of any cross-reactive antigen, as measured using experimental techniques such as radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA). Typically, the specific or selective reaction will be at least twice the background signal or noise, and more typically, more than 10 times (such as more than 15 times, more than 20 times, more than 50 times, or more than 100 times) of the background. Discussion about antibody specificity is provided in, for example, Paul, 1989, Fundamental Immunology Second Edition, Raven Press, New York, pp. 332-336.
[0591] Any suitable method can be used to determine whether the antibody is bound to the surface of the Acinetobacter baumannii bacteria. This method can include ELISA to determine the specificity of the antibody. If the binding level of the antibody to the antigen is at least 2.5 times, for example at least 10 times, the antibody can be said to bind to its antigen. The binding between the antibody and its cognate antigen is generally referred to as specific binding. X-ray crystallography can usually be used to accurately identify the residues that the antibody binds to. This technology can be used to determine that the antibody as herein described binds to one or more residues of the Oxa-23 enzyme, OC1LOS or KL49 at the surface of the Acinetobacter baumannii bacteria.
[0592] Measurements of binding assays can conveniently be made using indirect whole bacterial cell ELISAs. Alternatively, measurements of binding assays can conveniently be made using OMVs rather than bacterial cells. Thus, when, for example, an ELISA assay is used to study binding to live bacteria, binding to OMVs can be suitably used as plate coating antigens.
[0593] If the antibody epitope is a linear, continuous epitope, binding and binding affinity can be determined using a synthetically purified peptide sequence.
[0594] The specific binding antigen (e.g., Oxa-23, OC1 LOS, or KL49) of the antibody can be determined using a phage expression library, for example as described in Example 5. For example, shotgun Acinetobacter baumannii genomic DNA is incorporated into a phage expression library. The antibody is then screened for reactivity with phage plaques from the expression library, and individual phage that bind to the antibody are identified. The identified phage are sequenced, and the sequencing information is used to elucidate the binding antigen of the antibody. Suitable phage methods for antigen identification are known to those skilled in the art. For example, suitable phage methods are described in Lodes MJ, Dillon DC, Houghton RL, Skeiky YA. Expression cloning. Methods Mol Med. 2004; 94: 91-106. doi: 10.1385 / 1-59259-679-7: 91. PMID: 14959824, the contents of which are incorporated herein by reference.
[0595] Identification of Oxa-23, OC1 LOS, or KL49 as binding antigens can also be performed using Western blotting of specific GC2 strains genetically identified as producing the corresponding molecules.
[0596] High-content imaging (HCI) assays and systems for image-based morphological analysis can be used to screen mAbs for binding to a panel of clinically relevant CRAB isolates to assess binding affinity and cross-reactivity. (Maes M, Dyson ZA, Smith SE, Goulding DA, Ludden C, Baker S, Kellam P, Reece ST, Dougan G, Bartholdson Scott JA. Novel therapeutic antibody screening method using bacterial high-content imaging reveals functional antibody binding phenotypes of Escherichia coli ST131. Sci Rep. 2020 Jul 24;10(1):12414. doi:10.1038 / s41598-020-69300-8, the contents of which are incorporated herein by reference).
[0597] SPR may be used to determine antibody binding to Oxa-23, OC1 LOS, or KL49 outside of the cell wall environment. A suitable SPR protocol is shown below:
[0598] 1. Couple mouse anti-human (or other relevant human, rat, or non-human vertebrate antibody constant region species-matched) IgG to a biosensor chip (e.g., a dextran-coated gold chip), such as by primary amine coupling. Thus, amine coupling can be used to covalently immobilize anti-Fc antibodies on the chip surface.
[0599] 2. Expose mouse anti-human IgG (or other matched species antibody) to the test antibody (e.g., in human IgG format) to capture the test antibody on the chip;
[0600] 3. Run the test antigen over the capture surface of the chip at a series of concentrations up to 100 nM (e.g., 0.39, 1.56, 6.25, 25, and 100 nM) and a 0 nM (i.e., buffer only) control. The buffer can optionally be an aqueous solution of 0.01 M HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 0.15 M NaCl, and 0.05% v / v surfactant P20, buffered to pH 7.4; and
[0601] 4. Use surface plasmon resonance to determine the binding affinity of the test antibody to the test antigen. KD, Ka, and Kd can then be calculated.
[0602] SPR can be performed using any standard SPR apparatus, such as by Biacore™ or using the ProteOn XPR36™ (Bio- ).
[0603] The capture surface can be regenerated with a 3M magnesium chloride solution. This will remove the captured test antibody and allow the surface to be used for another interaction. Standard techniques can be used to fit the binding data to a 1:1 model, for example using analytical software such as Biacore Insight evaluation software.
[0604] Methods to determine binding (eg, ELISA) can also be used to determine competition between molecules, such as competition between a test antibody and a known antibody, and can be performed with the test antibody and known antibody in IgG or, optionally, scFv format.
[0605] Methods that determine binding (eg, ELISA) can also be used to determine cross-reactivity of antibodies to different clones or strains of A. baumannii.
[0606] 5.6 Antibody Function—Inducing Complement Activation
[0607] The complement cascade is a powerful serum-based mechanism that causes protein pores to be inserted into the membranes of Gram-negative bacteria, thereby killing the bacteria. This protein pathway is triggered by antibodies, and therefore, the ability of antibodies to trigger the complement cascade is a key functional consequence of certain antibodies of the present invention.
[0608] C3b is cleaved from serum C3 protein, driving the complement cascade, and mAb binding to the bacterial cell membrane triggers the formation of an enzyme complex involving complement proteins C1q, C2, and C4, which cleave C3. Therefore, detection of C3b on the bacterial membrane correlates with successful initiation of the complement cascade.
[0609] The ability of an antibody to induce complement activation can be determined by in vitro assays, such as flow cytometry-based assays to detect mAb-induced deposition of complement component C3b on the surface of OMVs. Fishinger et al., Journal of Immunological Methods, https: / / doi.org / 10.1016 / j.jim.2019.07.002 Such an assay is described in , the contents of which are incorporated herein by reference. Such an assay is used in the examples herein and involves 5 main steps:
[0610] 1. FM4-64-stained GC2 A. baumannii OMVs were incubated with compensation beads for non-specific binding of OMVs for 10 min, then the bead-OMV complexes were washed and blocked with PBS 0.1% (w / v) BSA.
[0611] 2. Bead-OMV complexes were added to small-scale expressed mAbs in HEK 293 supernatant, normalized to 100 μg / ml, and incubated at 37°C for 3 hours.
[0612] 3. Complement proteins were prepared by reconstituting lyophilized guinea pig complement in gelatin veronal buffer, adding it to the bead-OMV-antibody complex, and incubating at 37°C for 15 minutes.
[0613] 4. After washing, FITC-conjugated anti-C3 detection antibody was added to the bead-based complex and incubated for another 15 minutes.
[0614] 5. After further washing, fluorescence was assessed on an Attune NxT flow cytometer equipped with a high-throughput autosampler to identify and quantify FM4-64+FITC+bead-based immune complexes.
[0615] C3b complement deposition is reported as the fold change in geometric mean fluorescence intensity on the FITC channel over the HuIgG1 isotype control.
[0616] 5.7 Gene segments
[0617] In some aspects, the antibodies comprise VH and / or VL domains and framework regions of human germline gene segment sequences. The gene segment sequences from which the exemplary antibodies described herein are derived are shown in Table 3.
[0618] In one example, the antibody comprises an antibody VH domain derived from the recombination of a human heavy chain V gene segment, a human heavy chain D gene segment, and a human heavy chain J gene segment.
[0619] In one example, the antibody comprises an antibody VL domain derived from the recombination of a human light chain V gene segment and a human light chain J gene segment.
[0620] In one example, the antibody comprises an antibody VH domain derived from the recombination of a human heavy chain V gene segment, a human heavy chain D gene segment, and a human heavy chain J gene segment, wherein the V gene segment is IGHV3-23*04, IGHV3-9*01, IGHV2-5*10, IGHV3-9*01, or IGHV3-30*18; and / or the J gene segment is IGHJ2*01, IGHJ3*02, IGHJ4*02, IGHJ6*02, or IGHJ5*02.
[0621] In one example, the antibody comprises an antibody VH domain derived from the recombination of a human heavy chain V gene segment, a human heavy chain D gene segment, and a human heavy chain J gene segment, wherein the V gene segment is IGHV3-23*04.
[0622] In one example, the antibody comprises an antibody VH domain derived from the recombination of a human heavy chain V gene segment, a human heavy chain D gene segment, and a human heavy chain J gene segment, wherein the V gene segment is IGHV3-9*01.
[0623] In one example, the antibody comprises an antibody VH domain derived from the recombination of a human heavy chain V gene segment, a human heavy chain D gene segment, and a human heavy chain J gene segment, wherein the V gene segment is IGHV2-5*10.
[0624] In one example, the antibody comprises an antibody VH domain derived from the recombination of a human heavy chain V gene segment, a human heavy chain D gene segment, and a human heavy chain J gene segment, wherein the V gene segment is IGHV3-9*01.
[0625] In one example, the antibody comprises an antibody VH domain derived from the recombination of a human heavy chain V gene segment, a human heavy chain D gene segment, and a human heavy chain J gene segment, wherein the V gene segment is IGHV3-30*18.
[0626] In one example, the antibody comprises an antibody VH domain derived from the recombination of a human heavy chain V gene segment, a human heavy chain D gene segment, and a human heavy chain J gene segment, wherein the J gene segment is IGHJ2*01.
[0627] In one example, the antibody comprises an antibody VH domain derived from the recombination of a human heavy chain V gene segment, a human heavy chain D gene segment, and a human heavy chain J gene segment, wherein the J gene segment is IGHJ3*02.
[0628] In one example, the antibody comprises an antibody VH domain derived from the recombination of a human heavy chain V gene segment, a human heavy chain D gene segment, and a human heavy chain J gene segment, wherein the J gene segment is IGHJ4*02.
[0629] In one example, the antibody comprises an antibody VH domain derived from the recombination of a human heavy chain V gene segment, a human heavy chain D gene segment, and a human heavy chain J gene segment, wherein the J gene segment is IGHJ6*02.
[0630] In one example, the antibody comprises an antibody VH domain derived from the recombination of a human heavy chain V gene segment, a human heavy chain D gene segment, and a human heavy chain J gene segment, wherein the J gene segment is IGHJ5*02.
[0631] In one example, the antibody comprises an antibody VH domain derived from the recombination of a human heavy chain V gene segment, a human heavy chain D gene segment, and a human heavy chain J gene segment, wherein the V gene segment and the J gene segment of the heavy chain are a combination of any one of the antibodies shown in Table 3.
[0632] In one example, the antibody comprises an antibody VL domain derived from the recombination of a human light chain V gene segment and a human light chain J gene segment, wherein the V gene segment is IGKV3-15*01, IGKV3D-15*d01, IGKV1-17*01, IGKV1-9*d01, IGKV1D-39*01, IGKV1-16*02, IGKV1-6*01, IGKV3D-15*d01, IGKV1-12*01 or IGKV1D-16*01; and / or the J gene segment is IGKJ4*01, IGKJ3*01, IGKJ1*01 or IGKJ2*04.
[0633] In one example, the antibody comprises an antibody VL domain derived from the recombination of a human light chain V gene segment and a human light chain J gene segment, wherein the V gene segment is IGKV3-15*01.
[0634] In one example, the antibody comprises an antibody VL domain derived from the recombination of a human light chain V gene segment and a human light chain J gene segment, wherein the V gene segment is IGKV3D-15*d01.
[0635] In one example, the antibody comprises an antibody VL domain derived from the recombination of a human light chain V gene segment and a human light chain J gene segment, wherein the V gene segment is IGKV1-17*01.
[0636] In one example, the antibody comprises an antibody VL domain derived from the recombination of a human light chain V gene segment and a human light chain J gene segment, wherein the V gene segment is IGKV1-9*d01.
[0637] In one example, the antibody comprises an antibody VL domain derived from the recombination of a human light chain V gene segment and a human light chain J gene segment, wherein the V gene segment is IGKV1D-39*01.
[0638] In one example, the antibody comprises an antibody VL domain derived from the recombination of a human light chain V gene segment and a human light chain J gene segment, wherein the V gene segment is IGKV1-16*02.
[0639] In one example, the antibody comprises an antibody VL domain derived from the recombination of a human light chain V gene segment and a human light chain J gene segment, wherein the V gene segment is IGKV1-6*01.
[0640] In one example, the antibody comprises an antibody VL domain derived from the recombination of a human light chain V gene segment and a human light chain J gene segment, wherein the V gene segment is IGKV3D-15*d01.
[0641] In one example, the antibody comprises an antibody VL domain derived from the recombination of a human light chain V gene segment and a human light chain J gene segment, wherein the V gene segment is IGKV1-12*01.
[0642] In one example, the antibody comprises an antibody VL domain derived from the recombination of a human light chain V gene segment and a human light chain J gene segment, wherein the J gene segment is IGKJ4*01.
[0643] In one example, the antibody comprises an antibody VL domain derived from the recombination of a human light chain V gene segment and a human light chain J gene segment, wherein the J gene segment is IGKJ3*01.
[0644] In one example, the antibody comprises an antibody VL domain derived from the recombination of a human light chain V gene segment and a human light chain J gene segment, wherein the J gene segment is IGKJ1*01.
[0645] In one example, the antibody comprises an antibody VL domain derived from the recombination of a human light chain V gene segment and a human light chain J gene segment, wherein the J gene segment is IGKJ2*04.
[0646] In one example, the antibody comprises an antibody VL domain derived from the recombination of a human light chain V gene segment and a human light chain J gene segment, wherein the V gene segment and the J gene segment of the light chain are a combination of any one of the antibodies shown in Table 3.
[0647] 5.8 Sequence Identity
[0648] In some examples, the antibody comprises an amino acid sequence that has a high level of sequence identity to the amino acid sequence of one of the exemplary antibodies described herein and shown in Table 1.
[0649] In one example, the amino acid sequence is at least 70% identical to the designated SEQ ID No. In one example, the amino acid sequence is at least 75% identical to the designated SEQ ID No. In one example, the amino acid sequence is at least 95% identical to the designated SEQ ID No. In one example, the amino acid sequence is at least 96% identical to the designated SEQ ID No. In one example, the amino acid sequence is at least 97% identical to the designated SEQ ID No. In one example, the amino acid sequence is at least 98% identical to the designated SEQ ID No. In one example, the amino acid sequence is at least 99% identical to the designated SEQ ID No. In one example, the amino acid sequence is at least 99.5% identical to the designated SEQ ID No.
[0650] In one example, an antibody is provided having a complete heavy chain sequence that is at least 70% identical to the amino acid sequence of the complete heavy chain sequence of any antibody disclosed herein, such as a combination of the SEQ ID Nos of the heavy chain variable domain and the heavy chain constant domain sequences disclosed herein. In one example, an antibody is provided having a complete heavy chain sequence that is at least 75% identical to the amino acid sequence of the complete heavy chain sequence of any antibody disclosed herein, such as a combination of the SEQ ID Nos of the heavy chain variable domain and the heavy chain constant domain sequences disclosed herein. In one example, an antibody is provided having a complete heavy chain sequence that is at least 80% identical to the amino acid sequence of the complete heavy chain sequence of any antibody disclosed herein, such as a combination of the SEQ ID Nos of the heavy chain variable domain and the heavy chain constant domain sequences disclosed herein. In one example, an antibody is provided having a complete heavy chain sequence that is at least 85% identical to the amino acid sequence of the complete heavy chain sequence of any antibody disclosed herein, such as a combination of the SEQ ID Nos of the heavy chain variable domain and the heavy chain constant domain sequences disclosed herein. In one example, an antibody is provided having a complete heavy chain sequence that is at least 90% identical to the amino acid sequence of the complete heavy chain sequence of any antibody disclosed herein, such as a combination of the SEQ ID Nos of the heavy chain variable domain and the heavy chain constant domain sequences disclosed herein. In one example, an antibody is provided having a complete heavy chain sequence that is at least 95% identical to the amino acid sequence of the complete heavy chain sequence of any antibody disclosed herein, such as a combination of the SEQ ID Nos of the heavy chain variable domain and the heavy chain constant domain sequences disclosed herein. In one example, an antibody is provided having a complete heavy chain sequence that is at least 96% identical to the amino acid sequence of the complete heavy chain sequence of any antibody disclosed herein, such as a combination of the SEQ ID Nos of the heavy chain variable domain and the heavy chain constant domain sequences disclosed herein. In one example, an antibody is provided having a complete heavy chain sequence that is at least 97% identical to the amino acid sequence of the complete heavy chain sequence of any antibody disclosed herein, such as a combination of the SEQ ID Nos of the heavy chain variable domain and the heavy chain constant domain sequences disclosed herein. In one example, an antibody having a complete heavy chain sequence that is at least 98% identical to the amino acid sequence of the complete heavy chain sequence of any antibody disclosed herein, such as a combination of SEQ ID Nos. of the heavy chain variable domain and heavy chain constant domain sequences disclosed herein is provided. In one example, an antibody having a complete heavy chain sequence that is at least 99% identical to the amino acid sequence of the complete heavy chain sequence of any antibody disclosed herein, such as a combination of SEQ ID Nos. of the heavy chain variable domain and heavy chain constant domain sequences disclosed herein is provided.In one example, an antibody is provided having a complete heavy chain sequence that is at least 99.5% identical in amino acid sequence to the complete heavy chain sequence of any antibody disclosed herein, such as a combination of SEQ ID Nos. of the heavy chain variable domain and heavy chain constant domain sequences disclosed herein.
[0651] In one example, an antibody having a complete light chain sequence is provided, the complete light chain sequence being at least 70% identical to the amino acid sequence of the complete light chain sequence of any antibody disclosed herein, such as a combination of the SEQ ID Nos of the light chain variable domain and the light chain constant domain sequences disclosed herein. In one example, an antibody having a complete light chain sequence is provided, the complete light chain sequence being at least 75% identical to the amino acid sequence of the complete light chain sequence of any antibody disclosed herein, such as a combination of the SEQ ID Nos of the light chain variable domain and the light chain constant domain sequences disclosed herein. In one example, an antibody having a complete light chain sequence is provided, the complete light chain sequence being at least 80% identical to the amino acid sequence of the complete light chain sequence of any antibody disclosed herein, such as a combination of the SEQ ID Nos of the light chain variable domain and the light chain constant domain sequences disclosed herein. In one example, an antibody having a complete light chain sequence is provided, the complete light chain sequence being at least 85% identical to the amino acid sequence of the complete light chain sequence of any antibody disclosed herein, such as a combination of the SEQ ID Nos of the light chain variable domain and the light chain constant domain sequences disclosed herein. In one example, an antibody is provided having a complete light chain sequence that is at least 90% identical to the amino acid sequence of the complete light chain sequence of any antibody disclosed herein, such as a combination of the SEQ ID Nos of the light chain variable domain and the light chain constant domain sequences disclosed herein. In one example, an antibody is provided having a complete light chain sequence that is at least 95% identical to the amino acid sequence of the complete light chain sequence of any antibody disclosed herein, such as a combination of the SEQ ID Nos of the light chain variable domain and the light chain constant domain sequences disclosed herein. In one example, an antibody is provided having a complete light chain sequence that is at least 96% identical to the amino acid sequence of the complete light chain sequence of any antibody disclosed herein, such as a combination of the SEQ ID Nos of the light chain variable domain and the light chain constant domain sequences disclosed herein. In one example, an antibody is provided having a complete light chain sequence that is at least 97% identical to the amino acid sequence of the complete light chain sequence of any antibody disclosed herein, such as a combination of the SEQ ID Nos of the light chain variable domain and the light chain constant domain sequences disclosed herein. In one example, an antibody having a complete light chain sequence is provided, and the complete light chain sequence is at least 98% identical to the amino acid sequence of the complete light chain sequence of any antibody disclosed herein, such as a combination of SEQ ID Nos of the light chain variable domain and the light chain constant domain sequences disclosed herein. In one example, an antibody having a complete light chain sequence is provided, and the complete light chain sequence is at least 99% identical to the amino acid sequence of the complete light chain sequence of any antibody disclosed herein, such as a combination of SEQ ID Nos of the light chain variable domain and the light chain constant domain sequences disclosed herein.In one example, an antibody is provided having a complete light chain sequence that is at least 99.5% identical in amino acid sequence to the complete light chain sequence of any antibody disclosed herein, such as a combination of SEQ ID Nos. of the light chain variable domain and light chain constant domain sequences disclosed herein.
[0652] In one example, an antibody is provided that has at least 70% sequence identity over the complete heavy and light chain sequences with the sequence of any antibody disclosed herein. In one example, an antibody is provided that has at least 75% sequence identity over the complete heavy and light chain sequences with the sequence of any antibody disclosed herein. In one example, an antibody is provided that has at least 80% sequence identity over the complete heavy and light chain sequences with the sequence of any antibody disclosed herein. In one example, an antibody is provided that has at least 85% sequence identity over the complete heavy and light chain sequences with the sequence of any antibody disclosed herein. In one example, an antibody is provided that has at least 90% sequence identity over the complete heavy and light chain sequences with the sequence of any antibody disclosed herein. In one example, an antibody is provided that has at least 95% sequence identity over the complete heavy and light chain sequences with the sequence of any antibody disclosed herein. In one example, an antibody is provided that has at least 96% sequence identity over the complete heavy and light chain sequences with the sequence of any antibody disclosed herein. In one example, an antibody is provided that has at least 97% sequence identity over the entire heavy and light chain sequence to the sequence of any antibody disclosed herein. In one example, an antibody is provided that has at least 98% sequence identity over the entire heavy and light chain sequence to the sequence of any antibody disclosed herein. In one example, an antibody is provided that has at least 99% sequence identity over the entire heavy and light chain sequence to the sequence of any antibody disclosed herein. In one example, an antibody is provided that has at least 99.5% sequence identity over the entire heavy and light chain sequence to the sequence of any antibody disclosed herein.
[0653] 5.9 Replacement
[0654] In some examples, the antibodies comprise amino acid substitutions compared to the sequences defined herein.
[0655] In some examples, an antibody is provided that is defined by the same sequence as one of the exemplary antibodies described herein and shown in Table 1, but wherein the sequence comprises an amino acid substitution.
[0656] Amino acid substitutions include changes in which an amino acid is replaced by a different naturally occurring amino acid residue. Such substitutions can be classified as "conservative," in which the amino acid residue comprised in the polypeptide is replaced by another naturally occurring amino acid having similar characteristics in terms of polarity, side chain functionality, or size. Such conservative substitutions are well known in the art. Substitutions encompassed by the present invention can also be "non-conservative," in which the amino acid residue present in the peptide is replaced by an amino acid having different properties, such as naturally occurring amino acids from different groups (e.g., replacing a charged or hydrophobic amino acid with alanine), or alternatively, wherein a naturally occurring amino acid is replaced by an unconventional amino acid.
[0657] In one embodiment, conservative amino acid substitutions are as described herein. For example, a substitution can be F for Y, S or K for T, A for P, D or Q for E, D or G for N, K for R, N or A for G, S or K for T, N or E for D, L or V for I, Y for F, T or A for S, K for R, N or A for G, R for K, S, K or P for A. In another embodiment, a conservative amino acid substitution can be wherein F replaces Y, A or S replaces T, L or V replaces I, Y replaces W, L replaces M, D replaces N, A replaces G, A or S replaces T, N replaces D, L or V replaces I, Y or L replaces F, A or T replaces S, and S, G, T or V replaces A.
[0658] In one example, the amino acid substitution is outside the CDR sequence.
[0659] 5.10 Light Chain
[0660] In some embodiments, the antibody comprises a kappa light chain, and the amino acid and nucleotide sequences of the kappa light chain constant region are shown in SEQ ID Nos: 447-456.
[0661] In one example, the light chain can be a lambda light chain. The lambda light chain constant region amino acid and nucleotide sequences can be found in SEQ ID Nos: 457-481.
[0662] 5.11 Isotypes, Constant Regions, and Modifications
[0663] Selection of the appropriate antibody format (eg, IgG4 or IgG1) can be used to achieve desired results.
[0664] The antibody may be in the form of an antibody with limited Fc effector function, such as IgG4, such as a stable IgG4 isotype.
[0665] The antibodies described herein may comprise a constant region, such as a human constant region, e.g., an effector-less human constant region, e.g., an IgG4 constant region or an IgG1 constant region, optionally wherein the constant region is IgG4-PE (SEQ ID Nos: 441-446 and 482-483), or a disabled IgG1 as defined in SEQ ID Nos: 425-426.
[0666] In a preferred embodiment, the constant region of the antibody is SEQ ID NO:418.
[0667] In other embodiments, the antibody is any isotype or constant region as defined above. In one embodiment, the constant region is a wild-type human IgG1 (SEQ ID No: 417-424). For example, the constant region is an effector-enabled IgG1 constant region, optionally with ADCC and / or CDC activity. In one embodiment, the constant region is engineered for enhanced ADCC and / or CDC and / or ADCP. In another embodiment, the constant region is engineered for enhanced effector function.
[0668] In some embodiments, the antibody may comprise modifications that enhance the antibody's ability to aggregate, thereby becoming a better substrate for complement fixation. The Fc domain of IgG1 may be mutated, for example, at E345 or E430 to enhance inter-antibody Fc:Fc interactions and stimulate the formation of hexamer, which enhances the induction of CDC and ADCC on target cells (de Jong et al., PloS Biol [Public Library of Science Biology] 14 (1) e1002344 2016). Hexamer formation is optionally combined with a bispecific antibody format.
[0669] The IgG4 constant region can be any IgG4 constant region amino acid sequence, or encoded by any nucleic acid sequence (SEQ ID No: 435-440). The heavy chain constant region can be an IgG4 comprising both a Leu235Glu mutation and a Ser228Pro mutation. The "IgG4-PE" heavy chain constant region (SEQ ID No: 441-446 and 482-483) is effector-free.
[0670] The alternative effector-free human constant region is a disabled IgG1, which is an IgG1*01 allele comprising the L235A and / or G237A mutations (e.g., LAGA, SEQ ID Nos: 425-426). In one example, the antibodies or antibody fragments disclosed herein comprise an IgG1 heavy chain constant region wherein the sequence contains alanine at positions 235 and / or 237 (EU index numbering). The mechanism of antibody-dependent cellular phagocytosis (ADCP) is discussed in Gül et al., "Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer," Cancer Res., 75(23), December 1, 2015.
[0671] The effectiveness of Fc-mediated effects can be enhanced by engineering Fc domains using various established technologies. Such methods increase affinity for certain Fc receptors or reduce affinity for inhibitory Fc receptors, thereby generating potential diversified activation enhancement features. This can be achieved by modifying one or more amino acid residues (e.g., as described in Lazar et al., 2006, Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States of America], March 14; 103(11): 4005-10; the modifications disclosed therein are incorporated herein by reference). It has been shown that human IgG1 constant regions containing specific mutations or altered glycosylation at residue Asn297 (e.g., N297Q, EU index numbering) can enhance binding to certain Fc receptors. In one example, such mutations are selected from one or more residues of 239, 332, and 330 (or equivalent positions in other IgG isotypes) of the human IgG1 constant region. In one example, the antibody or fragment comprises a human IgG1 constant region having one or more mutations independently selected from N297Q, S239D, I332E, and A330L (EU index numbering).
[0672] In another example, increased affinity for Fc receptors is achieved by altering the native glycosylation characteristics of the Fc domain, for example, by generating hypofucosylated or afucosylated variants (as described in Natsume et al., 2009, Drug Des. Devel. Ther. [Drug Design, Development and Therapy], 3:7–16 or Zhou Q., Biotechnol. Bioeng. [Biotechnology and Bioengineering], February 15, 2008, 99(3):652-65, the modifications described therein being incorporated herein by reference). Non-fucosylated antibodies have a trimannosyl core structure of the complex N-glycans of Fc without fucose residues. These glycoengineered antibodies lacking the core fucose residues of the Fc N-glycans may exhibit enhanced ADCC compared to fucosylated antibodies due to enhanced FcγRIIIa binding ability. For example, to increase ADCC, residues in the hinge region can be altered to increase binding to Fc-γRIII (see, e.g., Shields et al., 2001, J. Biol. Chem., Mar 2; 276(9): 6591-604; modifications described therein are incorporated herein by reference). Thus, in one example, the antibody or fragment comprises a human IgG heavy chain constant region that is a variant of a wild-type human IgG heavy chain constant region, wherein the variant human IgG heavy chain constant region binds to a human Fcγ receptor selected from the group consisting of FcγRIIB and FcγRIIA with a higher affinity than the wild-type human IgG heavy chain constant region binds to a human Fcγ receptor. In one example, the antibody or fragment comprises a human IgG heavy chain constant region that is a variant of a wild-type human IgG heavy chain constant region, wherein the variant human IgG heavy chain constant region binds to human FcγRIIB with a higher affinity than the wild-type human IgG heavy chain constant region binds to human FcγRIIB. In one example, the variant human IgG heavy chain constant region is a variant human IgG1, variant human IgG2 or variant human IgG4 heavy chain constant region. In one example, the variant human IgG heavy chain constant region comprises one or more amino acid mutations selected from G236D, P238D, S239D, S267E, L328F and L328E (EU index numbering system). In another example, the variant human IgG heavy chain constant region comprises a set of amino acid mutations selected from the group consisting of: S267E and L328F; P238D and L328E; P238D and one or more substitutions selected from the group consisting of: E233D, G237D, H268D, P271G and A330R; P238D, E233D, G237D, H268D, P271G and A330R; G236D and S267E; S239D and S267E; V262E, S267E and L328F; and V264E, S267E and L328F (EU index numbering system).In another example, the variant human IgG heavy chain constant region further includes one or more amino acid mutations that reduce the affinity of IgG to human FcγRIIIA, human FcγRIIA or human FcγRI. In one example, FcγRIIB is expressed on cells selected from macrophages, monocytes, B cells, dendritic cells, endothelial cells and activated T cells. In one embodiment, the variant human IgG heavy chain constant region includes the following one or more amino acid mutations: G236A, S239D, F243L, T256A, K290A, R292P, S298A, Y300L, V305I, A330L, I332E, E333A, K334A, A339T and P396L (EU index numbering system). In one example, the variant human IgG heavy chain constant region comprises a set of amino acid mutations selected from the group consisting of: S239D; T256A; K290A; S298A; I332E; E333A; K334A; A339T; S239D and I332E; S239D, A330L and I332E; S298A, E333A and K334A; G236A, S239D and I332E; and F243L, R292P, Y300L, V305I and P396L (EU index numbering system). In one example, the variant human IgG heavy chain constant region comprises S239D, A330L or I332E amino acid mutations (EU index numbering system). In one example, the variant human IgG heavy chain constant region comprises S239D and I332E amino acid mutations (EU index numbering system). In one example, the variant human IgG heavy chain constant region is a variant human IgG1 heavy chain constant region comprising the S239D and I332E amino acid mutations (EU index numbering system). In one example, the antibody or fragment comprises an afucosylated Fc region. In another example, the antibody or fragment thereof is afucosylated. In another example, the antibody or fragment is hypofucosylated.
[0673] In another example, the antibodies and fragments disclosed herein may comprise a triple mutation (M252Y / S254T / T256E) that enhances binding to FcRn. See Dall'Aqua et al., Immunol [Immunology] 2002; 169: 5171-5180 for a discussion of mutations affecting FcRn binding in Table 2, the mutations described therein being incorporated herein by reference.
[0674] Likewise, enhancement of CDC can be achieved by amino acid changes that increase affinity for C1q, the first component of the classical complement activation cascade (see Idusogie et al., J. Immunol., 2001, 166:2571–2575; the modifications described are incorporated herein by reference). Another approach is to generate chimeric Fc domains made from human IgG1 and human IgG3 fragments, taking advantage of the higher affinity of IgG3 for C1q (Natsume et al., 2008, Cancer Cell Biology, 1996). Res. Cancer Res, 68:3863–3872; these modifications are incorporated herein by reference. In another example, the antibodies or antibody fragments disclosed herein may comprise amino acid mutations at residues 329, 331, and / or 322 to alter C1q binding and / or reduce or eliminate CDC activity. In another example, the antibodies or antibody fragments disclosed herein may contain an Fc region with modifications at residues 231 and 239, thereby replacing amino acids to alter the antibody's ability to fix complement. In one example, the antibody or fragment comprises a constant region comprising one or more mutations selected from E345K, E430G, R344D, and D356R, particularly a double mutation comprising R344D and D356R (EU index numbering system).
[0675] The antibody may have a heavy chain constant region that binds to one or more types of Fc receptors but does not induce cellular effector functions, i.e., does not mediate ADCC, CDC, or ADCP activity. Such a constant region may not be able to bind to the specific Fc receptor responsible for triggering ADCC, CDC, or ADCP activity. The antibody may have a heavy chain constant region that does not bind to Fcγ receptors. Therefore, in one example, the constant region may include a Leu235Glu mutation (EU index numbering system).
[0676] In another example, the antibodies disclosed herein are modified to extend or shorten serum half-life. In one embodiment, one or more of the following mutations are introduced: T252L, T254S, or T256F to extend the biological half-life of the antibody. The biological half-life can also be increased by changing the heavy chain constant region CH1 domain or CL region to include salvage receptor binding epitopes from two loops of the CH2 domain of the Fc region of IgG, as described in U.S. Patent Nos. 5,869,046 and 6,121,022, the modifications described therein are incorporated herein by reference. In another example, the Fc hinge region of the antibody or antigen-binding fragment of the present invention is mutated to shorten the biological half-life of the antibody or fragment. One or more amino acid mutations are introduced into the CH2-CH3 domain interface region of the Fc hinge fragment so that the antibody or fragment has impaired SpA binding relative to the native Fc hinge domain Staphylococcus protein A (SpA). Other methods of extending serum half-life are known to those skilled in the art. Therefore, in one example, the antibody or fragment is PEGylated. In another example, the antibody or fragment is fused to an albumin binding domain, such as an albumin binding single domain antibody (dAb). In another example, the antibody or fragment is PASylated (i.e., genetic fusion of a polypeptide sequence consisting of PAS (XL-Protein GmbH), which forms an uncharged random coil structure with a large hydrodynamic volume). In another example, the antibody or fragment is In some embodiments, the antibody or fragment is PEGylated (i.e., genetically fused to an imprecise repeat sequence (Amunix, Versartis) with a therapeutic peptide). In another example, the antibody or fragment is ELPylated (i.e., genetically fused to an ELP repeat sequence (PhaseBio)). These various half-life-extending fusions are described in more detail in Strohl, BioDrugs (2015) 29:215-239, which is incorporated herein by reference.
[0677] Antibodies may have modified constant regions that increase stability. Thus, in one example, the heavy chain constant region comprises a Ser228Pro mutation. In another example, the antibodies and fragments disclosed herein comprise a heavy chain hinge region that has been modified to alter the number of cysteine residues. Such modifications can be used to facilitate assembly of the light and heavy chains or to increase or decrease the stability of the antibody.
[0678] 5.12 Classification of Acinetobacter baumannii Clones G2 and G2 Strains
[0679] GC2 strains are defined based on whole-genome sequencing data and phylogenetic analysis. Representative GC2 strains are available from ATCC and NCTC.
[0680] The publicly available strain NCTC 13424 can be used to reproduce all assays for OC1 LOS and Oxa-23 described herein.
[0681] (http: / / www.pheculturecollections.org.uk / products / bacteria / detail.jsp?refId=NCTC+13424&collection=nctc, the contents of which are incorporated herein by reference)
[0682] The prototype strain LAC-4 (GenBank reference number: GCA_000786735.1) is also widely cited in the literature and can be used to reproduce all KL49 assays described herein ( https: / / www.genome.jp / kegg-bin / show_ organism? org=abal. PMID: 25728466. Sci Rep [Scientific Report] 5: 8643 (2015) DOI: 10.1038 / srep08643, the content of which is incorporated herein by reference).
[0683] Antibodies that specifically bind to the G2 clone of Acinetobacter baumannii may cross-react with related antigens, such as antigens of other clones of Acinetobacter baumannii.
[0684] The methods for determining binding as described herein can also be used to determine cross-reactivity of antibodies to different clones or strains of Acinetobacter baumannii.
[0685] 5.13 Antibody Production
[0686] In some instances, the antibody is a monoclonal antibody. Methods for preparing monoclonal antibodies are known, including, for example, fusing myeloma cells with cells from an animal immunized with the desired antigen. In other instances, monoclonal antibodies can be produced using recombinant DNA technology.
[0687] In some instances, the antibody is a human antibody. In one instance, the antibody is a fully human antibody. In one instance, the antibody is a fully human monoclonal antibody.
[0688] 5.14 Nucleic Acids, Vectors, and Host Cells
[0689] Also provided are nucleic acids encoding the VH domain and / or VL domain of any of the antibodies described herein. Nucleic acids encoding the VH domain of any of the antibodies described herein are provided. Nucleic acids encoding the VL domain of any of the antibodies described herein are provided.
[0690] Table 1 lists the SEQ ID No. and nucleic acid sequences encoding the VH and VL domains of each exemplary antibody described herein.
[0691] In one example, the nucleic acid sequence is at least 70% identical to the designated SEQ ID No. In one example, the nucleic acid sequence is at least 80% identical to the designated SEQ ID No. In one example, the nucleic acid sequence is at least 90% identical to the designated SEQ ID No. In one example, the nucleic acid sequence is at least 95% identical to the designated SEQ ID No. In one example, the nucleic acid sequence is at least 96% identical to the designated SEQ ID No. In one example, the nucleic acid sequence is at least 97% identical to the designated SEQ ID No. In one example, the nucleic acid sequence is at least 98% identical to the designated SEQ ID No. In one example, the nucleic acid sequence is at least 99% identical to the designated SEQ ID No. In one example, the nucleic acid sequence is at least 99.5% identical to the designated SEQ ID No.
[0692] In one example, the nucleic acid encodes a heavy chain of any of the antibodies described herein. In another example, the nucleic acid encodes a light chain of any of the antibodies described herein.
[0693] In one example, the nucleic acid is isolated and purified nucleic acid.
[0694] Also provided is a vector comprising the above nucleic acid. In one example, the vector can be a CHO cell expression vector. In one example, the vector can be a HEK293 cell expression vector.
[0695] Also provided are host cells comprising the above nucleic acids. In some instances, the host cell is a eukaryotic cell, such as a mammalian cell, preferably a CHO cell (e.g., a CHO cell grown in suspension culture). HEK293 cells are an alternative cell line for manufacturing.
[0696] 5.15 Pharmaceutical Compositions
[0697] In one example, a pharmaceutical composition is provided, comprising an effective amount of an antibody as described herein and a pharmaceutically acceptable excipient. The effective amount of the antibody used in treatment will depend, for example, on the therapeutic purpose, the route of administration, and the patient's condition. In one example, the composition comprises other excipients or stabilizers.
[0698] Pharmaceutically acceptable excipients are known and include carriers, excipients, or stabilizers that are nontoxic to the cells or mammals exposed thereto at the dosages and concentrations employed. Typically, a physiologically acceptable excipient is an aqueous pH buffered solution. Examples of physiologically acceptable excipients include buffers such as phosphates, citrates, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as ethylenediaminetetraacetic acid (EDTA); sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and / or nonionic surfactants such as TWEEN®. TM , polyethylene glycol (PEG) and PLURONICS TM .
[0699] The antibody can be administered intravenously or through the nose or lungs, for example, in the form of a liquid or powder aerosol (lyophilized) or by atomization of a liquid. The composition can also be administered parenterally or subcutaneously. When administered systemically, the composition should be sterile, pyrogen-free and in a physiologically acceptable solution with appropriate consideration of pH, isotonicity and stability. These conditions are well known to those skilled in the art.
[0700] The method of administering a preventive or therapeutic agent (e.g., an antibody disclosed herein) or a pharmaceutical composition includes, but is not limited to, parenteral administration (e.g., intradermal, intramuscular, intraperitoneal, intravenous, and subcutaneous), epidural, and mucosal (e.g., intranasal and oral routes). In a specific example, a preventive or therapeutic agent (e.g., an antibody disclosed herein) or a pharmaceutical composition is administered intranasally, intramuscularly, intravenously, or subcutaneously. The preventive or therapeutic agent or composition can be administered by any convenient route, such as by infusion or bolus, by absorption through epithelial or mucosal skin linings (e.g., oral mucosa, intranasal mucosa, rectal and intestinal mucosa, etc.), and can be administered together with other bioactive agents. Administration can be systemic or local. Each dosage can be administered by or without the same route of administration.
[0701] Various delivery systems are known and can be used to administer prophylactic or therapeutic agents (e.g., antibodies as disclosed herein), including but not limited to encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the antibody, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)), constructing the nucleic acid as part of a retroviral or other vector, etc. In addition, pulmonary administration can also be employed, for example, by use of an inhaler or nebulizer and formulation with an aerosolizing agent. See, e.g., U.S. Patent Nos. 6,019,968, 5,985,320, 5,985,309, 5,934,272, 5,874,064, 5,855,913, 5,290,540, and 4,880,078; and PCT Publication Nos. WO 92 / 19244, WO 97 / 32572, WO 97 / 44013, WO 98 / 31346, and WO 99 / 66903, each of which is herein incorporated by reference in its entirety.
[0702] In a specific example, it may be necessary to administer a prophylactic or therapeutic agent or a pharmaceutical composition as described herein topically to the area in need of treatment. This can be achieved, for example, by local infusion, by topical administration (e.g., by intranasal spray), by injection, or by implants made of porous, non-porous, or gel-like materials, including membranes (such as silicone rubber membranes) or fibers. When administering antibodies, care must be taken to use materials that the antibody does not absorb.
[0703] In the case of a medicine for local and / or topical application, for example, by being absorbed into the epithelium or mucocutaneous lining, the antibody can be provided as an IgA isotype antibody. For human patients, preferably human IgA1 or human IgA2 antibodies. Preparations for inhalation and / or for delivery of antibodies (or their encoding nucleic acids, for example in DNA vectors) to the medicine of the upper and / or lower respiratory tract include preparations for delivering aerosolized medicines, which can include IgA (for example, human IgA1 or human IgA2) antibodies. Therefore, inhalers, nebulizers and similar devices can be provided, which contain medicines comprising IgA antibodies or their encoding nucleic acids, and any buffer or other excipients suitable for stabilizing the medicine and / or promoting its delivery to the target tissue.
[0704] 5.16 Therapeutic Uses
[0705] The antibodies described herein can be used to treat or prevent bacterial infections caused by Acinetobacter baumannii. One aspect includes the use of an antibody or composition described herein as a medicament.
[0706] Therefore, in one example, there is provided an antibody as herein described or a composition as herein described, which is used in a method for treating a bacterial infection caused by Acinetobacter baumannii, comprising administering the antibody or composition to the patient. In another example, there is provided an antibody as herein described or a composition as herein described, which is used in a method for preventing a bacterial infection caused by Acinetobacter baumannii, comprising administering the antibody or composition to the patient.
[0707] The patient can be any animal, including but not limited to mammals. In one embodiment, the patient is a human. In one embodiment, the patient is an adult. In one embodiment, the patient is a human over the age of 12.
[0708] In one embodiment, the bacterial infection caused by Acinetobacter baumannii is a nosocomial bacterial infection caused by Acinetobacter baumannii.
[0709] In one embodiment, the patient has a lower respiratory tract infection, such as pneumonia, such as ventilator-associated pneumonia.
[0710] In one embodiment, the patient has sepsis.
[0711] In one embodiment, the patient has bacteremia.
[0712] In one example, the antibody for use above or the composition for use above reduces one or more symptoms of a bacterial infection caused by Acinetobacter baumannii.
[0713] In one example, the progression of a bacterial infection caused by Acinetobacter baumannii is reduced.
[0714] In one example, the risk of developing a bacterial infection caused by Acinetobacter baumannii is reduced.
[0715] In one example, the risk of transmission of a bacterial infection caused by Acinetobacter baumannii to and / or from a patient is reduced.
[0716] Provided herein are the purposes of antibodies as herein described or compositions as herein described in the manufacture of medicines for the treatment of the bacterial infection caused by Acinetobacter baumannii. Also provided are the purposes of antibodies as herein described or compositions as herein described in the manufacture of medicines for the prevention of the bacterial infection caused by Acinetobacter baumannii. Therefore, in one example, one or more symptoms of the bacterial infection caused by Acinetobacter baumannii are reduced. In another example, the progress of the bacterial infection caused by Acinetobacter baumannii is reduced. In another example, the risk of the bacterial infection caused by Acinetobacter baumannii is reduced. In another example, the risk of the bacterial infection caused by Acinetobacter baumannii is reduced and propagated to people and / or from people.
[0717] A method for treating the bacterial infection caused by Acinetobacter baumannii is provided, the method comprising administering an antibody as herein described or a composition as herein described to the people for the treatment of a significant amount. A method for preventing the bacterial infection caused by Acinetobacter baumannii is also provided, the method comprising administering an antibody as herein described or a composition as herein described to the people for the treatment of a significant amount. In one example, one or more symptoms of the bacterial infection caused by Acinetobacter baumannii are reduced. In one example, the progress of the bacterial infection caused by Acinetobacter baumannii is reduced. In one example, the risk of the bacterial infection caused by Acinetobacter baumannii is reduced. In one example, the risk of the bacterial infection caused by Acinetobacter baumannii is spread to people and / or from people.
[0718] In one example, the purposes or method of the antibody or composition as described herein further comprises administering at least one other therapeutic agent. In one example, the first antibody and the other therapeutic agent are administered simultaneously, separately or sequentially. In one example, the other therapeutic agent is another antibody.
[0719] In one example, the additional therapeutic agent is a carbapenem. In this regard, the inventors have identified a synergistic effect between the administration of a carbapenem and the administration of an anti-Oxa-23 mAb described herein, which is due to the mode of action of the anti-Oxa-23 antibody, i.e., the antibody inhibits the activity of the Oxa-23 carbapenemase, thereby suppressing the associated resistance to the carbapenem.
[0720] In one embodiment, the additional therapeutic agent is colistin.
[0721] In one example, the antibody is administered in the form of an antibody-drug conjugate, wherein the antibody is linked to a drug moiety. For example, the antibody can be linked to a drug moiety, which can be a cytokine, a chemokine, or a small molecule antiviral agent.
[0722] Antibodies described herein can be used to prevent death and shorten recovery and discharge time in patients with bacterial infections caused by Acinetobacter baumannii. Patients are typically human patients and can be patients diagnosed with bacterial infections caused by Acinetobacter baumannii. In addition, patients can be patients who have been admitted to the hospital for other reasons.
[0723] In another example, a kit for treating a bacterial infection caused by Acinetobacter baumannii is provided, wherein the kit comprises an antibody as described herein and instructions for administering the antibody to a subject in need of treatment. Also provided is a pharmaceutical or diagnostic package or kit comprising one or more containers filled with one or more ingredients of a pharmaceutical composition as disclosed herein, such as one or more anti-Oxa-23 antibodies provided herein. Also provided is a pharmaceutical or diagnostic package or kit comprising one or more containers filled with one or more ingredients of a pharmaceutical composition as disclosed herein, such as one or more anti-OC1 LOS antibodies provided herein. Also provided is a pharmaceutical or diagnostic package or kit comprising one or more containers filled with one or more ingredients of a pharmaceutical composition as disclosed herein, such as one or more anti-KL49 antibodies provided herein. Optionally, associated with such container may be a notice in a form prescribed by a governmental agency regulating the manufacture, use, or sale of drugs or biological products, reflecting the agency's approval of manufacture, use, or sale for human administration, such as a license number.
[0724] In another example, there is provided a product including a container and a package insert or label, containing an antibody as described herein in the container, the package insert or label indicating that the composition can be used to treat the bacterial infection caused by Acinetobacter baumannii. In one example, there is provided a kit for treating and / or preventing the bacterial infection caused by Acinetobacter baumannii, the kit comprising the antibody disclosed in any example or example combination herein (and optionally another therapeutic agent as described elsewhere herein), optionally in combination with a label or instructions for treating and / or preventing the infection of a person; optionally, wherein the label or instructions include a marketing authorization number (e.g., FDA or EMA authorization number); optionally, wherein the kit includes an IV device or an injection device containing the antibody. In another example, the kit includes the antibody contained in a container or IV bag. In another example, the container or IV bag is a sterile container or sterile IV bag. In another example, the antibody is formulated into a pharmaceutical composition contained in a (sterile) container or in a (sterile) IV bag. In another example, the kit further includes instructions for use.
[0725] In another example, a kit for treating a bacterial infection caused by Acinetobacter baumannii is provided, wherein the kit comprises an antibody as described herein and instructions for administering the antibody to a subject in need of treatment. In the kit, the desired subject can be specifically defined as a person belonging to a specific high-risk group, where the specific high-risk group is defined based on epidemiological data, risk stratification data in a person's health record, the genotype of certain genes in the individual, or certain biomarkers present in a blood or other tissue sample of the individual for risk stratification. When risk stratification involves another drug or diagnostic kit or test kit, the combination product will serve as a linked diagnostic / prognostic and therapeutic kit.
[0726] 5.17 Prevention of infection—prophylactic use
[0727] Antibodies as described herein can be used prophylactically. Administering antibodies can prevent infection or reduce the risk of Acinetobacter baumannii infection. Antibodies can, for example, be used to prevent infection in high-transmission environments (e.g., hospitals) of those at risk. Antibodies can be administered to patients connected to a ventilator to reduce the risk of a patient contracting ventilator-associated pneumonia.
[0728] 5.18 Diagnosis
[0729] Antibodies as herein described can be used for detecting the presence, absence and / or level of Acinetobacter baumannii in the biological sample of the patient.In one example, biological sample is a tissue sample (for example, in pathological studies or for diagnosis and prognosis of tissue biopsy samples).In other examples, biological sample is blood, blood plasma, serum, urine, feces, cerebrospinal fluid (CFS).In other examples, biological sample is from nasal swab or pharyngeal swab.Liquid sample is convenient to use in many types of diagnostic assays.
[0730] The antibodies described herein can be used to identify the presence, absence, and / or levels of Acinetobacter baumannii at baseline (ie, prior to treatment).
[0731] The antibodies described herein can be used to guide treatment, in particular to identify the presence, absence and / or levels of Acinetobacter baumannii during or after treatment.
[0732] The antibodies described herein can be used for patient monitoring to help assess whether a course of treatment is effective and whether treatment should be continued.
[0733] In one example, the antibodies described herein are labeled with a detectable moiety, such as a radioactive marker, a fluorescent marker, an enzyme marker, a chemiluminescent marker, or a biotin group. Radioisotopes or radionuclides can include 3H, 14C, 15N, 35S, 90Y, 99Tc, 115In, 125I, 131I, fluorescent markers can include rhodamine, lanthanide phosphors, or FITC, and enzyme markers can include horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase. By way of illustration and not limitation, additional labels include: enzymes such as glucose-6-phosphate dehydrogenase ("G6PDH"), α-D-galactosidase, glucose oxidase, glucoamylase, carbonic anhydrase, acetylcholinesterase, lysozyme, malate dehydrogenase, and peroxidase; dyes; additional fluorescent labels or fluorophores include, for example, fluorescein and its derivatives, fluorescent dyes, GFP (GFP stands for "green fluorescent protein"), dansyl, umbelliferone, phycoerythrin, phycocyanin, allophycocyanin, o-phthalaldehyde, and fluorescamine; fluorophores such as lanthanide cryptates and chelates, for example, europium, and the like (PerkinElmer and Cisbio). Assays); chemiluminescent labels or chemiluminescent agents, such as isoluminol, luminol and dioxetane; sensitizers; coenzymes; enzyme substrates; particles, such as latex or carbon particles; metal sols; microcrystals; liposomes; cells, etc., which may be further labeled with a dye, catalyst or other detectable group; molecules, such as biotin, digoxigenin or 5-bromodeoxyuridine; toxin moieties, for example, toxin moieties selected from the group consisting of: Pseudomonas exotoxin (PE or a cytotoxic fragment or mutant thereof), diphtheria toxin or a cytotoxic fragment or mutant thereof, botulinum toxin A, B, C, D, E or F, ricin or a cytotoxic fragment thereof (e.g., ricin A), abrin or a cytotoxic fragment thereof, saporin or a cytotoxic fragment thereof, pokeweed antiviral toxin or a cytotoxic fragment thereof, and brentuxine 1 or a cytotoxic fragment thereof.
[0734] In one example, an antibody can be administered to a patient, wherein the antibody is conjugated to a marker. The presence of the marker in the patient can be measured or observed, wherein a relatively high amount of the marker can indicate a higher risk of infection, while a relatively low amount of the marker can indicate a relatively lower risk of infection. In one example, the marker is a contrast agent, an isotope label, or a fluorescent marker, such as green fluorescent protein.
[0735] For use in diagnostics, antibodies with high affinity, particularly those with fast on-rates and slow off-rates (eg, as measured by SPR), are particularly valuable.
[0736] In certain embodiments, it is desirable to include 2 kinds of antibodies in the diagnostic assay, and these antibodies should preferably be directed against different targets on Acinetobacter baumannii. The diagnostic assay can be a dual antigen binding assay (DABA). In DABA, a first antibody is used as a capture antibody to bind to the Acinetobacter baumannii in the sample (for this purpose, as mentioned above, it is necessary to have a high-affinity antibody with a fast association rate and a slow dissociation rate), and a second antibody specific for the epi-position that is different from the epi-position of the capture antibody is used to detect. Therefore, the second antibody can be detected by direct or indirect labeling. DABA can include providing a first antibody (optionally fixed on the surface), contacting the surface with the sample to allow capture antigen (if present), subsequently washing to remove unconjugated antigen and sample, then exposing the surface to detection antibody to allow bound antigen (if present), washing to remove unconjugated detection antibody, and detecting the presence of the detection antibody. The presence of detection antibody shows that the sample is positive for Acinetobacter baumannii. This type of mensuration can be used to determine whether a patient has been infected with Acinetobacter baumannii.
[0737] In one example, a test kit for detecting the Acinetobacter baumannii in a biological sample is provided. This test kit can be used for screening Acinetobacter baumannii infection. In one example, this test kit comprises an antibody according to the present invention as described anywhere herein and an instrument for determining whether this antibody is combined with the Acinetobacter baumannii in a sample. In one example, this antibody is specific to Acinetobacter baumannii. In one example, this antibody is a mark. In another example, this antibody is an unlabeled one, and this test kit comprises an instrument for detecting one. In one example, the instrument for detecting comprises a second antibody of a mark, and this second antibody is an anti-immunoglobulin antibody. Antibodies can be labeled with any suitable marker, including, for example, fluorescent dyes, enzymes, radionuclides, and radiopaque materials.
[0738] In one example, a kit for detecting Acinetobacter baumannii is provided, wherein the kit comprises an antibody as described herein. In one example, the kit may further comprise instructions and one or more reagents for detecting Acinetobacter baumannii.
[0739] 5.19 Antibody Discovery
[0740] The present invention represents a completely new approach for antibody production and discovery for the diagnosis and treatment of pathogen (particularly bacterial) infections. This novel approach involves immunizing transgenic mice (such as humanized mice) with bacteria or other pathogens to produce antibodies in an antigen-agnostic manner because it has no inherent bias towards any potential target antigen on the pathogen. In addition, this novel approach provides the opportunity to combine multiple strains of pathogens in the immunization step, whereby the inventors have found that it is possible to discover monoclonal antibodies that are cross-reactive against multiple strains of pathogens. The inventors have further found that this approach is particularly suitable for bacteria that produce outer membrane vesicles (OMVs), wherein pooled, purified vesicles from multiple bacterial strains can be used to immunize humanized mice. In this regard, the inventors have found that there is a good correlation between antibodies that can bind to purified vesicles produced by bacteria and antibodies that can bind to live bacteria. In addition, the inventors have found that pooled OMVs have the potential to induce cross-reactive serum responses to other bacterial strains, thereby generating cross-reactive mAbs in mouse polyclonal reactions.
[0741] Therefore, the present invention provides a sample comprising multiple different strains of pathogens (e.g., bacteria), wherein the sample is suitable for immunizing transgenic mice, such as humanized mice. In one embodiment, the sample comprises pooled membrane vesicles isolated from multiple identical bacterial strains.
[0742] In addition, the present invention provides a method for preparing polyclonal human antibodies, which comprises: a) exposing transgenic mice (such as humanized mice) to antigen stimulation, so that the mice produce polyclonal antibodies against the antigen; b) isolating polyclonal antibodies from the mice; wherein the antigen comprises multiple different strains of pathogens (such as bacteria).
[0743] In addition, the present invention provides a method comprising preparing a sample comprising a plurality of different strains of a pathogen (e.g., a bacterium), the sample being suitable for immunizing a transgenic mouse (such as a humanized mouse). In one embodiment, the method further comprises immunizing a mouse with the prepared sample and collecting polyclonal antibodies produced by the mouse.
[0744] In one embodiment, the method further comprises characterizing the binding of the antibody produced by the mouse.
[0745] In one embodiment, the method further comprises isolating a monoclonal antibody, such as a fully human monoclonal antibody, from the polyclonal antibody produced by the mouse.
[0746] The present invention further provides antibody-producing transgenic mice, such as humanized mice, wherein the mice have been immunized with samples comprising multiple different strains of pathogens (eg, bacteria).
[0747] In one embodiment, transgenic mouse is a transgenic mouse that produces a hybrid antibody containing people's variable region and mouse constant region. In one embodiment, transgenic mouse is a humanized mouse that produces an antibody (e.g., a fully human antibody) with people's variable region, such as the proprietary IntelliSelect transgenic mouse platform (e.g., " Darwin ") of Kymab.
[0748] As an alternative to mice, rats or other non-human animals such as chickens or llamas can be used to discover antibodies by immunization, which is well known in the art.
[0749] 6. Examples
[0750] 6.1 Example 1: Antibody Generation
[0751] An end-to-end process enables the generation of mAbs against contemporary clinical strains of Acinetobacter baumannii. Figure 1 outlines this process. Broadly, our strategy targets the most relevant strains for which mAb-based therapies would be ideal due to multidrug resistance (MDR). Transgenic mice harboring humanized immunoglobulin loci are immunized with OMV preparations, resulting in the generation of antibodies with human heavy and light chain variable regions.
[0752] Figure 1a Time-resolved core genome phylogeny of GC2 Acinetobacter baumannii isolates in the Ho Chi Minh ICU. Shading indicates the period of empirical treatment of VAP in the ICU with the carbapenem antibiotic imipenem. Labeled AEs are the five carbapenem-resistant genomic subclades of GC2. Also listed on the right are the capsular K locus subtypes of the 10 strains tested for OMV production. Four strains successfully generated OMVs and used to immunize Kymab Intellisellect transgenic mice are marked with an asterisk (*).
[0753] Figure 1b Scanning electron microscopy images of unfixed OMV preparations produced from clinical isolates of Acinetobacter baumannii used for immunization. OMVs were prepared from Acinetobacter baumannii strains BAL_191, BAL_276, BAL_215, and BAL_084. Approximately 95% of the OMVs in this preparation had diameters between 25 and 70 nm, while larger OMVs with diameters >80 nm comprised 2% of the preparation. Amorphous structures were also observed, comprising 3% of the preparation.
[0754] Figure 2a.Protocol for OMV immunization. Ten mice received a prime dose of approximately 1 μg of OMV on day 0 of the study. Subsequently, the mice were divided into two study groups and five mice in group 1 were sacrificed on day 7 to harvest their spleens and lymph nodes. Five mice in group 2 received an additional boost on day 36 and were then sacrificed on day 43. Blood was collected before the prime and boost doses and on day 7. The reactivity of these sera to the immunizing OMVs was assessed by ELISA. Organs harvested on day 7 versus organs harvested on day 43 can be analyzed for B cell reactivity using IntelliSelect screening technology. PB = pre-bleed; SB = serial bleed; TB = endpoint bleed.
[0755] Figure 2b . with the Kymab Intellisellect transgenic mice of the mixed pool immunity of 4 kinds of GC2 Acinetobacter baumannii OMV to the polyclonal serum reaction of immune OMV, as determined by ELISA.(a) for the antigen-specific IgG1 kinetics of 4 kinds of GC2 Acinetobacter baumannii OMV of immunity reaction.To the total antigen-specific IgG1 reaction of 4 kinds of independent GC2 Acinetobacter baumannii OMV (BAL_084, BAL_191, BAL_215 and BAL_276 shown in bold) for immunity and suitable for the reaction of other 2 kinds of GC2 Acinetobacter baumannii OMV (BAL_339 and BAL_377) that do not exist in the 43rd day immunity pool of research.The specific IgG1 reaction of all immune mice is suitable, and all human Ig isotypes are represented by the specific antibody existing in the polyclonal serum.With respect to the pre-blood collection before the initial exemption, calculated the antigen-specific relative endpoint titer.
[0756] 6.2 Example 2: Antibody Screening
[0757] We developed a method for isolating antigen-specific IgG+ B cells from the spleens of mice immunized with GC2 CRAB OMVs. Figure 3 Using the gating strategy shown, we successfully isolated 2,087 OMV-bound IgG+ B cells from the spleens of GC2 CRAB OMV-immunized mice using FM4-64-stained OMVs as sorting bait ( Figure 3 After successful antigen-specific sorting, IgH / L sequencing and bioinformatics analysis were performed on the sorted single cells. This analysis revealed 951 pairs of heavy and light chain reads, of which 530 pairs were found to belong to the IgG subclass ( Figure 4b). In addition, the study revealed 372 sequence pairs within clusters containing >2 sequences derived from a common B cell progenitor. These clusters suggest that B cell IgH / L affinity maturation occurs within germinal centers formed in the spleens of immunized mice and, more strikingly, that convergent antibody evolution occurs between immunized mice, as evidenced by clusters containing related sequences from more than one mouse. Based on these findings, we selected heavy and light chain antibody pairs that met the following criteria: high-quality next-generation sequencing (NGS) data, 2 or more amino acid mutations on both the heavy and light chains indicating affinity maturation, an FM4-64 GC2 Acinetobacter baumannii OMV mean fluorescence intensity ≥7.2 after arcsine (inverse of the hyperbolic sine function) transformation, and no duplications at the amino acid level. The four most mutated sequences were selected from clusters containing a large number of related sequences, while even more mutated sequences were selected from doublets (containing 2 related sequences). In addition, we have also selected paired sequences, found that these sequences are relevant to the clones that we previously separated from the bone marrow plasma cells of the same immune mouse, and are combined with GC2 acinetobacter baumannii OMV by ELISA.Use these standards, 284 pairs of sequences have been selected to carry out DNA synthesis, thereby allow to be expressed as human IgG1 by vector subsequently.From the sorting plasma cell library of the bone marrow that is separated from the same GC2 acinetobacter baumannii OMV immune mouse, select other 9 sequences, these sequences are clustered with the sequence that is combined with immune OMV that we previously found by ELISA.In selected clones, 252 are IgG, 28 are IgM, 2 are IgE, and 11 clones are unassigned subclasses in the original classification.To express single IgH and IgL to as the DNA construct transfection of human IgG1, be carried out small-scale antibody expression in human embryonic kidney 293 (HEK 293) cells.
[0758] Antigen-binding IgG+ B cells were sorted from the spleens of mice immunized with GC2 CRAB OMVs. Figure 4 Selection was performed to include only those antigen-binding enriched B cells that bound to FM4-64 fluorescently labeled GC2 CRAB OMVs.
[0759] Figure 4 a. Sunspot diagram of 951 pairs of VH and VL chain sequences recovered from the spleens of four Kymab Intellisellect transgenic mice immunized with GC2 CRAB OMVs. Each VH and VL paired sequence is represented by a circle, colored according to the individual mouse from which it originated. Sequences within the lineage inferred to be derived from a common B cell progenitor are connected by black lines.
[0760] Figure 4b. Table indicating the number of IgH&L paired sequences, the proportion that mapped to high quality sequences and assigned to clusters of related sequences indicative of actively evolving B cell responses to the immunogen.
[0761] 6.3 Example 3: Antibody Binding
[0762] We used ELISA to detect the binding of mAbs expressed in small quantities (100-500 μg / ml) in human HEK 293 cells to GC2 Acinetobacter baumannii OMVs used for immunization. In this ELISA, OMVs were used as plate coating antigens. Using this ELISA method, we identified 179 mAbs that bound to immune OMVs at levels above the threshold (determined by isotype control: human IgG1+3 standard deviations). It is important to note that the binding of mAbs to immune GC2 Acinetobacter baumannii OMVs only represents the correlation with binding to intact bacterial cell walls, and the target protein may be more abundant in OMVs than in natural bacterial membranes. To address this issue, we evaluated the ability of mAbs to bind to intact, unfixed GC2 Acinetobacter baumannii strains derived from immune OMVs. The ELISA protocol is suitable for using intact, unfixed bacterial cells as plate coating antigens. Using this assay, the number of mAbs that bound to bacterial cells at levels above threshold (determined by isotype control: human IgG1 + 3 standard deviations) was 136, while that bound to OMVs was 179. To further elucidate how mAb binding to OMVs correlated with mAb binding to the intact, native bacterial wall of the GC2 clinical strain from which the OMVs were derived, we compared the results of the two binding assays, which showed a tight correlation between mAb binding to the target in both cases. 75% of the GC2 A. baumannii OMV-binding mAbs also bound to intact, unfixed cells of the OMV-derived GC2 A. baumannii strain ( Figure 5a ). Although 25% of the OMV-binding mAbs did not bind to native bacterial membranes, only two clones were identified that bound to intact, unfixed bacterial cells but not to OMVs. Our data demonstrate that using OMVs as a sorting reagent for B cell plasmablasts is highly effective in identifying IgH / L pairs that also bind to the intact, unfixed bacterial cell wall of the clinical strains used to generate OMVs. Furthermore, these data demonstrate concordance in bacterial target configuration between OMVs and the native cell wall environment. While we are confident that this also applies to other Gram-negative pathogens as well as Acinetobacter spp., the level of this concordance should be determined for each bacterial species used in our procedures.
[0763] The complement cascade is a powerful serum-based mechanism that results in the insertion of protein pores into the membranes of Gram-negative bacteria, leading to bacterial killing. This protein pathway is triggered by antibodies, and therefore, the ability of antibodies to trigger the complement cascade is a key functional outcome of target engagement in our mAb discovery approach. C3b is cleaved from the serum C3 protein, driving the complement cascade, and mAb binding to the bacterial cell membrane triggers the formation of an enzyme complex involving complement proteins C1q, C2, and C4, which cleave C3. Therefore, detection of C3b on the bacterial membrane correlates with successful initiation of the complement cascade. To evaluate the ability of HEK 293-expressed mAbs to induce complement activation, we developed an in-house high-throughput, flow cytometry-based assay to detect the deposition of complement component C3b on the surface of OMVs. We adapted a published assay to FM4-64-stained GC2 Acinetobacter baumannii OMVs, replacing antigen-conjugated beads, since these contain the target antigen within the bacterial membrane environment. We previously observed and evaluated the nonspecific association of FM4-64-stained OMVs with specific flow cytometry compensation beads and were able to exploit this association in our assay. Using this assay, we identified 76 mAbs that enhanced complement activation above the assay threshold (determined by isotype control: human IgG1 + 3 standard deviations) ( Figure 5b ). Therefore, we describe an assay that is preferentially used for the preliminary screening of mAbs as small-scale HEK293 supernatants. We selected assays based on the ability to distinguish the binding signal between selected IgH / L chain pairs as IgG1 antibodies and IgG1 controls. These assays enabled us to identify a large panel of mAbs for further functional characterization. This classification yielded a total of 136 mAbs that were able to bind to the natural bacterial surface of at least one of the four clinical strains used to produce the OMVs combined in the immunization panel. The next level of analysis involved expression in Chinese hamster ovary (CHO) cells and purification of the selected mAbs, resulting in sufficiently pure material to enable a variety of in vitro and in vivo assays. In order to select clones for downstream analysis and further characterization, we evaluated the data from the primary assay in combination with the sequence data to ensure that the selected IgH / L pairs covered a wide range of diversity at the sequence level. By selecting the most diverse sequences at this time, we maximized the likelihood of selecting mAbs with different functional properties and the likelihood of targeting multiple epitopes on the bacterial surface.
[0764] Based on this clustering data, we selected clones with small-scale HEK 293 expression levels >100 μg / ml for CHO cell expression, purification of larger quantities (5-10 mg) and subsequent further analysis in in vitro and in vivo assays. Figure 5 illustrates the screening and selection process.
[0765] Figure 5aComparison of mAb binding to GC2 A. baumannii OMVs and intact, unfixed bacterial cells, as determined by ELISA. mAbs identified as binders in both ELISA binding assays: mAbs that bound to both intact, unfixed GC2 A. baumannii bacterial cells and OMVs at levels above the assay threshold shown in the graph are represented in green. Two mAbs that only bound to intact, unfixed bacterial cells are represented in orange. mAbs that failed to bind to the intact bacterial cell wall are represented in white.
[0766] Figure 5b mAbs were selected for CHO expression and purification based on their ability to bind to intact bacterial cell walls and to elicit C3b deposition, as described above. Examples of selections for subsequent CHO expression are shown in bold.
[0767] 6.4 Example 5: Target Identification
[0768] Focusing on the cross-reactive mAbs identified, we used a phage expression library containing shotgun-generated A. baumannii genomic DNA from strains BAL 084 and BAL 276. Since mAbs may bind to peptide epitopes, we screened the phage expression library for mAbs that reacted with phage plaques. Using this screening mechanism, we were able to identify individual phages that bound to antibodies 1348 and 1349. By sequencing the phages, we were able to elucidate that 1348 and 1349 bound Oxa-23, a class D beta-lactamase, which is the main group of enzymes involved in resistance to carbapenem antibiotics. Our identification of mAbs binding to Oxa-23 in a target-agnostic screen is of great significance. First, this suggests that Oxa-23 can be targeted by antibodies in or closely associated with the A. baumannii cell membrane, which was previously unknown. Second, because Oxa-23 is the functional enzyme that inactivates carbapenems, and carbapenem resistance is a major clinical problem in the treatment of nosocomial A. baumannii infections, it might be possible to block the enzymatic function of Oxa-23 and sensitize A. baumannii to carbapenems using mAbs. We also assayed bacterial lysates separated by SDS-PAGE and subjected them to Western blotting for reactivity with individual mAbs. Figure 7b The blots for the six major linear targets observed are shown. Figure 7bBased on the cross-reactive binding patterns observed with mAbs 1042, 1043, 1403, 1405, 1407, 1408, and 1413 and their binding pattern to a 10 kDa target, we hypothesized that the target might be a lipooligosaccharide (LOS) type, OC1. The LOS type used to select isolates was determined by OCL-specific PCR. PCR confirmed that all clinical A. baumannii isolates tested were OC1, with only ATCC 17978 being OCL2. Subsequently, LOS were extracted (treated with copious amounts of proteinase K to remove any protein) and subjected to Western blot analysis using mAb 1042. E. coli NCTC 13441 LPS was extracted using the same method as the control and probed with a mAb specific for the O25b O antigen (ASN-4). Specific binding of 1-42 to the 10 kD target was observed for OC1 isolates A. baumannii BAL_191, BAL_339, and BAL_372, whereas no binding was observed for ATCC 17978 (OCL2) or E. coli NCTC13441 (O25b), as expected. This data suggests that the 10 kD target is the OC1 LOS. We hypothesized that mAbs that bind only to strains carrying the K49 capsular subtype may bind directly to the capsular antigen. Capsular antigens were extracted from selected strains carrying KL49 and analyzed using mAb 1416 by subsequent SDS-PAGE and Western blot analysis. These results indicate that mAb 1416 binds to KL49 isolated from strains BAL_186 (KL49), BAL_242 (KL49), BAL_191 (KL49), BAL_316 (KL49), CM5132 (KL49), CM4980 (KL49), and CM15768 (KL49), but not to capsular antigens isolated from strains 91an (KL2) or BAL_339 (KL58). The presence of the KL49 capsule is associated with increased virulence and mortality, and A. baumannii KL49 is currently becoming the predominant clone in Southeast Asia. We were able to demonstrate that all mAbs that bound to A. baumannii bearing KL49 capsular subtypes 1345, 1347, 1350, 1351, 1363, 1364, 1397, 1398, 1400, 1401, 1402, 1404, 1409, 1410, 1412, 1414, 1415, and 1416 bound to KL49 by Western blotting and correlated with the strong binding pattern observed to KL49 isolates in the HCl screen.
[0769] Figure 7aTable indicating the identified targets of each mAb. The methods used included collecting phylogenetic information from HCI (see above), serological expression cloning (SEC) using genomic phage libraries, and western blotting (WB) with specific mAbs. mAbs indicated in bold (*) were tested in an in vivo challenge model of Acinetobacter baumannii to demonstrate therapeutic efficacy.
[0770] Figure 7b Example Western blot analysis reveals that the mAb binds to three different targets: a high molecular weight target (KL49 capsule - top panel), a 10 kD target (OC1 LOS - middle panel), and a 30 kD protein (Oxa-23 - bottom panel).
[0771] 7. Sequence
[0772] Table 1 - CDR, VH and VL sequences:
[0773] The CDRs in the table below are determined according to IMGT.
[0774]
[0775]
[0776]
[0777]
[0778]
[0779]
[0780]
[0781]
[0782]
[0783]
[0784]
[0785]
[0786]
[0787]
[0788]
[0789]
[0790]
[0791]
[0792]
[0793]
[0794]
[0795]
[0796]
[0797]
[0798]
[0799]
[0800]
[0801]
[0802]
[0803]
[0804]
[0805]
[0806]
[0807]
[0808]
[0809]
[0810]
[0811]
[0812]
[0813]
[0814]
[0815]
[0816]
[0817]
[0818]
[0819]
[0820]
[0821]
[0822]
[0823] Table 2 - Constant region sequences:
[0824]
[0825]
[0826]
[0827]
[0828]
[0829]
[0830]
[0831]
[0832]
[0833]
[0834]
[0835]
[0836]
[0837]
[0838]
[0839]
[0840]
[0841]
[0842]
[0843]
[0844]
[0845]
[0846]
[0847]
[0848]
[0849]
[0850]
[0851]
[0852]
[0853]
[0854]
[0855]
[0856]
[0857]
[0858]
[0859]
[0860]
[0861]
[0862]
[0863]
[0864] Table 3 - Gene segments:
[0865]
[0866]
[0867] 8. Clauses containing antibodies
[0868] In the clauses herein referring to an antibody defined by an antibody sequence, the antibody sequence may be defined by reference to an internal reference number of the antibody or a SEQ ID NO. Any clause herein citing an internal reference number of an antibody should also be considered a disclosure of the same subject matter, wherein the sequence defined by the internal reference number of the antibody is replaced by the corresponding SEQ ID NO.
[0869] 1. An antibody that specifically binds to the surface of Acinetobacter baumannii bacteria.
[0870] 2. The antibody according to clause 1, wherein the antibody induces complement activation (eg, as measured by a flow cytometry-based assay).
[0871] 3. The antibody according to clause 1 or clause 2, which specifically binds to Oxa-23 at the surface of Acinetobacter baumannii bacteria.
[0872] 4. The antibody according to Item 1 or Item 2, which specifically binds to Oxa-23 on the outer membrane vesicles (OMV) of Acinetobacter baumannii bacteria.
[0873] 5. The antibody of any one of clauses 1 to 4, wherein the antibody comprises a variable heavy chain (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, and a variable light chain (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, and wherein the HCDR3 is the HCDR3 of antibody 1348, 1349, 1540, 1548 or 1550.
[0874] 6. The antibody according to clause 5, wherein the HCDR3 is the HCDR3 of antibody 1348.
[0875] 7. The antibody according to clause 5, wherein the HCDR3 is the HCDR3 of antibody 1349.
[0876] 8. The antibody according to clause 5, wherein the HCDR3 is the HCDR3 of antibody 1540.
[0877] 9. The antibody according to clause 5, wherein the HCDR3 is the HCDR3 of antibody 1548.
[0878] 10. The antibody according to clause 5, wherein the HCDR3 is the HCDR3 of antibody 1550.
[0879] 11. An antibody according to any one of clauses 1 to 4, wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, the variable heavy chain (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, the variable light chain (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, and wherein the 6 CDRs are the CDRs of antibody 1348, 1349, 1540, 1548 or 1550.
[0880] 12. The antibody according to clause 11, wherein the antibody has 6 CDRs of antibody 1348.
[0881] 13. The antibody according to clause 11, wherein the antibody has 6 CDRs of antibody 1349.
[0882] 14. The antibody according to clause 11, wherein the antibody has 6 CDRs of antibody 1540.
[0883] 15. The antibody according to clause 11, wherein the antibody has 6 CDRs of antibody 1548.
[0884] 16. The antibody according to clause 11, wherein the antibody has 6 CDRs of antibody 1550.
[0885] 17. The antibody of any one of clauses 1 to 4, wherein the antibody comprises a variable heavy (VH) domain sequence and a variable light (VL) domain sequence, and wherein the variable heavy (VH) domain sequence and the variable light (VL) domain sequence comprise the variable heavy (VH) domain sequence and variable light (VL) domain sequence of antibody 1348, 1349, 1540, 1548 or 1550, respectively, optionally with 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs) in the variable heavy (VH) domain sequence, and optionally with 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs) in the variable light (VL) domain sequence.
[0886] 18. The antibody according to clause 17, wherein the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1348, and the variable light chain (VL) domain sequence of antibody 1348, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0887] 19. The antibody according to clause 17, wherein the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1349 and the variable light chain (VL) domain sequence of antibody 1349, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0888] 20. The antibody according to clause 17, wherein the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1540 and the variable light chain (VL) domain sequence of antibody 1349, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0889] 21. The antibody according to clause 17, wherein the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1548 and the variable light chain (VL) domain sequence of antibody 1349, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0890] 22. The antibody according to clause 17, wherein the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1550 and the variable light chain (VL) domain sequence of antibody 1349, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0891] 23. The antibody of any one of clauses 1 to 4, wherein the antibody comprises a variable heavy (VH) domain sequence and a variable light (VL) domain sequence, and wherein the variable heavy (VH) domain sequence and the variable light (VL) domain sequence comprise sequences that are at least 90%, at least 95%, at least 98% or at least 99% identical to the variable heavy (VH) domain sequence and variable light (VL) domain sequence of antibody 1348, 1349, 1540, 1548 or 1550, respectively,
[0892] Provided that the antibody possesses these CDRs of antibody 1348, 1349, 1540, 1548 or 1550, respectively.
[0893] 24. An antibody according to clause 23, wherein the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to the VH domain sequence of antibody 1348, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to the VL domain sequence of antibody 1348, provided that the antibody has these CDRs of antibody 1348.
[0894] 25. An antibody according to clause 23, wherein the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to the VH domain sequence of antibody 1349, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to the VL domain sequence of antibody 1349, provided that the antibody has these CDRs of antibody 1349.
[0895] 26. An antibody according to clause 23, wherein the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to the VH domain sequence of antibody 1349, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to the VL domain sequence of antibody 1540, provided that the antibody has these CDRs of antibody 1540.
[0896] 27. An antibody according to clause 23, wherein the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to the VH domain sequence of antibody 1349, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to the VL domain sequence of antibody 1548, provided that the antibody has these CDRs of antibody 1548.
[0897] 28. An antibody according to clause 23, wherein the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to the VH domain sequence of antibody 1349, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to the VL domain sequence of antibody 1550, provided that the antibody has these CDRs of antibody 1550.
[0898] 29. The antibody of any one of clauses 1 to 4, wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and wherein the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence comprise the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence of antibody 1348, 1349, 1540, 1548 or 1550, respectively.
[0899] 30. The antibody according to clause 29, wherein the antibody comprises the VH domain sequence and VL domain sequence of antibody 1348.
[0900] 31. The antibody according to clause 29, wherein the antibody comprises the VH domain sequence and VL domain sequence of antibody 1349.
[0901] 32. The antibody according to clause 29, wherein the antibody comprises the VH domain sequence and VL domain sequence of antibody 1540.
[0902] 33. The antibody according to clause 29, wherein the antibody comprises the VH domain sequence and VL domain sequence of antibody 1548.
[0903] 34. The antibody according to clause 29, wherein the antibody comprises the VH domain sequence and VL domain sequence of antibody 1550.
[0904] 35. An antibody that binds to the same epitope on Oxa-23 as the antibody according to any one of clauses 1 to 34.
[0905] 36. An antibody capable of competing with the antibody according to any one of clauses 1 to 34 for binding to Oxa-23.
[0906] 37. The antibody according to clause 1 or clause 2, which specifically binds to OCL1 lipooligosaccharide (LOS) at the surface of Acinetobacter baumannii bacteria.
[0907] 38. The antibody according to clause 1 or clause 2, which specifically binds to OCL1 LOS on the outer membrane vesicles (OMV) of Acinetobacter baumannii bacteria.
[0908] 39. The antibody of clause 37 or clause 38, wherein the antibody comprises a variable heavy chain (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, and a variable light chain (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, and wherein the HCDR3 is the HCDR3 of antibody 1042, 1043, 1403, 1405, 1407, 1408 or 1413.
[0909] 40. The antibody according to clause 39, wherein the HCDR3 is the HCDR3 of antibody 1042.
[0910] 41. The antibody according to clause 39, wherein the HCDR3 is the HCDR3 of antibody 1043.
[0911] 42. The antibody according to clause 39, wherein the HCDR3 is the HCDR3 of antibody 1403.
[0912] 43. The antibody according to clause 39, wherein the HCDR3 is the HCDR3 of antibody 1405.
[0913] 44. The antibody according to clause 39, wherein the HCDR3 is the HCDR3 of antibody 1407.
[0914] 45. The antibody according to clause 39, wherein the HCDR3 is the HCDR3 of antibody 1408.
[0915] 46. The antibody according to clause 39, wherein the HCDR3 is the HCDR3 of antibody 1413.
[0916] 47. An antibody according to clause 37 or clause 38, wherein the antibody comprises a variable heavy chain (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, and a variable light chain (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, and wherein the six CDRs are the CDRs of antibody 1042, 1043, 1403, 1405, 1407, 1408 or 1413.
[0917] 48. The antibody according to clause 47, wherein the antibody has 6 CDRs of antibody 1042.
[0918] 49. The antibody according to clause 47, wherein the antibody has 6 CDRs of antibody 1043.
[0919] 50. The antibody according to clause 47, wherein the antibody has 6 CDRs of antibody 1403.
[0920] 51. The antibody according to clause 47, wherein the antibody has 6 CDRs of antibody 1405.
[0921] 52. The antibody according to clause 47, wherein the antibody has 6 CDRs of antibody 1407.
[0922] 53. The antibody according to clause 47, wherein the antibody has 6 CDRs of antibody 1408.
[0923] 54. The antibody according to clause 47, wherein the antibody has 6 CDRs of antibody 1413.
[0924] 55. The antibody of clause 37 or clause 38, wherein the antibody comprises a variable heavy (VH) domain sequence and a variable light (VL) domain sequence, and wherein the variable heavy (VH) domain sequence and the variable light (VL) domain sequence comprise the variable heavy (VH) domain sequence and variable light (VL) domain sequence of antibody 1042, 1043, 1403, 1405, 1407, 1408 or 1413, respectively, optionally with 1, 2, 3, 4 or 5 amino acid alterations outside the complementarity determining regions (CDRs) in the variable heavy (VH) domain sequence, and optionally with 1, 2, 3, 4 or 5 amino acid alterations outside the complementarity determining regions (CDRs) in the variable light (VL) domain sequence.
[0925] 56. The antibody according to clause 55, wherein the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1042, and the variable light chain (VL) domain sequence of antibody 1042, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0926] 57. The antibody according to clause 55, wherein the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1043, and the variable light chain (VL) domain sequence of antibody 1043, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0927] 58. The antibody according to clause 55, wherein the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1403, and the variable light chain (VL) domain sequence of antibody 1403, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0928] 59. The antibody according to clause 55, wherein the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1405, and the variable light chain (VL) domain sequence of antibody 1405, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0929] 60. The antibody according to clause 55, wherein the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1407 and the variable light chain (VL) domain sequence of antibody 1407, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0930] 61. The antibody according to clause 55, wherein the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1408, and the variable light chain (VL) domain sequence of antibody 1408, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0931] 62. The antibody according to clause 55, wherein the antibody comprises the variable heavy chain (VH) domain sequence of antibody 1413 and the variable light chain (VL) domain sequence of antibody 1413, wherein the variable heavy chain (VH) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs), and the variable light chain (VL) domain sequence optionally has 1, 2, 3, 4 or 5 amino acid changes outside the complementarity determining regions (CDRs).
[0932] 63. The antibody of clause 37 or clause 38, wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and wherein the variable heavy chain (VH) domain sequence and the variable light chain (VL) domain sequence comprise sequences that are at least 90%, at least 95%, at least 98% or at least 99% identical to the variable heavy chain (VH) domain sequence and variable light chain (VL) domain sequence of antibody 1042, 1043, 1403, 1405, 1407, 1408 or 1413, respectively, with the proviso that the antibody has 6 CDRs of antibody 1042, 1043, 1403, 1405, 1407, 1408 or 1413, respectively.
[0933] 64. An antibody according to clause 63, wherein the variable heavy chain (VH) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to the VH domain sequence of antibody 1042, and the variable light chain (VL) domain sequence comprises a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to the VL domain sequence of antibody 1042, provided that the antibody has 6 CDRs ...
Claims
1. An antibody that specifically binds to the surface of Acinetobacter baumannii bacteria.
2. The antibody of claim 1, wherein the antibody induces complement activation (eg, as measured by a flow cytometry-based assay).
3. The antibody of claim 1 or claim 2, which specifically binds to Oxa-23 at the surface of Acinetobacter baumannii bacteria.
4. The antibody according to claim 1 or claim 2, which specifically binds to Oxa-23 on the outer membrane vesicle (OMV) of Acinetobacter baumannii bacteria.
5. The antibody according to any one of claims 1 to 4, wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, the variable heavy chain (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, the variable light chain (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, and wherein the HCDR3 is selected from the group consisting of SEQ ID NO: 34, SEQ ID NO: 24, SEQ ID NO: 174 and SEQ ID NO:
182.
6. The antibody according to any one of claims 1 to 4, wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, the variable heavy chain (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, the variable light chain (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, and in: (i) HCDR1 consists of SEQ ID NO:32, HCDR2 consists of SEQ ID NO:33, HCDR3 consists of SEQ ID NO:34, LCDR1 consists of SEQ ID NO:37, LCDR2 consists of SEQ ID NO:28, and LCDR3 consists of SEQ ID NO:38, (ii) HCDR1 consists of SEQ ID NO:22, HCDR2 consists of SEQ ID NO:23, HCDR3 consists of SEQ ID NO:24, LCDR1 consists of SEQ ID NO:27, LCDR2 consists of SEQ ID NO:28, and LCDR3 consists of SEQ ID NO:29, (iii) HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:173, HCDR3 consists of SEQ ID NO:174, LCDR1 consists of SEQ ID NO:149, LCDR2 consists of SEQ ID NO:177, and LCDR3 consists of SEQ ID NO:178, or (iv) HCDR1 consists of SEQ ID NO:181, HCDR2 consists of SEQ ID NO:173, HCDR3 consists of SEQ ID NO:182, LCDR1 consists of SEQ ID NO:185, LCDR2 consists of SEQ ID NO:28, and LCDR3 consists of SEQ ID NO:
186.
7. The antibody according to any one of claims 1 to 4, wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and in: (i) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 31, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 36, (ii) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 21, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 26, (iii) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 172, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 176, or (iv) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 180, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 184, Optionally there are 1, 2, 3, 4 or 5 amino acid changes outside of the complementarity determining regions (CDRs) in the variable heavy chain (VH) domain sequence, and optionally there are 1, 2, 3, 4 or 5 amino acid changes outside of the complementarity determining regions (CDRs) in the variable light chain (VL) domain sequence.
8. The antibody according to any one of claims 1 to 4, wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and in: (i) the variable heavy chain (VH) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 31, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 36, provided that HCDR1 consists of SEQ ID NO:32, HCDR2 consists of SEQ ID NO:33, HCDR3 consists of SEQ ID NO:34, LCDR1 consists of SEQ ID NO:37, LCDR2 consists of SEQ ID NO:28, and LCDR3 consists of SEQ ID NO:38, (ii) the variable heavy chain (VH) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 21, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 26, provided that HCDR1 consists of SEQ ID NO:22, HCDR2 consists of SEQ ID NO:23, HCDR3 consists of SEQ ID NO:24, LCDR1 consists of SEQ ID NO:27, LCDR2 consists of SEQ ID NO:28, and LCDR3 consists of SEQ ID NO:29, (iii) the variable heavy chain (VH) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 172, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 176, Provided that HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:173, HCDR3 consists of SEQ ID NO:174, LCDR1 consists of SEQ ID NO:149, LCDR2 consists of SEQ ID NO:177, and LCDR3 consists of SEQ ID NO:178, or (iv) the variable heavy chain (VH) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 180, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 184, Provided that HCDR1 consists of SEQ ID NO:181, HCDR2 consists of SEQ ID NO:173, HCDR3 consists of SEQ ID NO:182, LCDR1 consists of SEQ ID NO:185, LCDR2 consists of SEQ ID NO:28, and LCDR3 consists of SEQ ID NO:
186.
9. The antibody according to any one of claims 1 to 4, wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and in: (i) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 31, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 36, (ii) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 21, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 26, (iii) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 172, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 176, or (iv) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 180, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO:
184.
10. An antibody that binds to the same epitope on Oxa-23 as the antibody of any one of claims 1 to 9.
11. An antibody capable of competing with the antibody according to any one of claims 1 to 9 for binding to Oxa-23.
12. The antibody of claim 1 or claim 2, which specifically binds to OCL1 lipooligosaccharide (LOS) at the surface of Acinetobacter baumannii bacteria.
13. The antibody according to claim 1 or claim 2, which specifically binds to OCL1 LOS on the outer membrane vesicle (OMV) of Acinetobacter baumannii bacteria.
14. The antibody of claim 12 or claim 13, wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, the variable heavy chain (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, the variable light chain (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, and wherein the HCDR3 is selected from the group consisting of SEQ ID NO: 189, SEQ ID NO: 196, SEQ ID NO: 90, SEQ ID NO: 105, SEQ ID NO: 112, SEQ ID NO: 119 and SEQ ID NO:
146.
15. The antibody according to claim 12 or claim 13, wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, the variable heavy chain (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, the variable light chain (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, and in: (i) HCDR1 consists of SEQ ID NO:32, HCDR2 consists of SEQ ID NO:33, HCDR3 consists of SEQ ID NO:189, LCDR1 consists of SEQ ID NO:37, LCDR2 consists of SEQ ID NO:28, and LCDR3 consists of SEQ ID NO:192, (ii) HCDR1 consists of SEQ ID NO: 195, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 196, LCDR1 consists of SEQ ID NO: 37, LCDR2 consists of SEQ ID NO: 9, and LCDR3 consists of SEQ ID NO: 199, (iii) HCDR1 consists of SEQ ID NO:22, HCDR2 consists of SEQ ID NO:89, HCDR3 consists of SEQ ID NO:90, LCDR1 consists of SEQ ID NO:93, LCDR2 consists of SEQ ID NO:28, and LCDR3 consists of SEQ ID NO:94, (iv) HCDR1 consists of SEQ ID NO: 104, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 105, LCDR1 consists of SEQ ID NO: 27, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 108, (v) HCDR1 consists of SEQ ID NO: 111, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 112, LCDR1 consists of SEQ ID NO: 115, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 116, (vi) HCDR1 consists of SEQ ID NO: 104, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 119, LCDR1 consists of SEQ ID NO: 122, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 123, or (vii) HCDR1 consists of SEQ ID NO:145, HCDR2 consists of SEQ ID NO:33, HCDR3 consists of SEQ ID NO:146, LCDR1 consists of SEQ ID NO:149, LCDR2 consists of SEQ ID NO:150, and LCDR3 consists of SEQ ID NO:
151.
16. The antibody of claim 12 or claim 13, wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and in: (i) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 188, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 191, (ii) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 194, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 198, (iii) the variable heavy chain (VH) domain comprises, preferably consists of SEQ ID NO: 88, and the variable light chain (VL) domain comprises, preferably consists of SEQ ID NO: 92, (iv) the variable heavy chain (VH) domain comprises, preferably consists of SEQ ID NO: 103, and the variable light chain (VL) domain comprises, preferably consists of SEQ ID NO: 107, (v) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 110, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 114, (vi) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 118, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 121, or (vii) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 144, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 148, Optionally there are 1, 2, 3, 4 or 5 amino acid changes outside of the complementarity determining regions (CDRs) in the variable heavy chain (VH) domain sequence, and optionally there are 1, 2, 3, 4 or 5 amino acid changes outside of the complementarity determining regions (CDRs) in the variable light chain (VL) domain sequence.
17. The antibody of claim 12 or claim 13, wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and in: (i) the variable heavy chain (VH) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 188, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 191, provided that HCDR1 consists of SEQ ID NO:32, HCDR2 consists of SEQ ID NO:33, HCDR3 consists of SEQ ID NO:189, LCDR1 consists of SEQ ID NO:37, LCDR2 consists of SEQ ID NO:28, and LCDR3 consists of SEQ ID NO:192, (ii) the variable heavy chain (VH) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 194, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 198, provided that HCDR1 consists of SEQ ID NO: 195, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 196, LCDR1 consists of SEQ ID NO: 37, LCDR2 consists of SEQ ID NO: 9, and LCDR3 consists of SEQ ID NO: 199, (iii) the variable heavy chain (VH) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 88, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 92, provided that HCDR1 consists of SEQ ID NO:22, HCDR2 consists of SEQ ID NO:89, HCDR3 consists of SEQ ID NO:90, LCDR1 consists of SEQ ID NO:93, LCDR2 consists of SEQ ID NO:28, and LCDR3 consists of SEQ ID NO:94, (iv) the variable heavy chain (VH) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 103, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 107, provided that HCDR1 consists of SEQ ID NO: 104, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 105, LCDR1 consists of SEQ ID NO: 27, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 108, (v) the variable heavy chain (VH) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 110, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 114, provided that HCDR1 consists of SEQ ID NO: 111, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 112, LCDR1 consists of SEQ ID NO: 115, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 116, (vi) the variable heavy chain (VH) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 118, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 121, Provided that HCDR1 consists of SEQ ID NO: 104, HCDR2 consists of SEQ ID NO: 33, HCDR3 consists of SEQ ID NO: 119, LCDR1 consists of SEQ ID NO: 122, LCDR2 consists of SEQ ID NO: 28, and LCDR3 consists of SEQ ID NO: 123, or (vii) the variable heavy chain (VH) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 144, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 148, Provided that HCDR1 consists of SEQ ID NO:145, HCDR2 consists of SEQ ID NO:33, HCDR3 consists of SEQ ID NO:146, LCDR1 consists of SEQ ID NO:149, LCDR2 consists of SEQ ID NO:150, and LCDR3 consists of SEQ ID NO:
151.
18. The antibody of claim 12 or claim 13, wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and in: (i) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 188, and the variable light chain (VL) domain comprises SEQ ID NO: 191, (ii) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 194, and the variable light chain (VL) domain comprises SEQ ID NO: 198, (iii) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 88, and the variable light chain (VL) domain comprises SEQ ID NO: 92, (iv) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 103, and the variable light chain (VL) domain comprises SEQ ID NO: 107, (v) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 110, and the variable light chain (VL) domain comprises SEQ ID NO: 114, (vi) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 118, and the variable light chain (VL) domain comprises SEQ ID NO: 121, (vii) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO:144, and the variable light chain (VL) domain comprises SEQ ID NO:
148.
19. An antibody that binds to the same epitope on OCL1 LOS as the antibody according to any one of claims 12 to 18.
20. An antibody capable of competing with the antibody according to any one of claims 12 to 18 for binding to OCL1LOS.
21. The antibody of claim 1 or claim 2, which specifically binds to KL49 at the surface of Acinetobacter baumannii bacteria.
22. The antibody according to claim 1 or claim 2, which specifically binds to KL49 on the outer membrane vesicle (OMV) of Acinetobacter baumannii bacteria.
23. The antibody of claim 21 or claim 22, wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, the variable heavy chain (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, the variable light chain (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, and wherein the HCDR3 is selected from the group consisting of SEQ ID NO: 168, SEQ ID NO: 5, SEQ ID NO: 14, SEQ ID NO: 41, SEQ ID NO: 45, SEQ ID NO: 50, SEQ ID NO: 55, SEQ ID NO: 62, SEQ ID NO: 67, SEQ ID NO: 72, SEQ ID NO: 77, SEQ ID NO: 83, SEQ ID NO: 98, SEQ ID NO: 126, SEQ ID NO: 132, SEQ ID NO: 139, SEQ ID NO: 156 and SEQ ID NO:
163.
24. The antibody of claim 21 or claim 22, wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, the variable heavy chain (VH) domain sequence comprising complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, the variable light chain (VL) domain sequence comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, and in: (i) HCDR1 consists of SEQ ID NO: 3, HCDR2 consists of SEQ ID NO: 13, HCDR3 consists of SEQ ID NO: 168, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 10, (ii) HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:4, HCDR3 consists of SEQ ID NO:5, LCDR1 consists of SEQ ID NO:8, LCDR2 consists of SEQ ID NO:9, and LCDR3 consists of SEQ ID NO:10, (iii) HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:14, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:19, (iv) HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:41, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:19, (v) HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:45, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:10, (vi) HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:50, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:19, (vii) HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:55, LCDR1 consists of SEQ ID NO:58, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:59, (viii) HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:62, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:59, (ix) HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:67, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:59, (x) HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:72, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:59, (xi) HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:77, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:80, (xii) HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:83, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:86, (xiii) HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:97, HCDR3 consists of SEQ ID NO:98, LCDR1 consists of SEQ ID NO:101, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:59, (xiv) HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:126, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:129, (xv) HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:132, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:135, (xvi) HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:138, HCDR3 consists of SEQ ID NO:139, LCDR1 consists of SEQ ID NO:142, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:86, (xvii) HCDR1 consists of SEQ ID NO: 154, HCDR2 consists of SEQ ID NO: 155, HCDR3 consists of SEQ ID NO: 156, LCDR1 consists of SEQ ID NO: 17, LCDR2 consists of SEQ ID NO: 18, and LCDR3 consists of SEQ ID NO: 159, or (xviii) HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:162, HCDR3 consists of SEQ ID NO:163, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:
135.
25. The antibody of claim 21 or claim 22, wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and in: (i) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 167, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 170, (ii) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 2, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 7, (iii) the variable heavy chain (VH) domain comprises SEQ ID NO: 12, preferably consists of it, and the variable light chain (VL) domain comprises SEQ ID NO: 16, preferably consists of it, (iv) the variable heavy chain (VH) domain comprises SEQ ID NO: 40, preferably consists of it, and the variable light chain (VL) domain comprises SEQ ID NO: 16, preferably consists of it, (v) the variable heavy chain (VH) domain comprises SEQ ID NO: 44, preferably consists of it, and the variable light chain (VL) domain comprises SEQ ID NO: 47, preferably consists of it, (vi) the variable heavy chain (VH) domain comprises SEQ ID NO: 49, preferably consists of it, and the variable light chain (VL) domain comprises SEQ ID NO: 52, preferably consists of it, (vii) the variable heavy chain (VH) domain comprises SEQ ID NO: 54, preferably consists of it, and the variable light chain (VL) domain comprises SEQ ID NO: NO:57, preferably consisting of it, (viii) the variable heavy chain (VH) domain comprises SEQ ID NO:61, preferably consisting of it, and the variable light chain (VL) domain comprises SEQ ID NO:64, preferably consisting of it, (ix) the variable heavy chain (VH) domain comprises SEQ ID NO:66, preferably consisting of it, and the variable light chain (VL) domain comprises SEQ ID NO:69, preferably consisting of it, (x) the variable heavy chain (VH) domain comprises SEQ ID NO:71, preferably consisting of it, and the variable light chain (VL) domain comprises SEQ ID NO:74, preferably consisting of it, (xi) the variable heavy chain (VH) domain comprises SEQ ID NO:76, preferably consisting of it, and the variable light chain (VL) domain comprises SEQ ID NO:79, preferably consisting of it, (xii) the variable heavy chain (VH) domain comprises SEQ ID NO:82, preferably consisting of it, and the variable light chain (VL) domain comprises SEQ ID NO:85, preferably consisting of it, (xiii) the variable heavy chain (VH) domain comprises SEQ ID NO:96, preferably consisting of it, and the variable light chain (VL) domain comprises SEQ ID NO:100, preferably consisting of it, (xiv) the variable heavy chain (VH) domain comprises SEQ ID NO:125, preferably consisting of it, and the variable light chain (VL) domain comprises SEQ ID NO:128, preferably consisting of it, (xv) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 131, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 134, (xvi) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 137, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 141, (xvii) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 153, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 158, or (xviii) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 161, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 165, Optionally there are 1, 2, 3, 4 or 5 amino acid changes outside of the complementarity determining regions (CDRs) in the variable heavy chain (VH) domain sequence, and optionally there are 1, 2, 3, 4 or 5 amino acid changes outside of the complementarity determining regions (CDRs) in the variable light chain (VL) domain sequence.
26. The antibody of claim 21 or claim 22, wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and in: (i) the variable heavy chain (VH) comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 167, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 170, provided that HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:168, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:10, (ii) the variable heavy chain (VH) comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 2, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO:7, provided that HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:4, HCDR3 consists of SEQ ID NO:5, LCDR1 consists of SEQ ID NO:8, LCDR2 consists of SEQ ID NO:9, and LCDR3 consists of SEQ ID NO:10, (iii) the variable heavy chain (VH) comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 12, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 16, provided that HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:14, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:19, (iv) the variable heavy chain (VH) comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 40, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 16, provided that HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:41, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:19, (v) the variable heavy chain (VH) comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 44, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 47, provided that HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:45, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:10, (vi) the variable heavy chain (VH) comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 49, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 52, provided that HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:50, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:19, (vii) the variable heavy chain (VH) comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO:54, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 57, provided that HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:55, LCDR1 consists of SEQ ID NO:58, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:59, (viii) the variable heavy chain (VH) comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 61, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 64, provided that HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:62, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:59, (ix) the variable heavy chain (VH) comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 66, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 69, provided that HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:67, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:59, (x) the variable heavy chain (VH) comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO:71, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 74, provided that HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:72, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:59, (xi) the variable heavy chain (VH) comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO:76, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 79, provided that HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:77, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:80, (xii) the variable heavy chain (VH) comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 82, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 85, provided that HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:83, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:86, (xiii) the variable heavy chain (VH) comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 96, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 100, provided that HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:97, HCDR3 consists of SEQ ID NO:98, LCDR1 consists of SEQ ID NO:101, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:59, (xiv) the variable heavy chain (VH) comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 125, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 128, provided that HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:126, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:129, (xv) the variable heavy chain (VH) comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 131, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 134, provided that HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:13, HCDR3 consists of SEQ ID NO:132, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:135, (xvi) the variable heavy chain (VH) comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 137, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 141, provided that HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:138, HCDR3 consists of SEQ ID NO:139, LCDR1 consists of SEQ ID NO:142, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:86, (xvii) the variable heavy chain (VH) comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 153, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 158, Provided that HCDR1 has SEQ ID NO: 154, HCDR2 has SEQ ID NO: 155, HCDR3 has SEQ ID NO: 156, LCDR1 has SEQ ID NO: 17, LCDR2 has SEQ ID NO: 18, and LCDR3 has SEQ ID NO: 159, or (xviii) the variable heavy chain (VH) comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 161, and The variable light (VL) domain comprises, preferably consists of, a sequence that is at least 90%, at least 95%, at least 98% or at least 99% identical to SEQ ID NO: 165, Provided that HCDR1 consists of SEQ ID NO:3, HCDR2 consists of SEQ ID NO:162, HCDR3 consists of SEQ ID NO:163, LCDR1 consists of SEQ ID NO:17, LCDR2 consists of SEQ ID NO:18, and LCDR3 consists of SEQ ID NO:
135.
27. The antibody of claim 21 or claim 22, wherein the antibody comprises a variable heavy chain (VH) domain sequence and a variable light chain (VL) domain sequence, and in: (i) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 167, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 170, (ii) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 2, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 7, (iii) the variable heavy chain (VH) domain comprises SEQ ID NO: 12, preferably consists of it, and the variable light chain (VL) domain comprises SEQ ID NO: 16, preferably consists of it, (iv) the variable heavy chain (VH) domain comprises SEQ ID NO: 40, preferably consists of it, and the variable light chain (VL) domain comprises SEQ ID NO: 16, preferably consists of it, (v) the variable heavy chain (VH) domain comprises SEQ ID NO: 44, preferably consists of it, and the variable light chain (VL) domain comprises SEQ ID NO: 47, preferably consists of it, (vi) the variable heavy chain (VH) domain comprises SEQ ID NO: 49, preferably consists of it, and the variable light chain (VL) domain comprises SEQ ID NO: 52, preferably consists of it, (vii) the variable heavy chain (VH) domain comprises SEQ ID NO: 54, preferably consists of it, and the variable light chain (VL) domain comprises SEQ ID NO: NO:57, preferably consisting of it, (viii) the variable heavy chain (VH) domain comprises SEQ ID NO:61, preferably consisting of it, and the variable light chain (VL) domain comprises SEQ ID NO:64, preferably consisting of it, (ix) the variable heavy chain (VH) domain comprises SEQ ID NO:66, preferably consisting of it, and the variable light chain (VL) domain comprises SEQ ID NO:69, preferably consisting of it, (x) the variable heavy chain (VH) domain comprises SEQ ID NO:71, preferably consisting of it, and the variable light chain (VL) domain comprises SEQ ID NO:74, preferably consisting of it, (xi) the variable heavy chain (VH) domain comprises SEQ ID NO:76, preferably consisting of it, and the variable light chain (VL) domain comprises SEQ ID NO:79, preferably consisting of it, (xii) the variable heavy chain (VH) domain comprises SEQ ID NO:82, preferably consisting of it, and the variable light chain (VL) domain comprises SEQ ID NO:85, preferably consisting of it, (xiii) the variable heavy chain (VH) domain comprises SEQ ID NO:96, preferably consisting of it, and the variable light chain (VL) domain comprises SEQ ID NO:100, preferably consisting of it, (xiv) the variable heavy chain (VH) domain comprises SEQ ID NO:125, preferably consisting of it, and the variable light chain (VL) domain comprises SEQ ID NO:128, preferably consisting of it, (xv) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 131, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 134, (xvi) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 137, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 141, (xvii) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 153, and the variable light chain (VL) domain comprises, preferably consists of, SEQ ID NO: 158, or (xviii) the variable heavy chain (VH) domain comprises, preferably consists of, SEQ ID NO: 161, and the variable light chain (VL) domain comprises, preferably consists of SEQ ID NO:
165.
28. An antibody that binds to the same epitope on KL49 as the antibody according to any one of claims 21 to 27.
29. An antibody capable of competing with any antibody according to any one of claims 21 to 27 for binding to KL49.
30. The antibody according to any one of the preceding claims, wherein the antibody exhibits complement dependent cytotoxicity (CDC) activity.
31. The antibody according to any one of the preceding claims, wherein the antibody is human IgG1 or human IgG4.
32. The antibody of claim 31 , wherein the antibody is human IgG1, optionally wherein the antibody comprises the constant region sequence of SEQ ID NO:
418.
33. The antibody of claim 31 , wherein the antibody is human IgG4, optionally wherein the antibody comprises the constant region sequence of SEQ ID NO:
436.
34. The antibody of any one of claims 1 to 30, wherein the antibody is human IgA1 (eg, comprising the constant region sequence SEQ ID NO: 484) or human IgA2 (eg, comprising the constant region sequence SEQ ID NO: 485).
35. The antibody according to any one of claims 1 to 34, wherein the antibody comprises a kappa light chain constant region, preferably the constant domain sequence SEQ ID NO:
448.
36. A nucleic acid sequence comprising a sequence encoding the VH domain and / or VL domain of an antibody according to any preceding claim.
37. A nucleic acid sequence comprising a sequence encoding the heavy chain and / or light chain of an antibody according to any preceding claim.
38. A vector comprising the nucleic acid according to claim 36 or claim 37, optionally wherein the vector is a CHO vector.
39. A host cell comprising the nucleic acid of claim 36 or claim 37 or the vector of claim 38.
40. A pharmaceutical composition comprising (i) an isolated nucleic acid encoding the antibody of any one of claims 1 to 35, or (ii) a nucleic acid according to claim 36 or claim 37, and a pharmaceutically acceptable excipient.
41. A pharmaceutical composition comprising the antibody according to any one of claims 1 to 35 and a pharmaceutically acceptable excipient.
42. The pharmaceutical composition of claim 40 or 41, wherein the pharmaceutical composition is formulated for intravenous, intramuscular or subcutaneous administration.
43. The pharmaceutical composition according to any one of claims 40 to 42, wherein the pharmaceutical composition further comprises at least one additional therapeutic agent.
44. The pharmaceutical composition according to claim 43, wherein the additional therapeutic agent is at least one, preferably one or two additional antibodies.
45. The pharmaceutical composition of claim 43, wherein the additional therapeutic agent is a carbapenem.
46. The pharmaceutical composition of claim 43, wherein the additional therapeutic agent is colistin.
47. A kit comprising the antibody of any one of claims 1 to 35.
48. A kit comprising the pharmaceutical composition according to any one of claims 40 to 46.
49. according to the described test kit of claim 48, wherein this test kit further comprises the label or instructions for preventing and / or treating the bacterial infection caused by Acinetobacter baumannii of people; Optionally, wherein this label or instructions comprise the listing authorization number (for example, FDA or EMA authorization number); Optionally, wherein this test kit comprises IV device or injection device containing this antibody.
50. The kit of claim 47 or claim 49, wherein the antibody is contained in a sealed container.
51. An antibody according to any one of claims 1 to 35, or a pharmaceutical composition according to any one of claims 40 to 46, or a nucleic acid according to claim 36 or claim 37, for use as a medicament.
52. An antibody according to any one of claims 1 to 35, or a pharmaceutical composition according to any one of claims 40 to 46, or a nucleic acid according to claim 36 or claim 37, for use in a method for treating a bacterial infection caused by Acinetobacter baumannii, the method comprising administering the antibody, composition or nucleic acid to a patient.
53. An antibody according to any one of claims 1 to 35, or a pharmaceutical composition according to any one of claims 40 to 46, or a nucleic acid according to claim 36 or claim 37, for use in a method for preventing a bacterial infection caused by Acinetobacter baumannii, the method comprising administering the antibody, composition or nucleic acid to a patient.
54. An antibody according to any one of claims 1 to 35, or a pharmaceutical composition according to any one of claims 40 to 46, or a nucleic acid according to claim 36 or claim 37, for use according to claim 52 or claim 53, wherein the presence or absence of Oxa-23 in a sample from the patient has been determined prior to administering the antibody, composition or nucleic acid to the patient.
55. The antibody of any one of claims 1 to 35, or the pharmaceutical composition of any one of claims 40 to 46, or the nucleic acid of claim 36 or claim 37, for use according to claim 52, claim 53 or claim 54, wherein the presence or absence of OCL1 LOS in a sample of the patient has been determined prior to administering the antibody, composition or nucleic acid to the patient.
56. An antibody according to any one of claims 1 to 35, or a pharmaceutical composition according to any one of claims 40 to 46, or a nucleic acid according to claim 36 or claim 37, for use according to any one of claims 52 to 55, wherein the presence or absence of KL49 in a sample of the patient has been determined before administering the antibody, composition or nucleic acid to the patient.
57. Use of an antibody according to any one of claims 1 to 35, or a pharmaceutical composition according to any one of claims 40 to 46, or a nucleic acid according to claim 36 or claim 37 in the manufacture of a medicament for use in a method for treating a bacterial infection caused by Acinetobacter baumannii in a patient.
58. An antibody according to any one of claims 1 to 35, or a pharmaceutical composition according to any one of claims 40 to 46, or a nucleic acid according to claim 36 or claim 37 in the manufacture of a medicament for use in a method for preventing a bacterial infection caused by Acinetobacter baumannii in a patient.
59. A method of treating a bacterial infection caused by Acinetobacter baumannii in a patient, the method comprising administering to the patient a therapeutically effective amount of an antibody according to any one of claims 1 to 35, or a pharmaceutical composition according to any one of claims 40 to 46, or a nucleic acid according to claim 36 or claim 37.
60. A method of preventing a bacterial infection caused by Acinetobacter baumannii in a patient, the method comprising administering to the patient a therapeutically effective amount of an antibody according to any one of claims 1 to 35, or a pharmaceutical composition according to any one of claims 40 to 46, or a nucleic acid according to claim 36 or claim 37.
61. The antibody, composition or nucleic acid for use according to any one of claims 52 to 56, the use according to claim 57 or claim 58, or the method according to claim 59 or claim 60, wherein the bacterial infection caused by Acinetobacter baumannii is a nosocomial bacterial infection caused by Acinetobacter baumannii.
62. The antibody, composition or nucleic acid for use according to any one of claims 52 to 56, the use according to claim 57 or claim 58, or the method according to claim 59 or claim 60, wherein the patient has a lower respiratory tract infection, such as pneumonia.
63. The antibody, composition or nucleic acid for use according to any one of claims 52 to 56, the use according to claim 57 or claim 58, or the method according to claim 59 or claim 60, wherein the patient suffers from sepsis.
64. The antibody, composition or nucleic acid for use according to any one of claims 52 to 56, the use according to claim 57 or claim 58, or the method according to claim 59 or claim 60, wherein the patient has bacteremia.
65. The antibody, composition or nucleic acid for use according to any one of claims 52 to 56, the use according to claim 57 or claim 58, or the method according to claim 59 or claim 60, wherein the method further comprises administering at least one additional therapeutic agent.
66. The antibody, composition or nucleic acid for use according to claim 65, the use according to claim 65, or the method according to claim 65, wherein administration of the additional therapeutic agent is simultaneous, separate or sequential.
67. The antibody, composition or nucleic acid for use according to claim 65 or claim 66, the use according to claim 65 or claim 66, or the method according to claim 65 or claim 66, wherein the additional therapeutic agent is at least one, preferably one or two additional antibodies.
68. The antibody, composition or nucleic acid for use according to any one of claims 65 to 67, the use according to any one of claims 65 to 67, or the method according to any one of claims 65 to 67, wherein the at least one additional therapeutic agent is a carbapenem.
69. The antibody, composition or nucleic acid for use according to any one of claims 65 to 67, the use according to any one of claims 65 to 67, or the method according to any one of claims 65 to 67, wherein the at least one additional therapeutic agent is colistin.
70. Use of the antibody according to any one of claims 1 to 35 for determining the presence or absence of Acinetobacter baumannii in a sample.
71. A method for determining the presence or absence of Acinetobacter baumannii in a sample, the method comprising contacting the sample with an antibody according to any one of 1 to 35; and testing the binding between the antibody and Acinetobacter baumannii in the sample; wherein detection of binding indicates the presence of Acinetobacter baumannii in the sample, and wherein the absence of binding indicates the absence of Acinetobacter baumannii in the sample.
72. Use of an antibody according to any one of claims 1 to 11 for determining the presence or absence of Oxa-23 in a sample, optionally wherein determining the presence or absence of Oxa-23 in a sample is used to determine a treatment regimen for a patient.
73. Use of an antibody according to any one of claims 1, 2 or 12 to 20 for determining the presence or absence of OCL1 LOS in a sample, optionally wherein determining the presence or absence of OCL1 LOS in a sample is used to determine a treatment regimen for a patient.
74. Use of an antibody according to any one of claims 1, 2 or 21 to 29 for determining the presence or absence of KL49 in a sample, optionally wherein determining the presence or absence of KL49 in a sample is used to determine a treatment regimen for a patient.
75. The use according to any one of claims 72 to 74, wherein the antibody is conjugated to a detectable label.
76. The use according to any one of claims 72 to 75, wherein the sample is obtained from a human who has been or is suspected of having been infected with Acinetobacter baumannii.
77. The use according to claim 76, wherein the sample is obtained from a human who has been or is suspected of having been infected with Acinetobacter baumannii and who exhibits one or more symptoms of bacterial infection.
78. The use according to any one of claims 72 to 77, wherein the sample is a serum, plasma or whole blood sample, an oral or nasal swab, urine, feces or cerebrospinal fluid (CFS), or wherein the sample is from any organ or tissue suspected of being infected with Acinetobacter baumannii.
79. A diagnostic kit comprising the antibody according to any one of claims 1 to 35, and optionally one or more buffer solutions.
80. The diagnostic kit of claim 79, wherein the kit comprises a first reagent and a second reagent, the first reagent comprising the antibody according to any one of claims 1 to 35, the second reagent comprising a detection molecule that binds to the first reagent.
81. The diagnostic kit of claim 80, wherein the detection molecule is an antibody comprising a detectable marker or conjugated to the detectable marker.
Citation Information
Cited By
Antibody for treating ulcerative colitis and application thereof
CN121108335A
An antibody for treating ulcerative colitis and use thereof
CN121108335B
